0001628280-24-020283.txt : 20240503 0001628280-24-020283.hdr.sgml : 20240503 20240503161043 ACCESSION NUMBER: 0001628280-24-020283 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 24913161 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-Q 1 mrk-20240331.htm 10-Q mrk-20240331
FALSE2024Q1000031015812/31http://fasb.org/us-gaap/2023#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2023#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense00003101582024-01-012024-03-310000310158us-gaap:CommonStockMember2024-01-012024-03-310000310158mrk:A0.500Notesdue2024Member2024-01-012024-03-310000310158mrk:A1.875Notesdue2026Member2024-01-012024-03-310000310158mrk:A2.500Notesdue2034Member2024-01-012024-03-310000310158mrk:A1.375Notesdue2036Member2024-01-012024-03-3100003101582024-04-30xbrli:sharesiso4217:USD00003101582023-01-012023-03-31iso4217:USDxbrli:shares00003101582024-03-3100003101582023-12-3100003101582022-12-3100003101582023-03-310000310158mrk:HarpoonTherapeuticsInc.Member2024-03-012024-03-310000310158mrk:HarpoonTherapeuticsInc.Member2024-01-012024-03-310000310158srt:ScenarioForecastMembermrk:ElancoAnimalHealthIncorporatedAquaBusinessMember2024-06-012024-07-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2023-02-28mrk:candidate0000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2023-10-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2023-01-310000310158mrk:ImagoBioSciencesIncMember2023-01-012023-01-310000310158mrk:ImagoBioSciencesIncMember2023-01-012023-03-310000310158us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMembermrk:OrganonCo.Member2024-03-31mrk:jurisdiction0000310158srt:MinimumMembermrk:ManufacturingAndSupplyAgreementsMemberus-gaap:RelatedPartyMember2021-06-022021-06-020000310158srt:MaximumMembermrk:ManufacturingAndSupplyAgreementsMemberus-gaap:RelatedPartyMember2021-06-022021-06-020000310158mrk:ManufacturingAndSupplyAgreementsMemberus-gaap:RelatedPartyMember2024-01-012024-03-310000310158mrk:ManufacturingAndSupplyAgreementsMemberus-gaap:RelatedPartyMember2023-01-012023-03-310000310158us-gaap:RelatedPartyMember2024-03-310000310158us-gaap:RelatedPartyMember2023-12-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMembermrk:LynparzaMember2022-01-012022-12-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMembermrk:LynparzaMember2022-12-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMembermrk:LynparzaMember2024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMembermrk:LynparzaMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMembermrk:LynparzaMember2023-01-012023-03-310000310158us-gaap:OtherIntangibleAssetsMembermrk:LicensesAndOtherMembermrk:LynparzaMember2024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMember2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AllianceRevenueKoselugoMembermrk:AstraZenecaMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AllianceRevenueKoselugoMembermrk:AstraZenecaMember2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMember2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMember2024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMember2023-12-310000310158mrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:EisaiMember2023-01-012023-03-310000310158mrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:EisaiMember2023-07-012023-09-300000310158mrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:EisaiMember2023-09-300000310158mrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:EisaiMember2023-04-012023-06-300000310158mrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:EisaiMember2024-03-310000310158mrk:EisaiMember2023-01-012023-03-310000310158mrk:EisaiMember2023-07-012023-09-300000310158us-gaap:OtherIntangibleAssetsMembermrk:LenvimaMembermrk:LicensesAndOtherMember2024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:EisaiMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:EisaiMember2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:EisaiMember2024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:EisaiMember2023-12-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:BayerAGMember2024-03-310000310158us-gaap:OtherIntangibleAssetsMembermrk:AdempasMembermrk:LicensesAndOtherMember2024-03-310000310158us-gaap:OtherIntangibleAssetsMembermrk:VerquvoMembermrk:LicensesAndOtherMember2024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:BayerAGMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:BayerAGMember2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:BayerAGMembermrk:AdempasMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:BayerAGMembermrk:AdempasMember2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:BayerAGMembermrk:VerquvoMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:BayerAGMembermrk:VerquvoMember2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:BayerAGMember2023-12-310000310158mrk:LagevrioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:RidgebackBiotherapeuticsLPMember2024-01-012024-03-310000310158mrk:LagevrioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:RidgebackBiotherapeuticsLPMember2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:RidgebackBiotherapeuticsLPMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:RidgebackBiotherapeuticsLPMember2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:RidgebackBiotherapeuticsLPMember2024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:RidgebackBiotherapeuticsLPMember2023-12-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:DaiichiSankyoMember2023-10-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:IfinatamabDeruxtecanMembermrk:DaiichiSankyoMember2023-10-310000310158mrk:PatritumabDeruxtecanMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:DaiichiSankyoMember2023-10-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:RaludotatugDeruxtecanMembermrk:DaiichiSankyoMember2023-10-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:DaiichiSankyoMember2023-10-012023-12-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:DaiichiSankyoMembermrk:PatritumabDeruxtecanAndRaludotatugDeruxtecanMember2023-12-31xbrli:pure0000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:DaiichiSankyoMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:DaiichiSankyoMember2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:DaiichiSankyoMember2024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:DaiichiSankyoMember2023-12-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:ModernaInc.Member2024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:ModernaInc.Member2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:ModernaInc.Member2023-01-012023-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:ModernaInc.Member2023-12-310000310158mrk:BristolMyersSquibbCompanyMembersrt:MinimumMemberus-gaap:LicensingAgreementsMember2024-01-012024-03-310000310158mrk:BristolMyersSquibbCompanyMembersrt:MaximumMemberus-gaap:LicensingAgreementsMember2024-01-012024-03-310000310158mrk:BristolMyersSquibbCompanyMemberus-gaap:LicensingAgreementsMember2024-01-012024-03-310000310158mrk:BristolMyersSquibbCompanyMembermrk:SalesBasedMilestonesMemberus-gaap:LicensingAgreementsMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:BristolMyersSquibbCompanyMember2024-01-012024-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:BristolMyersSquibbCompanyMember2023-01-012023-03-310000310158mrk:RestructuringProgram2024Member2024-03-310000310158mrk:RestructuringProgram2024Member2024-01-012024-03-310000310158mrk:RestructuringProgram2019Member2023-01-012023-03-310000310158us-gaap:CostOfSalesMembermrk:RestructuringProgram2024Membermrk:AcceleratedDepreciationMember2024-01-012024-03-310000310158us-gaap:EmployeeSeveranceMemberus-gaap:CostOfSalesMembermrk:RestructuringProgram2024Member2024-01-012024-03-310000310158us-gaap:CostOfSalesMembermrk:RestructuringProgram2024Memberus-gaap:OtherRestructuringMember2024-01-012024-03-310000310158us-gaap:CostOfSalesMembermrk:RestructuringProgram2024Member2024-01-012024-03-310000310158mrk:RestructuringProgram2024Membermrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310000310158mrk:RestructuringProgram2024Memberus-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310000310158mrk:RestructuringProgram2024Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RestructuringProgram2024Membermrk:AcceleratedDepreciationMember2024-01-012024-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Member2024-01-012024-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RestructuringProgram2024Memberus-gaap:OtherRestructuringMember2024-01-012024-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RestructuringProgram2024Member2024-01-012024-03-310000310158us-gaap:RestructuringChargesMembermrk:RestructuringProgram2024Membermrk:AcceleratedDepreciationMember2024-01-012024-03-310000310158us-gaap:EmployeeSeveranceMemberus-gaap:RestructuringChargesMembermrk:RestructuringProgram2024Member2024-01-012024-03-310000310158us-gaap:RestructuringChargesMembermrk:RestructuringProgram2024Memberus-gaap:OtherRestructuringMember2024-01-012024-03-310000310158us-gaap:RestructuringChargesMembermrk:RestructuringProgram2024Member2024-01-012024-03-310000310158mrk:RestructuringProgram2024Membermrk:AcceleratedDepreciationMember2024-01-012024-03-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Member2024-01-012024-03-310000310158mrk:RestructuringProgram2024Memberus-gaap:OtherRestructuringMember2024-01-012024-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:CostOfSalesMembermrk:AcceleratedDepreciationMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:EmployeeSeveranceMemberus-gaap:CostOfSalesMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:CostOfSalesMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Membermrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:EmployeeSeveranceMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:RestructuringChargesMembermrk:AcceleratedDepreciationMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:EmployeeSeveranceMemberus-gaap:RestructuringChargesMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:RestructuringChargesMemberus-gaap:OtherRestructuringMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:RestructuringChargesMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Membermrk:AcceleratedDepreciationMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:EmployeeSeveranceMember2023-01-012023-03-310000310158mrk:RestructuringProgram2019Memberus-gaap:OtherRestructuringMember2023-01-012023-03-310000310158mrk:AcceleratedDepreciationMember2023-12-310000310158us-gaap:EmployeeSeveranceMember2023-12-310000310158us-gaap:OtherRestructuringMember2023-12-310000310158mrk:AcceleratedDepreciationMember2024-01-012024-03-310000310158us-gaap:EmployeeSeveranceMember2024-01-012024-03-310000310158us-gaap:OtherRestructuringMember2024-01-012024-03-310000310158mrk:AcceleratedDepreciationMember2024-03-310000310158us-gaap:EmployeeSeveranceMember2024-03-310000310158us-gaap:OtherRestructuringMember2024-03-310000310158us-gaap:DesignatedAsHedgingInstrumentMembersrt:MaximumMember2024-01-012024-03-310000310158us-gaap:NondesignatedMembersrt:MaximumMember2024-01-012024-03-310000310158us-gaap:ForeignExchangeContractMember2024-01-012024-03-310000310158us-gaap:ForeignExchangeContractMember2023-01-012023-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2024-01-012024-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310000310158mrk:EurodominatedNotesMember2024-01-012024-03-310000310158mrk:EurodominatedNotesMember2023-01-012023-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMembermrk:EurodominatedNotesMember2024-01-012024-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMembermrk:EurodominatedNotesMember2023-01-012023-03-310000310158mrk:A450NoteDue2033Memberus-gaap:InterestRateSwapMember2024-03-31mrk:interest_rate_swap0000310158us-gaap:SeniorNotesMembermrk:A450NotesDue2033Member2024-03-310000310158us-gaap:InterestRateSwapMemberus-gaap:SubsequentEventMember2024-04-300000310158mrk:A450NoteDue2033Memberus-gaap:InterestRateSwapMemberus-gaap:SubsequentEventMember2024-04-300000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2024-03-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2024-03-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMember2024-03-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2024-03-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2024-03-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000310158us-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2024-03-310000310158us-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310000310158us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMember2024-03-310000310158us-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2024-03-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2024-03-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:NondesignatedMember2024-03-310000310158us-gaap:NondesignatedMember2023-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2024-01-012024-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2023-01-012023-03-310000310158us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMember2024-01-012024-03-310000310158us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310000310158us-gaap:InterestRateContractMember2024-01-012024-03-310000310158us-gaap:InterestRateContractMember2023-01-012023-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2024-01-012024-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2023-01-012023-03-310000310158us-gaap:ForeignExchangeFutureMemberus-gaap:SalesMember2024-01-012024-03-310000310158us-gaap:ForeignExchangeFutureMemberus-gaap:SalesMember2023-01-012023-03-310000310158us-gaap:CommercialPaperMember2024-03-310000310158us-gaap:CommercialPaperMember2023-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000310158us-gaap:CorporateDebtSecuritiesMember2024-03-310000310158us-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:EquityFundsMember2024-03-310000310158us-gaap:EquityFundsMember2023-03-310000310158us-gaap:EquityFundsMember2024-01-012024-03-310000310158us-gaap:EquityFundsMember2023-01-012023-03-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2024-03-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2024-03-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2024-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2024-03-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2024-03-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2024-03-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2024-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2024-03-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2023-12-310000310158us-gaap:FairValueInputsLevel2Member2024-03-310000310158us-gaap:FairValueInputsLevel2Member2023-12-310000310158mrk:SanofiPasteurMember2024-03-3100003101582023-01-012023-12-310000310158mrk:AccountsReceivableFactoringCollectionsMember2024-03-310000310158mrk:AccountsReceivableFactoringCollectionsMember2023-12-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2023-12-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2024-03-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2024-03-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2023-12-310000310158us-gaap:PendingLitigationMembermrk:Dr.SchollsMembercountry:US2024-03-31mrk:case0000310158mrk:GardasilGardasil9Memberus-gaap:PendingLitigationMembercountry:US2024-03-310000310158mrk:GardasilGardasil9Memberus-gaap:PendingLitigationMemberus-gaap:NonUsMember2024-03-310000310158mrk:ZetiaantitrustlitigationMember2023-01-012023-03-310000310158us-gaap:PendingLitigationMembermrk:CommercialAndOtherLitigationMember2024-01-012024-03-31mrk:employee0000310158us-gaap:PendingLitigationMembermrk:CommercialAndOtherLitigationMember2023-07-27mrk:motion_for_summary_judgment0000310158us-gaap:PendingLitigationMembermrk:CommercialAndOtherLitigationMember2024-03-310000310158us-gaap:PatentsMemberus-gaap:PendingLitigationMembermrk:BridionMember2022-12-192022-12-190000310158us-gaap:PatentsMembermrk:BridionMember2024-01-012024-03-31mrk:company0000310158us-gaap:PatentsMemberus-gaap:PendingLitigationMembermrk:BridionMember2024-03-310000310158mrk:JanuviaJanumetMember2024-01-012024-03-310000310158us-gaap:PatentsMemberus-gaap:PendingLitigationMembermrk:KeytrudaMember2023-04-132023-04-13mrk:patent0000310158mrk:LegalDefenseCostsMember2024-03-310000310158mrk:LegalDefenseCostsMember2023-12-310000310158us-gaap:CommonStockMember2022-12-310000310158us-gaap:AdditionalPaidInCapitalMember2022-12-310000310158us-gaap:RetainedEarningsMember2022-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000310158us-gaap:TreasuryStockCommonMember2022-12-310000310158us-gaap:NoncontrollingInterestMember2022-12-310000310158us-gaap:RetainedEarningsMember2023-01-012023-03-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000310158us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000310158us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000310158us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000310158us-gaap:CommonStockMember2023-03-310000310158us-gaap:AdditionalPaidInCapitalMember2023-03-310000310158us-gaap:RetainedEarningsMember2023-03-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000310158us-gaap:TreasuryStockCommonMember2023-03-310000310158us-gaap:NoncontrollingInterestMember2023-03-310000310158us-gaap:CommonStockMember2023-12-310000310158us-gaap:AdditionalPaidInCapitalMember2023-12-310000310158us-gaap:RetainedEarningsMember2023-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000310158us-gaap:TreasuryStockCommonMember2023-12-310000310158us-gaap:NoncontrollingInterestMember2023-12-310000310158us-gaap:RetainedEarningsMember2024-01-012024-03-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000310158us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000310158us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000310158us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000310158us-gaap:CommonStockMember2024-03-310000310158us-gaap:AdditionalPaidInCapitalMember2024-03-310000310158us-gaap:RetainedEarningsMember2024-03-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000310158us-gaap:TreasuryStockCommonMember2024-03-310000310158us-gaap:NoncontrollingInterestMember2024-03-310000310158us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-03-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-03-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-03-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-03-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-03-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-03-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-03-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2024-03-31mrk:segment0000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:LenvimaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158mrk:LenvimaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158mrk:LenvimaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158mrk:LenvimaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158mrk:LenvimaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158mrk:LenvimaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:WeliregMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:WeliregMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:WeliregMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:WeliregMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:WeliregMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:WeliregMember2023-01-012023-03-310000310158mrk:AllianceRevenueReblozylMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158mrk:AllianceRevenueReblozylMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158mrk:AllianceRevenueReblozylMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158mrk:AllianceRevenueReblozylMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158mrk:AllianceRevenueReblozylMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158mrk:AllianceRevenueReblozylMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158mrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158mrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158mrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158mrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158mrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaxneuvanceMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:VaxneuvanceMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaxneuvanceMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaxneuvanceMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:VaxneuvanceMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaxneuvanceMember2023-01-012023-03-310000310158mrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158mrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158mrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158mrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158mrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158mrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158mrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158mrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158mrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158mrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158mrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:USmrk:BridionMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:BridionMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BridionMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:USmrk:BridionMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:BridionMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BridionMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DificidMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:DificidMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DificidMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DificidMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:DificidMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DificidMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZerbaxaMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZerbaxaMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZerbaxaMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZerbaxaMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZerbaxaMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZerbaxaMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NoxafilMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:NoxafilMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NoxafilMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NoxafilMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:NoxafilMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NoxafilMember2023-01-012023-03-310000310158mrk:AllianceRevenueAdempasVerquvoMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158mrk:AllianceRevenueAdempasVerquvoMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158mrk:AllianceRevenueAdempasVerquvoMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158mrk:AllianceRevenueAdempasVerquvoMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158mrk:AllianceRevenueAdempasVerquvoMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158mrk:AllianceRevenueAdempasVerquvoMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:LagevrioMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158mrk:LagevrioMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158mrk:LagevrioMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158mrk:LagevrioMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158mrk:LagevrioMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158mrk:LagevrioMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:USmrk:DelstrigoMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:DelstrigoMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DelstrigoMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:USmrk:DelstrigoMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:DelstrigoMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DelstrigoMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMember2023-01-012023-03-310000310158mrk:RemicadeMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158mrk:RemicadeMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158mrk:RemicadeMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158mrk:RemicadeMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158mrk:RemicadeMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158mrk:RemicadeMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanumetMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanumetMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanumetMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanumetMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanumetMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanumetMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:OtherPharmaceuticalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:OtherPharmaceuticalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalMembermrk:AnimalHealthsegmentMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalMembermrk:AnimalHealthsegmentMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalMembermrk:AnimalHealthsegmentMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalMembermrk:AnimalHealthsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembercountry:US2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembermrk:InternationalMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMember2024-01-012024-03-310000310158us-gaap:OperatingSegmentsMembercountry:US2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:InternationalMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158us-gaap:CorporateNonSegmentMembercountry:US2024-01-012024-03-310000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2024-01-012024-03-310000310158us-gaap:CorporateNonSegmentMember2024-01-012024-03-310000310158us-gaap:CorporateNonSegmentMembercountry:US2023-01-012023-03-310000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2023-01-012023-03-310000310158us-gaap:CorporateNonSegmentMember2023-01-012023-03-310000310158country:US2024-01-012024-03-310000310158mrk:InternationalMember2024-01-012024-03-310000310158country:US2023-01-012023-03-310000310158mrk:InternationalMember2023-01-012023-03-310000310158us-gaap:EMEAMember2024-01-012024-03-310000310158us-gaap:EMEAMember2023-01-012023-03-310000310158country:CN2024-01-012024-03-310000310158country:CN2023-01-012023-03-310000310158country:JP2024-01-012024-03-310000310158country:JP2023-01-012023-03-310000310158srt:LatinAmericaMember2024-01-012024-03-310000310158srt:LatinAmericaMember2023-01-012023-03-310000310158srt:AsiaPacificMember2024-01-012024-03-310000310158srt:AsiaPacificMember2023-01-012023-03-310000310158mrk:OtherCountriesMember2024-01-012024-03-310000310158mrk:OtherCountriesMember2023-01-012023-03-310000310158us-gaap:MaterialReconcilingItemsMember2024-01-012024-03-310000310158us-gaap:MaterialReconcilingItemsMember2023-01-012023-03-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey22-1918501
(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)
126 East Lincoln Avenue
RahwayNew Jersey07065
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Securities Registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
0.500% Notes due 2024MRK 24New York Stock Exchange
1.875% Notes due 2026MRK/26New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒   No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒   No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐ Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒
The number of shares of common stock outstanding as of the close of business on April 30, 2024: 2,532,806,307




Table of Contents




Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Unaudited, $ in millions except per share amounts)
 
 Three Months Ended
March 31,
 20242023
Sales$15,775 $14,487 
Costs, Expenses and Other
Cost of sales3,540 3,926 
Selling, general and administrative2,483 2,479 
Research and development3,992 4,276 
Restructuring costs123 67 
Other (income) expense, net(33)89 
 10,105 10,837 
Income Before Taxes5,670 3,650 
Taxes on Income
903 825 
Net Income4,767 2,825 
Less: Net Income Attributable to Noncontrolling Interests5 4 
Net Income Attributable to Merck & Co., Inc.$4,762 $2,821 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders$1.88 $1.11 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$1.87 $1.11 
 
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited, $ in millions)
 
 Three Months Ended
March 31,
 20242023
Net Income Attributable to Merck & Co., Inc.$4,762 $2,821 
Other Comprehensive Loss Net of Taxes:
Net unrealized gain (loss) on derivatives, net of reclassifications
130 (133)
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization(5)(50)
Cumulative translation adjustment(238)68 
 (113)(115)
Comprehensive Income Attributable to Merck & Co., Inc.$4,649 $2,706 
 The accompanying notes are an integral part of these condensed consolidated financial statements.
- 3 -


MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
 
March 31, 2024December 31, 2023
Assets
Current Assets
Cash and cash equivalents$5,579 $6,841 
Short-term investments40 252 
Accounts receivable (net of allowance for doubtful accounts of $80 in 2024
 and $88 in 2023)
11,366 10,349 
Inventories (excludes inventories of $3,413 in 2024 and $3,348 in 2023
classified in Other assets - see Note 6)
6,510 6,358 
Other current assets7,950 8,368 
Total current assets31,445 32,168 
Investments280 252 
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,620
in 2024 and $18,266 in 2023
23,045 23,051 
Goodwill21,181 21,197 
Other Intangibles, Net17,572 18,011 
Other Assets12,326 11,996 
 $105,849 $106,675 
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt$3,077 $1,372 
Trade accounts payable3,514 3,922 
Accrued and other current liabilities14,102 15,766 
Income taxes payable2,398 2,649 
Dividends payable2,008 1,985 
Total current liabilities25,099 25,694 
Long-Term Debt31,142 33,683 
Deferred Income Taxes922 871 
Other Noncurrent Liabilities8,262 8,792 
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2024 and 2023
1,788 1,788 
Other paid-in capital44,598 44,509 
Retained earnings56,697 53,895 
Accumulated other comprehensive loss(5,274)(5,161)
97,809 95,031 
Less treasury stock, at cost:
1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023
57,445 57,450 
Total Merck & Co., Inc. stockholders’ equity40,364 37,581 
Noncontrolling Interests60 54 
Total equity40,424 37,635 
 $105,849 $106,675 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 4 -


MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, $ in millions)
 
 Three Months Ended
March 31,
 20242023
Cash Flows from Operating Activities
Net income
$4,767 $2,825 
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization473 543 
Depreciation511 448 
Income from investments in equity securities, net
(143)(450)
Charge for the acquisition of Harpoon Therapeutics, Inc.
656 — 
Charge for the acquisition of Imago BioSciences, Inc.— 1,192 
Deferred income taxes(51)(277)
Share-based compensation176 145 
Other83 (197)
Net changes in assets and liabilities(3,382)(2,890)
Net Cash Provided by Operating Activities 3,090 1,339 
Cash Flows from Investing Activities
Capital expenditures(861)(1,007)
Purchases of securities and other investments(15)(562)
Proceeds from sales of securities and other investments260 500 
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired
(746)— 
Acquisition of Imago BioSciences, Inc., net of cash acquired— (1,327)
Other(14)37 
Net Cash Used in Investing Activities (1,376)(2,359)
Cash Flows from Financing Activities
Payments on debt(751)(1)
Dividends paid to stockholders(1,950)(1,853)
Purchases of treasury stock(122)(149)
Proceeds from exercise of stock options87 30 
Other(78)(81)
Net Cash Used in Financing Activities
(2,814)(2,054)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash(138)87 
Net Decrease in Cash, Cash Equivalents and Restricted Cash
(1,238)(2,987)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of
$68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)
6,909 12,773 
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92
and $79 at March 31, 2024 and 2023, respectively, included in Other current assets)
$5,671 $9,786 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 5 -
Notes to Condensed Consolidated Financial Statements (unaudited)

1. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2024.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Recently Issued Accounting Standards Not Yet Adopted
In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The amended guidance is effective prospectively for all joint ventures with a formation date on or after January 1, 2025, however existing joint ventures have the option to apply the guidance retrospectively. Early adoption is permitted for both interim and annual periods. The Company anticipates there will be no impact to its consolidated financial statements upon adoption.
In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses. The guidance is effective for annual periods beginning in 2024, and interim periods beginning in 2025. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.
In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. Early adoption is permitted. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.
2.    Acquisitions, Divestitures, Research Collaborations and Licensing Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments; expense reimbursements or payments to the third party; milestone, royalty or profit share arrangements contingent upon the occurrence of certain future events linked to the success of the asset in development; and can also include option and continuation payments. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
2024 Transactions
In March 2024, Merck acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases, for $765 million and also incurred $56 million of transaction costs. Harpoon’s lead candidate, MK-6070 (formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small-cell lung cancer (SCLC) and neuroendocrine tumors. MK-6070 is currently being evaluated as monotherapy in a Phase 1/2 clinical trial in certain patients with advanced cancers associated with expression of DLL3. The study is also evaluating MK-6070 in combination with atezolizumab in certain patients with SCLC. The transaction was accounted for as an asset acquisition since MK-6070 represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $165 million, as well as a charge of $656 million to Research and development expenses in the first quarter of 2024 related to the transaction. There are no future contingent payments associated with the acquisition.
In February 2024, Merck entered into a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (Elanco) for $1.3 billion in cash. The Elanco aqua business to be acquired consists of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. Upon closing, the acquisition will broaden Animal Health’s aqua portfolio with products, such as Clynav, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic sea lice treatment. This acquisition also brings a portfolio of water treatment products for warm water production, complementing Animal Health’s warm water vaccine portfolio. In addition to these products, the DNA-based vaccine
- 6 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
technology that is a part of the business has the potential to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. The acquisition is expected to be completed by mid-2024, subject to approvals from regulatory authorities and other customary closing conditions. The transaction will be accounted for as a business combination.
2023 Transactions
In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded as a charge to Research and development expenses in the first quarter of 2023. In October 2023, Merck notified Kelun-Biotech it was terminating two of the seven candidates under the agreement. Subsequently, in April 2024, Merck notified Kelun-Biotech it was terminating an additional candidate under the agreement. Kelun-Biotech remains eligible to receive future contingent payments aggregating up to $600 million in development-related payments, $1.6 billion in regulatory milestones, and $3.1 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all remaining candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech shares in January 2023.
In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate, bomedemstat MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. A Phase 3 clinical trial evaluating bomedemstat for the treatment of certain patients with essential thrombocythemia is underway. The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as a charge of $1.2 billion to Research and development expenses in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
Spin-Off of Organon & Co.
In connection with the 2021 spin-off of Organon & Co. (Organon), Merck and Organon entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck continued to market, import and distribute such products on behalf of Organon until such time as the relevant licenses and permits transferred to Organon, with Organon receiving all of the economic benefits and burdens of such activities. As of March 31, 2024, only one jurisdiction remains under an interim operating agreement. Additionally, Merck and Organon entered into a number of manufacturing and supply agreements (MSAs) with terms ranging from four years to ten years. The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $107 million and $94 million and related cost of sales of $110 million and $107 million for the first quarter of 2024 and 2023, respectively. The amounts due from Organon for all spin-off related agreements were $462 million and $632 million at March 31, 2024 and December 31, 2023, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $193 million and $598 million at March 31, 2024 and December 31, 2023, respectively, and are included in Accrued and other current liabilities.
3.    Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca PLC
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca are developing and commercializing Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
- 7 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at March 31, 2024) and a corresponding increase to the intangible asset related to Lynparza. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. Lynparza received regulatory approvals triggering capitalized milestone payments from Merck to AstraZeneca of $245 million and $105 million in the first quarter of 2024 and 2023, respectively (each of which had been previously accrued for). Potential future regulatory milestone payments of $650 million remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.4 billion at March 31, 2024 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Lynparza$292 $275 
Alliance revenue - Koselugo38 23 
Total alliance revenue$330 $298 
Cost of sales (1)
82 70 
Selling, general and administrative39 47 
Research and development20 21 
($ in millions)March 31, 2024December 31, 2023
Receivables from AstraZeneca included in Other current assets
$334 $341 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
617 256 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
— 600 
(1)    Represents amortization of capitalized milestone payments.
(2)    Includes accrued milestone payments.
Eisai Co., Ltd.
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai are developing and commercializing Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a $125 million sales-based milestone payment from Merck to Eisai. Similarly, in the third quarter of 2023 an additional $125 million sales-based milestone payment to Eisai was deemed by the Company to be probable of payment. Accordingly, Merck recorded $250 million of liabilities for these payments (of which $125 million was subsequently paid in the second quarter of 2023 and $125 million remained accrued at March 31, 2024) and corresponding increases to the intangible asset related to Lenvima. Merck also recognized $72 million and $81 million of cumulative amortization catch-up expense related to the recognition of these milestones in the first and third quarters of 2023, respectively. Potential future sales-based milestone payments of $2.3 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $623 million at March 31, 2024 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.

- 8 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Lenvima$255 $232 
Cost of sales (1)
60 126 
Selling, general and administrative39 51 
Research and development8 39 
($ in millions)March 31, 2024December 31, 2023
Receivables from Eisai included in Other current assets
$255 $226 
Payables to Eisai included in Accrued and other current liabilities (2)
125 125 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.
(2)    Represents an accrued milestone payment.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat) and Verquvo (vericiguat). The two companies have implemented a joint development and commercialization strategy. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. There are no sales-based milestone payments remaining under this collaboration.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $483 million and $49 million, respectively, at March 31, 2024 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Adempas/Verquvo$98 $99 
Net sales of Adempas recorded by Merck70 59 
Net sales of Verquvo recorded by Merck5 7 
Total sales$173 $165 
Cost of sales (1)
62 57 
Selling, general and administrative33 33 
Research and development28 25 
($ in millions)March 31, 2024December 31, 2023
Receivables from Bayer included in Other current assets
$155 $156 
Payables to Bayer included in Accrued and other current liabilities
74 80 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Ridgeback Biotherapeutics LP
In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, Lagevrio has since received multiple additional authorizations.
- 9 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Net sales of Lagevrio recorded by Merck
$350 $392 
Cost of sales (1)
191 221 
Selling, general and administrative
16 27 
Research and development
(5)16 
($ in millions)March 31, 2024December 31, 2023
Payables to Ridgeback included in Accrued and other current liabilities (2)
$160 $113 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Daiichi Sankyo
In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments. The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.
Under the terms of the agreement, Merck made payments to Daiichi Sankyo totaling $4.0 billion in 2023. These payments included $1.0 billion ($500 million each for patritumab deruxtecan and ifinatamab deruxtecan) which may be refundable on a pro-rated basis in the event of early termination of development with respect to either program. In addition, the agreement provides for a continuation payment of $750 million related to patritumab deruxtecan due from Merck in October 2024 and a continuation payment of $750 million related to raludotatug deruxtecan due from Merck in October 2025. If Merck does not make the continuation payments on the dates noted for either patritumab deruxtecan and/or raludotatug deruxtecan, the rights for the applicable program will revert to Daiichi Sankyo and the non-refundable upfront payments already paid will be retained by Daiichi Sankyo. The agreement also provides for contingent payments from Merck to Daiichi Sankyo of up to an additional $5.5 billion for each DXd ADC upon the successful achievement of certain sales-based milestones. In conjunction with this transaction, Merck recorded an aggregate pretax charge of $5.5 billion to Research and development expenses in the fourth quarter of 2023 for the $4.0 billion of upfront payments and the $1.5 billion of continuation payments.
Merck and Daiichi Sankyo will equally share research and development costs, except for raludotatug deruxtecan, where Merck will be responsible for 75% of the first $2.0 billion of research and development expenses. Merck includes its share of development costs associated with the collaboration as part of Research and development expenses. Following regulatory approval, Daiichi Sankyo will generally record sales worldwide (Daiichi Sankyo will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights and Merck will receive a 5% sales-based royalty. Merck will record its share of product sales, net of cost of sales and commercialization costs, as alliance revenue.

- 10 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Selling, general and administrative $3 $— 
Research and development
69 — 
($ in millions)March 31, 2024December 31, 2023
Payables to Daiichi Sankyo included in Accrued and other current liabilities
$817 $800 
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities
750 750 
Moderna, Inc.
In 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna). V940 (mRNA-4157) is currently being evaluated in combination with Keytruda in multiple Phase 3 clinical trials. Merck and Moderna will share costs and any profits equally under this worldwide collaboration. Merck records its share of development costs associated with the collaboration as part of Research and development expenses. Any reimbursements received from Moderna for research and development expenses are recognized as reductions to Research and development costs. Merck has also capitalized certain of the shared costs, which aggregated $110 million at March 31, 2024 and will be amortized over the assets’ estimated useful lives.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Selling, general and administrative $2 $1 
Research and development
69 26 
($ in millions)March 31, 2024December 31, 2023
Payables to Moderna included in Accrued and other current liabilities
$72 $63 
Bristol-Myers Squibb Company
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Alliance revenue related to this collaboration, consisting of royalties (recorded within Sales) was $71 million and $43 million in the first quarter of 2024 and 2023, respectively.
4.    Restructuring
In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company recorded total pretax costs of $246 million in the first quarter of 2024 related to the 2024 Restructuring Program, bringing total cumulative pretax costs incurred through March 31, 2024 to $436 million.
In 2019, Merck approved a global restructuring program (2019 Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The Company recorded total pretax costs of $97 million in the first quarter of 2023 related to the 2019 Restructuring Program. The actions under the 2019 Restructuring Program were substantially complete at the end of 2023 and, as of January 1, 2024, any remaining activities are now being accounted for as part of the 2024 Restructuring Program.
For segment reporting, restructuring charges are unallocated expenses.
- 11 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The following tables summarize the charges related to the restructuring programs by type of cost:
 Three Months Ended March 31, 2024
($ in millions)
Accelerated Depreciation
Separation Costs
Other Exit Costs
Total
2024 Restructuring Program
Cost of sales$65 $— $51 $116 
Selling, general and administrative— — 5 5 
Research and development— — 2 2 
Restructuring costs— 92 31 123 
$65 $92 $89 $246 
 Three Months Ended March 31, 2023
($ in millions)
Accelerated Depreciation
Separation Costs
Other Exit Costs
Total
2019 Restructuring Program
Cost of sales$21 $— $8 $29 
Selling, general and administrative— — 1 1 
Restructuring costs— 41 26 67 
$21 $41 $35 $97 
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.
Other exit costs in 2024 and 2023 include asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 9) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2024:
($ in millions)
Accelerated Depreciation
Separation
Costs
Other Exit Costs
Total
Restructuring reserves January 1, 2024
$— $681 $31 $712 
Expenses65 92 89 246 
(Payments) receipts, net— (67)(32)(99)
Non-cash activity(65)— (58)(123)
Restructuring reserves March 31, 2024
$— $706 $30 $736 
5.    Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
- 12 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and foreign exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated Other Comprehensive Loss (AOCL) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of foreign exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of foreign exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the foreign exchange rate and the cost of the hedging instrument (primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi). The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in foreign exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Condensed Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended March 31,Three Months Ended March 31,
($ in millions)2024202320242023
Net Investment Hedging Relationships
Foreign exchange contracts$(2)$1 $— $1 
Euro-denominated notes(62)52 — — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.
- 13 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
At March 31, 2024, the Company was a party to four pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of a portion of fixed-rate notes as detailed in the table below.
March 31, 2024
($ in millions)
Par Value of Debt
Number of Interest Rate Swaps Held
Total Swap Notional Amount
4.50% notes due 2033
$1,500 4 $1,000 
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark Secured Overnight Financing Rate (SOFR) swap rate. The fair value changes in the notes attributable to changes in the SOFR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. In April 2024, the Company entered into two additional interest rate swaps with notional amounts of $250 million each also related to its 4.50% notes due 2033.
The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged Liabilities
Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount
($ in millions)
March 31, 2024December 31, 2023March 31, 2024December 31, 2023
Balance Sheet Caption
Long-Term Debt
$1,026 $1,056 $26 $56 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  March 31, 2024December 31, 2023
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption
Interest rate swap contracts
Other Assets
$27 $— $1,000 $57 $— $1,000 
Foreign exchange contractsOther current assets175 — 9,082 106 — 6,138 
Foreign exchange contractsOther Assets32 — 2,062 26 — 1,929 
Foreign exchange contractsAccrued and other current liabilities— 10 1,076 — 76 3,680 
Foreign exchange contractsOther Noncurrent Liabilities— 1 204 — 1 7 
  234 11 13,424 189 77 12,754 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets121 — 9,428 153 — 9,693 
Foreign exchange contractsOther Assets2 — 43 — — — 
Foreign exchange contractsAccrued and other current liabilities— 154 9,282 — 162 8,104 
Foreign exchange contractsOther Noncurrent Liabilities— 2 43 — — — 
  123 156 18,796 153 162 17,797 
  $357 $167 $32,220 $342 $239 $30,551 
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 March 31, 2024December 31, 2023
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$357 $167 $342 $239 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(111)(111)(215)(215)
Cash collateral received
(58)— (3)— 
Net amounts$188 $56 $124 $24 

- 14 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended March 31,
($ in millions)202420232024202320242023
Financial Statement Caption in which Effects of Fair Value or Cash Flow
Hedges are Recorded
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$15,775 $14,487 $(33)$89 $(113)$(115)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items— — (30)— — — 
Derivatives designated as hedging instruments— — 30 — — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain (loss) recognized in OCI on derivatives
— — — — 209 (66)
Increase in Sales as a result of AOCL reclassifications
44 101 — — (44)(101)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — — (1)— — 
Amount of loss recognized in OCI on derivatives
— — — — — (1)
(1)    Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended March 31,
($ in millions)20242023
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$65 $13 
Foreign exchange contracts (2)
Sales(10)2 
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)    These derivative contracts serve as economic hedges of forecasted transactions.
At March 31, 2024, the Company estimates $113 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual foreign exchange rates at maturity.
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 March 31, 2024December 31, 2023
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
Commercial paper$40 $— $— $40 $252 $— $— $252 
U.S. government and agency securities77 — — 77 72 — — 72 
Corporate notes and bonds— — — — 13 — — 13 
Total debt securities$117 $— $— $117 $337 $— $— $337 
Publicly traded equity securities (1)
908 764 
Total debt and publicly traded equity securities$1,025 $1,101 
(1)    Unrealized net gains of $143 million were recorded in Other (income) expense, net in the first quarter of 2024 on equity securities still held at March 31, 2024. Unrealized net gains of $338 million were recorded in Other (income) expense, net in the first quarter of 2023 on equity securities still held at March 31, 2023.
At March 31, 2024 and March 31, 2023, the Company also had $851 million and $942 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During the first quarter of 2024, the Company recorded unrealized gains of $4 million and unrealized losses of $5 million related to certain of these equity investments still held at March 31, 2024. During the first quarter of 2023, the Company recorded unrealized gains of $1 million and unrealized losses of $21 million related to certain of these equity investments still held at March 31, 2023. Cumulative unrealized gains and cumulative unrealized losses based on observable
- 15 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
price changes for investments in equity investments without readily determinable fair values still held at March 31, 2024 were $297 million and $69 million, respectively.
At March 31, 2024 and March 31, 2023, the Company also had $396 million and $725 million, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. Losses (gains) recorded in Other (income) expense, net relating to these investment funds were $2 million and $(132) million for the first quarter of 2024 and 2023, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)March 31, 2024December 31, 2023
Assets
Investments
Commercial paper$— $40 $— $40 $— $252 $— $252 
Publicly traded equity securities280 — — 280 252 — — 252 
 280 40 — 320 252 252 — 504 
Other assets (1)
U.S. government and agency securities77 — — 77 72 — — 72 
Corporate notes and bonds— — — — 13 — — 13 
Publicly traded equity securities (2)
628 — — 628 512 — — 512 
705 — — 705 597 — — 597 
Derivative assets (3)
Forward exchange contracts— 204 — 204 — 202 — 202 
Purchased currency options— 126 — 126 — 83 — 83 
Interest rate swaps
— 27 — 27 — 57 — 57 
 — 357 — 357 — 342 — 342 
Total assets$985 $397 $— $1,382 $849 $594 $— $1,443 
Liabilities
Other liabilities
Contingent consideration$— $— $226 $226 $— $— $354 $354 
Derivative liabilities (3)
Forward exchange contracts— 149 — 149 — 239 — 239 
Written currency options— 18 — 18 — — — — 
— 167 — 167 — 239 — 239 
Total liabilities$— $167 $226 $393 $— $239 $354 $593 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    Balance at March 31, 2024 includes securities with a fair value of $266 million, which are subject to a contractual sale restriction that expires in July 2024.
(3)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of March 31, 2024 and December 31, 2023, Cash and cash equivalents included $4.6 billion and $6.0 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
- 16 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions)20242023
Fair value January 1$354 $456 
Changes in estimated fair value (1)
(2)14 
Payments(126)(117)
Fair value March 31 (2)
$226 $353 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    Balance at March 31, 2024, includes $133 million of current liabilities, all of which relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows.
The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at March 31, 2024, was $30.4 billion compared with a carrying value of $34.2 billion and at December 31, 2023, was $32.0 billion compared with a carrying value of $35.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers, distributors and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.7 billion and $3.0 billion of accounts receivable as of March 31, 2024 and December 31, 2023, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions, generally within thirty days after receipt. As of March 31, 2024 and December 31, 2023, the Company had collected $43 million and $44 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets and the related obligation to remit the cash within Accrued and other current liabilities. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $58 million and $3 million at March 31, 2024 and December 31, 2023, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities.

- 17 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
6.    Inventories
Inventories consisted of:
($ in millions)March 31, 2024December 31, 2023
Finished goods$1,902 $1,954 
Raw materials and work in process8,366 8,037 
Supplies276 277 
Total10,544 10,268 
Decrease to LIFO cost(621)(562)
 $9,923 $9,706 
Recognized as:
Inventories$6,510 $6,358 
Other Assets3,413 3,348 
Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At both March 31, 2024 and December 31, 2023, these amounts included $2.6 billion of inventories not expected to be sold within one year. In addition, these amounts included $861 million and $790 million at March 31, 2024 and December 31, 2023, respectively, of inventories produced in preparation for product launches.
7.    Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Generally, for product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Dr. Scholl’s Foot Powder
Merck is a defendant in product liability lawsuits in the U.S. arising from consumers’ alleged exposure to talc in Dr. Scholl’s foot powder, which Merck acquired through its merger with Schering-Plough Corporation and sold as part of the divestiture of Merck’s consumer care business to Bayer in 2014. In these actions, plaintiffs allege that they were exposed to asbestos-contaminated talc and developed mesothelioma as a result. As of March 31, 2024, approximately 275 cases were pending against Merck in various state courts.
Gardasil/Gardasil 9
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of March 31, 2024, approximately 190 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the U.S. Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. In February 2024, the multidistrict litigation was reassigned to Judge Kenneth D. Bell. There are fewer than 15 product liability cases pending outside the U.S.
- 18 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Governmental Proceedings
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, Merck Sharp & Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) were defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.
As previously disclosed, in April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck agreed to pay $572.5 million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs’ claims, which was recorded as an expense in the Company’s financial results in the first quarter of 2023. In October 2023, the court granted final approval of the indirect purchaser class settlement.
In 2020 and 2021, United Healthcare Services, Inc. (United Healthcare), Humana Inc. (Humana), Centene Corporation and others (Centene), and Kaiser Foundation Health Plan, Inc. (Kaiser) (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases were transferred to the Eastern District of Virginia to proceed with the Zetia MDL.
In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. In December 2023, prior to a decision on the motion to dismiss, the U.S. Judicial Panel on Multidistrict Litigation remanded the four Insurer Plaintiff cases to the transferor courts in the Northern District of California (Kaiser), the District of Minnesota (United Healthcare), and the District of New Jersey (Humana and Centene). On March 15, 2024, the Merck Defendants filed motions to dismiss the Humana and Centene cases.
Qui Tam Litigation
As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company’s M-M-R II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In July 2023, the court denied relators’ motion for summary judgment, granted two of the Company’s motions for summary judgment, and denied the Company’s remaining motions for summary judgment as moot. The court entered judgment in favor of the Company and dismissed relators’ amended complaint in full with prejudice. Relators have appealed that decision. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the M-M-R II vaccine, which charge that the Company misrepresented the efficacy of the M-M-R II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In the antitrust case, the court granted the Company’s motion for summary judgment as to plaintiffs’ state law claims and denied the motion as to plaintiffs’ antitrust claim. The Company has appealed the antitrust decision.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.
- 19 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Bridion — As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies had filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey were consolidated. The West Virginia case was jointly dismissed with prejudice in August 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action stipulated to infringement of the asserted claims and withdrew all remaining claims and defenses other than a defense seeking to shorten the patent term extension (PTE) of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial in December 2022 on this remaining PTE calculation defense.
As previously disclosed, in June 2023, the U.S. District Court for the District of New Jersey ruled in Merck’s favor. The court held that Merck’s calculation of PTE for the sugammadex patent covering the compound is not invalid and that the U.S. Patent & Trademark Office correctly granted a full five-year extension. This ruling affirms and validates Merck’s U.S. patent protection for Bridion through at least January 2026. Also in June 2023, the U.S. District Court for the District of New Jersey issued a final judgment prohibiting the FDA from approving any of the pending or tentatively approved generic applications until January 27, 2026, except for any subsequent agreements between defendants and Merck or further order by the court.
In July 2023, defendants filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit. The appeal is currently pending.
While the New Jersey action was pending, the Company settled with five generic companies providing that these generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric exclusivity.
On February 5, 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Hikma Pharmaceuticals USA Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell a generic version of Bridion Injection. On March 15, 2024, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Hikma, postponing FDA approval of the Hikma generic drug for 30 months or until expiration of the sugammadex patent (January 27, 2026) and any potentially applicable pediatric exclusivity or an adverse court decision, if any, whichever may occur earlier. Expiration of the patent, and any potentially applicable pediatric exclusivity, will occur earlier than expiry of the 30-month stay.
Januvia, Janumet, Janumet XR — As previously disclosed, the FDA granted pediatric exclusivity with respect to Januvia (sitagliptin), Janumet (sitagliptin/metformin HCI), and Janumet XR (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent).
As previously disclosed, beginning in 2019, a number of generic drug companies filed ANDAs seeking approval of generic forms of Januvia and Janumet along with paragraph IV certifications challenging the validity of the 2027 salt/polymorph patent. The Company responded by filing infringement suits which have all been settled. The Company has settled with a total of 26 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the market in the U.S. in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in July 2026 or earlier under certain circumstances.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of a form of sitagliptin that is a different form than that used in Januvia. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product.
In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA’s Orange Book for Janumet will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Janumet. In November 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl Extended Release tablets. In January 2024, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable version containing a different form of sitagliptin than that used in Janumet XR.
- 20 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
As a result of these settlement agreements related to the later expiring 2027 salt/polymorph patent directed to the specific sitagliptin salt form of the products, the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although Zydus has received FDA approval for a non-automatically substitutable form of sitagliptin that differs from the form in the Company’s sitagliptin products.
Supplementary Protection Certificates (SPCs) for Janumet expired in April 2023 for the majority of European countries. Prior to expiration, generic companies sought revocation of the Janumet SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the Janumet SPCs in Europe, for which an oral hearing was held in March 2023 and an Advocate General Opinion is expected in June 2024 with a decision later in 2024. If the CJEU renders a decision that negatively impacts the validity of the Janumet SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the Janumet SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the Janumet SPC.
In October 2023, the Company filed a patent infringement lawsuit against Sawai Pharmaceuticals Co., Ltd. and Medisa Shinyaku Co., Ltd (collectively, Defendants) in the Tokyo District Court seeking an injunction to stop the manufacture, sale and offer for sale of the Defendants’ sitagliptin dihydrogen phosphate product, while the Company’s patents and patent term extensions are in force. The lawsuit is in response to the Defendants’ application for marketing authorization to sell a generic sitagliptin dihydrogen phosphate product, in the anhydrate form, which was approved on August 15, 2023. Merck asserts that the Defendants’ activity infringes a patent term extension associated with Merck’s patent directed to the sitagliptin compound patent.
Keytruda — As previously disclosed, in November 2022, the Company filed a complaint against The Johns Hopkins University (JHU) in the U.S. District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name Keytruda. Merck and JHU partnered to design and conduct a clinical study administering Keytruda to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract, declaratory judgment of noninfringement, and promissory estoppel. JHU answered the complaint in April and May 2023, denying Merck’s claims, and counterclaiming for willful infringement of nine issued U.S. patents, including a demand for damages. Between November 30, 2023, and March 13, 2024, the Company filed inter partes review petitions with the United States Patent & Trademark Office Patent Trial and Appeal Board, challenging the validity of all nine patents asserted in the case.
Lynparza — In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey/Delaware against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.
In December 2023, AstraZeneca Pharmaceuticals LP received a second Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Sandoz Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Sandoz. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2026 or until an adverse court decision, if any, whichever may occur earlier.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials; and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March 31, 2024 and December 31, 2023 of approximately $220 million and $210 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
- 21 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
8.    Equity
Three Months Ended March 31,
   Common StockOther
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		 Treasury StockNon-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 2023
3,577 $1,788 $44,379 $61,081 $(4,768)1,039 $(56,489)$67 $46,058 
Net income attributable to Merck & Co., Inc.— — — 2,821 — — — — 2,821 
Other comprehensive loss, net of taxes— — — — (115)— — — (115)
Cash dividends declared on common stock ($0.73 per share)
— — — (1,863)— — — — (1,863)
Treasury stock shares purchased— — — — — 1 (149)— (149)
Share-based compensation plans and other— — 88 — — — 61 — 149 
Net income attributable to noncontrolling interests— — — — — — — 4 4 
Balance at March 31, 20233,577 $1,788 $44,467 $62,039 $(4,883)1,040 $(56,577)$71 $46,905 
Balance at January 1, 2024
3,577 $1,788 $44,509 $53,895 $(5,161)1,045 $(57,450)$54 $37,635 
Net income attributable to Merck & Co., Inc.— — — 4,762 — — — — 4,762 
Other comprehensive loss, net of taxes
— — — — (113)— — — (113)
Cash dividends declared on common stock ($0.77 per share)
— — — (1,960)— — — — (1,960)
Treasury stock shares purchased— — — — — 1 (122)— (122)
Share-based compensation plans and other— — 89 — — (2)127 1 217 
Net income attributable to noncontrolling interests— — — — — — — 5 5 
Balance at March 31, 20243,577 $1,788 $44,598 $56,697 $(5,274)1,044 $(57,445)$60 $40,424 
9.    Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: 
  Three Months Ended
March 31,
20242023
($ in millions)U.S.InternationalU.S.International
Service cost$86 $61 $76 $49 
Interest cost134 74 133 74 
Expected return on plan assets(207)(139)(187)(128)
Amortization of unrecognized prior service credit
— (3)— (3)
Net loss (gain) amortization
10 1 — (1)
Termination benefits3 — — — 
Curtailments— — 2 — 
Settlements— — 21 — 
 $26 $(6)$45 $(9)
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
March 31,
($ in millions)20242023
Service cost$8 $8 
Interest cost14 16 
Expected return on plan assets(20)(16)
Amortization of unrecognized prior service credit(11)(12)
Net gain amortization(12)(11)
 $(21)$(15)
- 22 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of $21 million in the first quarter of 2023. This partial settlement triggered a remeasurement of some of the Company’s U.S. pension plans. The remeasurement, which was calculated using discount rates and asset values as of March 31, 2023, resulted in a net increase of $44 million to net pension liabilities and also resulted in a related adjustment to AOCL.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 10), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement related to restructuring actions.
10.    Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
March 31,
($ in millions)20242023
Interest income$(73)$(112)
Interest expense303 242 
Exchange losses83 61 
Income from investments in equity securities, net (1)
(143)(450)
Net periodic defined benefit plan (credit) cost other than service cost(160)(115)
Other, net(43)463 
 $(33)$89 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
Other, net (as reflected in the table above) in the first three months of 2023 includes a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 7).
Interest paid for the three months ended March 31, 2024 and 2023 was $217 million and $208 million, respectively.
11.    Income Taxes
The effective income tax rate of 15.9% for the first quarter of 2024 reflects a 1.6 percentage point unfavorable discrete impact of a charge for the acquisition of Harpoon for which no tax benefit was recognized. The effective income tax rate of 22.6% for the first quarter of 2023 reflects a 5.5 percentage point unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized.
The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the Tax Cuts and Jobs Act of 2017. If the IRS disagrees with the Company’s transition tax position, it may result in a significant tax liability. The statute of limitations for assessments with respect to the 2019 and 2020 federal return years will expire in June and October of 2024, respectively, unless extended.
12.    Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
March 31,
($ and shares in millions except per share amounts)20242023
Net Income Attributable to Merck & Co., Inc.$4,762 $2,821 
Average common shares outstanding2,533 2,538 
Common shares issuable (1)
11 13 
Average common shares outstanding assuming dilution 2,544 2,551 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders$1.88 $1.11 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$1.87 $1.11 
(1)    Issuable primarily under share-based compensation plans.
- 23 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
For the first quarter of 2024 and 2023, 3 million and 1 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computations of earnings per common share assuming dilution because the effect would have been antidilutive.
13.    Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended March 31,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance January 1, 2023, net of taxes
$73 $(2,408)$(2,433)$(4,768)
Other comprehensive income (loss) before reclassification adjustments, pretax(66)(47)79 (34)
Tax14 2 (20)(4)
Other comprehensive income (loss) before reclassification adjustments, net of taxes(52)(45)59 (38)
Reclassification adjustments, pretax(102)
(1)
(7)
(2)
9 (100)
Tax21 2 — 23 
Reclassification adjustments, net of taxes(81)

(5)

9 (77)
Other comprehensive income (loss), net of taxes(133)(50)68 (115)
Balance March 31, 2023, net of taxes
$(60)$(2,458)$(2,365)$(4,883)
Balance January 1, 2024, net of taxes
$(24)$(2,793)$(2,344)$(5,161)
Other comprehensive income (loss) before reclassification adjustments, pretax209 5 (225)(11)
Tax(44)(4)(13)(61)
Other comprehensive income (loss) before reclassification adjustments, net of taxes165 1 (238)(72)
Reclassification adjustments, pretax(44)
(1)
(15)
(2)
— (59)
Tax9 9 — 18 
Reclassification adjustments, net of taxes(35)

(6)

— (41)
Other comprehensive income (loss), net of taxes130 (5)(238)(113)
Balance March 31, 2024, net of taxes
$106 $(2,798)$(2,582)$(5,274)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 9).

14.    Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.

- 24 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Sales of the Company’s products were as follows:
Three Months Ended March 31,
20242023
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$4,119 $2,828 $6,947 $3,485 $2,310 $5,795 
Alliance revenue-Lynparza (1)
135 157 292 142 133 275 
Alliance revenue-Lenvima (1)
173 82 255 153 79 232 
Welireg77 7 85 41 1 42 
Alliance revenue-Reblozyl (2)
58 12 71 30 12 43 
Vaccines
Gardasil/Gardasil 9
488 1,761 2,249 416 1,556 1,972 
ProQuad/M-M-R II/Varivax
438 133 570 421 107 528 
Vaxneuvance161 58 219 94 13 106 
RotaTeq149 67 216 180 117 297 
Pneumovax 23
6 55 61 40 56 96 
Hospital Acute Care
Bridion329 111 440 276 210 487 
Prevymis74 100 174 54 75 129 
Dificid68 5 73 62 3 65 
Zerbaxa33 23 56 27 23 50 
Noxafil8 48 56 14 46 60 
Cardiovascular
Alliance revenue-Adempas/Verquvo (3)
90 8 98 83 16 99 
Adempas— 70 70 — 59 59 
Virology
Lagevrio45 305 350 (2)394 392 
Isentress/Isentress HD
50 61 111 52 71 123 
Delstrigo
12 44 56 11 33 44 
Pifeltro
29 13 42 24 10 34 
Neuroscience
Belsomra15 32 46 16 40 56 
Immunology
Simponi— 184 184 — 180 180 
Remicade— 39 39 — 51 51 
Diabetes
Januvia183 236 419 271 280 551 
Janumet39 212 251 56 272 329 
Other pharmaceutical (4)
157 419 576 171 457 626 
Total Pharmaceutical segment sales6,936 7,070 14,006 6,117 6,604 12,721 
Animal Health:
Livestock166 683 850 174 676 849 
Companion Animal308 354 661 308 334 642 
Total Animal Health segment sales474 1,037 1,511 482 1,010 1,491 
Total segment sales7,410 8,107 15,517 6,599 7,614 14,212 
Other (5)
68 190 258 60 214 275 
 $7,478 $8,297 $15,775 $6,659 $7,828 $14,487 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue for Reblozyl represents royalties (see Note 3).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $54 million and $99 million for the three months ended March 31, 2024 and 2023, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2024 and 2023 also includes $61 million and $51 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.

- 25 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.2 billion and $3.1 billion for the three months ended March 31, 2024 and 2023, respectively.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
March 31,
($ in millions)20242023
United States$7,478 $6,659 
Europe, Middle East and Africa3,563 3,303 
China1,772 1,715 
Japan821 758 
Latin America796 661 
Asia Pacific (other than China and Japan)724 846 
Other621 545 
 $15,775 $14,487 
A reconciliation of segment profits to Income Before Taxes is as follows:
 Three Months Ended
March 31,
($ in millions)20242023
Segment profits:
Pharmaceutical segment$10,904 $9,140 
Animal Health segment555 566 
Total segment profits11,459 9,706 
Other profits146 164 
Unallocated:
Interest income73 112 
Interest expense(303)(242)
Amortization(473)(543)
Depreciation(452)(398)
Research and development(3,851)(4,147)
Restructuring costs(123)(67)
Charge for Zetia antitrust litigation settlements— (573)
Other unallocated, net(806)(362)
 $5,670 $3,650 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and amortization of purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits (losses) related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.


- 26 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Business Development Transactions
Below is a summary of significant business development activity thus far in 2024.
In March 2024, Merck acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases, for $765 million and also incurred $56 million of transaction costs. Harpoon’s lead candidate, MK-6070 (formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small-cell lung cancer (SCLC) and neuroendocrine tumors. MK-6070 is currently being evaluated as monotherapy in a Phase 1/2 clinical trial in certain patients with advanced cancers associated with expression of DLL3. The study is also evaluating MK-6070 in combination with atezolizumab in certain patients with SCLC. The transaction was accounted for as an asset acquisition. Merck recorded net assets of $165 million, as well as a charge of $656 million, or $0.26 per share, to Research and development expenses in the first quarter of 2024 related to the transaction. There are no future contingent payments associated with the acquisition.
In February 2024, Merck entered into a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (Elanco) for $1.3 billion in cash. The Elanco aqua business to be acquired consists of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. Upon closing, the acquisition will broaden Animal Health’s aqua portfolio with products, such as Clynav, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic sea lice treatment. This acquisition also brings a portfolio of water treatment products for warm water production, complementing Animal Health’s warm water vaccine portfolio. In addition to these products, the DNA-based vaccine technology that is a part of the business has the potential to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. The acquisition is expected to be completed by mid-2024, subject to approvals from regulatory authorities and other customary closing conditions. The transaction will be accounted for as a business combination.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In 2021, the U.S. Congress passed the American Rescue Plan Act, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. Accordingly, manufacturers may have to pay state Medicaid programs more in rebates than they receive on sales of particular products. As a result of this provision, the Company has recognized increased discounts for Januvia (sitagliptin) and Janumet (sitagliptin and metformin HCl) in the first three months of 2024. In 2022, the U.S. Congress passed the Inflation Reduction Act (IRA), which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs (starting in 2026) and Medicare Part B drugs (starting in 2028). In August 2023, the U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), announced that Januvia would be included in the first year of the IRA’s “Drug Price Negotiation Program” (Program). Pursuant to the IRA’s Program, discussions with the government occurred in 2023 and will continue in 2024, with government price-setting becoming effective on January 1, 2026. The Company has sued the U.S. government regarding the IRA’s Program. Furthermore, the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in the first three months of 2024 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.
Operating Results
Sales
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20242023% Change
United States$7,478 $6,659 12 %12 %
International8,297 7,828 6 %12 %
Total$15,775 $14,487 9 %12 %
Worldwide sales were $15.8 billion in the first quarter of 2024, an increase of 9% compared with the first quarter of 2023, or 12% excluding the unfavorable effect of foreign exchange. Approximately 2 percentage points of the negative impact of foreign exchange was due to the devaluation of the Argentine peso, which was largely offset by inflation-related price increases consistent with practice in that market. Global sales growth in the first quarter of 2024 was primarily due to higher sales in the
- 27 -

oncology franchise, largely due to strong growth of Keytruda (pembrolizumab) and Welireg (belzutifan). Higher sales in the vaccines franchise also contributed to revenue growth in the first quarter, primarily attributable to increased combined sales of Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)/Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and the ongoing launch of Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for pediatric use, partially offset by lower sales of RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent) and Pneumovax 23 (pneumococcal vaccine polyvalent). Revenue growth in the first quarter of 2024 was partially offset by lower sales in the diabetes franchise attributable to Januvia and Janumet.
See Note 14 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows. All product or service marks appearing in type form different from that of the surrounding text are trademarks or service marks owned, licensed to, promoted or distributed by Merck, its subsidiaries or affiliates, except as noted. All other trademarks or services marks are those of their respective owners.
Pharmaceutical Segment
Oncology
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20242023% Change
Keytruda$6,947 $5,795 20 %24 %
Alliance Revenue - Lynparza (1)
292 275 6 %7 %
Alliance Revenue - Lenvima (1)
255 232 10 %10 %
Welireg85 42 **
Alliance Revenue - Reblozyl (2)
71 43 66 %66 %
* > 100%
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
(2)    Alliance revenue for Reblozyl represents royalties (see Note 3 to the condensed consolidated financial statements).
Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved in over 35 indications in the U.S., including 17 tumor types and 2 tumor-agnostic indications, and has similarly been approved in markets worldwide for many of these indications. The Keytruda clinical development program includes studies across a broad range of cancer types. See “Research and Development Update” below.
Global sales of Keytruda grew 20% in the first quarter of 2024, or 24% excluding the unfavorable effect of foreign exchange. Substantially all of the 4% negative impact of foreign exchange was due to the devaluation of the Argentine peso, which was largely offset by inflation-related price increases consistent with practice in that market. Keytruda sales growth in the first quarter 2024 was primarily driven by higher demand reflecting the launch of multiple new indications globally coupled with continued uptake in existing indications. Sales growth in the U.S. reflects increased uptake across earlier-stage indications including in certain types of non-small-cell lung cancer (NSCLC), high-risk early-stage triple-negative breast cancer (TNBC), as well as certain types of renal cell carcinoma (RCC), and higher demand across the multiple approved metastatic indications, in particular for the treatment of certain types of urothelial, endometrial, microsatellite instability-high (MSI-H) and renal cell cancers, as well as higher pricing. Keytruda sales growth in international markets reflects higher demand predominately for the TNBC and RCC earlier-stage indications, as well as uptake in head and neck squamous cell carcinoma and RCC metastatic indications, particularly in Europe and Latin America.
Keytruda received the following regulatory approvals thus far in 2024.
DateApproval
January 2024
U.S. Food and Drug Administration (FDA) approval in combination with chemoradiotherapy for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer, based on the KEYNOTE-A18 trial.
January 2024FDA full approval for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1 containing regimen. The conversion from an accelerated to full (regular) approval is based on the KEYNOTE-394 trial.
February 2024
China’s National Medical Products Administration approval in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic biliary tract carcinoma, based on the KEYNOTE-966 trial.
March 2024
European Commission (EC) approval in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable NSCLC at high risk of recurrence in adults, based on the KEYNOTE-671 trial.
The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of Keytruda. Under the terms of the more significant of these agreements, Merck paid a royalty of 6.5% on worldwide sales of Keytruda through December 2023 to one third party; this royalty declined to 2.5% in 2024 and will continue through 2026, terminating thereafter. The Company pays an additional 2% royalty on worldwide sales of Keytruda to another third party, the
- 28 -

termination date of which varies by country; this royalty will expire in the U.S. in September 2024 and on varying dates in major European markets in the second half of 2025. The royalty expenses are included in Cost of sales.
Lynparza (olaparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note 3 to the condensed consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers. Alliance revenue related to Lynparza increased 6% in the first quarter of 2024 primarily driven by higher demand in certain international markets, particularly in Latin America.
Lenvima (lenvatinib) is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 3 to the condensed consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with Keytruda for certain patients with advanced endometrial carcinoma or advanced RCC. Alliance revenue related to Lenvima grew 10% in the first quarter of 2024 primarily reflecting higher demand in the U.S.
Sales of Welireg, for the treatment of adult patients with certain von Hippel-Lindau (VHL) disease-associated tumors and certain adult patients with previously treated advanced RCC, more than doubled in the first quarter of 2024 due to higher demand in the U.S. for the treatment of VHL disease-associated tumors and uptake in a supplemental indication approved by the FDA in December 2023 for previously treated advanced RCC. Welireg is under review in the European Union (EU) for the treatment of previously treated advanced RCC based on the LITESPARK-005 clinical trial and for the treatment of VHL disease based on the LITESPARK-004 clinical trial.
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS) (see Note 3 to the condensed consolidated financial statements). Reblozyl is approved for the treatment of anemia in certain rare blood disorders. Alliance revenue related to this collaboration (consisting of royalties) increased 66% in the first quarter of 2024 due to strong underlying sales performance.
Vaccines
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20242023% Change
Gardasil/Gardasil 9
$2,249 $1,972 14 %17 %
ProQuad204 190 8 %7 %
M-M-R II
104 102 2 %2 %
Varivax262 236 11 %11 %
Vaxneuvance219 106 **
RotaTeq216 297 (27)%(27)%
Pneumovax 2361 96 (36)%(33)%
* > 100%
Combined worldwide sales of Gardasil and Gardasil 9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 14% in the first quarter of 2024 primarily due to strong demand, particularly in China, which also benefited from the timing of shipments, as well as public sector buying patterns in the U.S., and higher pricing.
The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of Gardasil/Gardasil 9. Under the terms of the more significant of these agreements, Merck pays a 7% royalty on sales of Gardasil/Gardasil 9 in the U.S. to one third party (this royalty expires in December 2028); Merck paid an additional 7% royalty on worldwide sales of Gardasil/Gardasil 9 to another third party, which expired in December 2023. The royalty expenses are included in Cost of sales.
Global sales of ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, grew 8% in the first quarter of 2024 primarily reflecting higher pricing in the U.S. and higher demand in certain ex-U.S. markets.
Worldwide sales of M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help prevent measles, mumps and rubella, were nearly flat in the first quarter of 2024.
Global sales of Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), increased 11% in the first quarter of 2024 primarily attributable to higher pricing in the U.S. and higher sales in Latin America due in part to the timing of government tenders.
Worldwide sales of Vaxneuvance, a vaccine to help protect against invasive pneumococcal disease, more than doubled in the first quarter of 2024 primarily reflecting continued uptake in the pediatric indication in the U.S. and Europe, as well as new market launches. Sales growth in the U.S. also reflects the beneficial impact of public sector buying patterns.
- 29 -

Global sales of RotaTeq, a vaccine to help protect against rotavirus gastroenteritis in infants and children, declined 27% in the first quarter of 2024 primarily due to lower sales in China reflecting first quarter 2023 inventory stocking, as well as lower sales in the U.S. due to public sector buying patterns.
Worldwide sales of Pneumovax 23, a vaccine to help prevent pneumococcal disease, declined 36% in the first quarter of 2024 largely due to lower demand in the U.S. as the market has shifted toward newer adult pneumococcal conjugate vaccines following changes in the recommendations of the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices in 2021.
Hospital Acute Care
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20242023% Change
Bridion$440 $487 (10)%(8)%
Prevymis174 129 35 %39 %
Worldwide sales of Bridion (sugammadex), for the reversal of two types of neuromuscular blocking agents used during surgery, declined 10% in the first quarter of 2024 driven by lower demand in certain ex-U.S. markets due to generic competition, particularly in the EU, partially offset by higher demand in the U.S. The patent that provided market exclusivity for Bridion in the EU expired in July 2023. Accordingly, the Company is experiencing sales declines of Bridion in these markets and expects the declines to continue. The patent that provided market exclusivity for Bridion in Japan expired in January 2024; the Company anticipates sales of Bridion in Japan will decline in future periods.
Worldwide sales of Prevymis (letermovir), a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in certain high risk adult recipients of an allogenic hematopoietic stem cell transplant and for prophylaxis of CMV disease in certain high risk adult recipients of a kidney transplant, grew 35% in the first quarter of 2024 largely due to higher global demand, particularly in the U.S. and China.
Cardiovascular
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20242023% Change
Alliance Revenue - Adempas/Verquvo (1)
$98 $99 (1)%(1)%
Adempas70 59 18 %18 %
(1) Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
Adempas (riociguat) and Verquvo (vericiguat) are part of a worldwide collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators (see Note 3 to the condensed consolidated financial statements). Adempas is approved for the treatment of certain types of pulmonary arterial hypertension (PAH) and chronic pulmonary hypertension (PH). Verquvo is approved to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Alliance revenue from the collaboration in the first quarter of 2024 was nearly flat compared with the corresponding prior year period. Revenue also includes sales of Adempas and Verquvo in Merck’s marketing territories. Sales of Adempas in Merck’s marketing territories grew 18% in the first quarter of 2024 primarily due to higher demand.
In March 2024, the FDA approved Winrevair (sotatercept-csrk) for the treatment of adults with PAH (World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. The approval is based on the STELLAR trial. Winrevair is the subject of a licensing agreement with Bristol-Myers Squibb Company (BMS) and Merck will pay 22% royalties on sales of Winrevair in the PH field to BMS.
Virology
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20242023% Change
Lagevrio$350 $392 (11)%(5)%
Lagevrio is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback Biotherapeutics LP (Ridgeback) (see Note 3 to the condensed consolidated financial statements). Sales of Lagevrio declined 11% in the first quarter of 2024 primarily due to lower demand in certain markets in the Asia Pacific region, partially offset by sales in the U.S. and higher demand in Japan.

- 30 -

Immunology
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20242023% Change
Simponi
$184 $180 2 %1 %
Remicade
39 51 (24)%(21)%
Simponi (golimumab) and Remicade (infliximab) are treatments for certain inflammatory diseases that the Company markets in Europe, Russia and Türkiye. The Company’s marketing rights with respect to these products will revert to Johnson & Johnson Innovative Medicine on October 1, 2024.
Diabetes
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20242023% Change
Januvia/Janumet$670 $880 (24)%(21)%
Worldwide combined sales of Januvia and Janumet, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 24% in the first quarter of 2024 primarily due to lower sales in the U.S., largely reflecting lower pricing and lower demand due to competitive pressures, as well as the ongoing impact of the loss of exclusivity in most markets in Europe and the Asia Pacific region, as well as in Canada.
The American Rescue Plan Act enacted in the U.S. in 2021 included a provision that eliminated the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. Accordingly, manufacturers may have to pay state Medicaid programs more in rebates than they receive on sales of particular products. As a result of this provision, the Company has recognized increased discounts for Januvia and Janumet in the first quarter of 2024. In August 2023, the U.S. Department of HHS, through the CMS, announced that Januvia would be included in the first year of the IRA’s Program. Pursuant to the IRA’s Program, discussions with the government occurred in 2023 and will continue in 2024, with government price-setting becoming effective on January 1, 2026. The Company has sued the U.S. government regarding the IRA’s Program.
While the key U.S. patent for Januvia and Janumet claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products (see Note 7 to the condensed consolidated financial statements), the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although a non-automatically substitutable form of sitagliptin that differs from the form in the Company’s sitagliptin products has been approved by the FDA. The Company anticipates pricing and volume declines for Januvia and Janumet in the U.S. for the remainder of 2024.
The Company lost market exclusivity for Januvia in all of the EU and for Janumet in some European countries in September 2022. Exclusivity for Janumet was lost in other European countries in April 2023. Accordingly, the Company is experiencing sales declines in these markets and expects the declines to continue. Generic equivalents of Januvia and Janumet have also launched in China.
Animal Health Segment
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20242023% Change
Livestock$850 $849 — %4 %
Companion Animal661 642 3 %4 %
$1,511 $1,491 1 %4 %
Animal Health sales grew 1% in the first quarter of 2024, or 4% excluding the unfavorable impact of foreign exchange. Approximately 3 percentage points of the negative impact of foreign exchange was due to the devaluation of the Argentine peso, which was largely offset by inflation-related price increases consistent with practice in that market. Sales of livestock products were nearly flat in the first quarter of 2024 primarily due to higher pricing, as well as increased demand for swine and poultry products, partially offset by lower demand for ruminant products. Sales of companion animal products grew 3% in the first quarter of 2024 due to higher pricing. Sales of Bravecto (fluralaner), a line of oral and topical parasitic control products, were $332 million for the first quarter of 2024, representing growth of 6% compared with the corresponding prior year period, or 7% excluding the unfavorable effect of foreign exchange.
In February 2024, Merck entered into a definitive agreement to acquire the aqua business of Elanco for $1.3 billion in cash. See “Business Development Transactions” above for additional information related to this transaction.

- 31 -

Costs, Expenses and Other
Three Months Ended
March 31,
($ in millions)20242023% Change
Cost of sales$3,540 $3,926 (10)%
Selling, general and administrative2,483 2,479 — %
Research and development3,992 4,276 (7)%
Restructuring costs123 67 84 %
Other (income) expense, net(33)89 *
$10,105 $10,837 (7)%
* > 100%
Cost of Sales
Cost of sales declined 10% in the first quarter of 2024. Cost of sales includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and licensing arrangements, which totaled $462 million and $532 million in the first quarter of 2024 and 2023, respectively. Amortization expense in the first quarter of 2023 includes $72 million of cumulative catch-up amortization related to Merck’s collaboration with Eisai. See Note 3 to the condensed consolidated financial statements for more information on Merck’s collaborative arrangements. Also included in cost of sales are expenses associated with restructuring activities, which amounted to $116 million and $29 million in the first quarter of 2024 and 2023, respectively, primarily reflecting accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in Restructuring costs as discussed below.
Gross margin was 77.6% in the first quarter of 2024 compared with 72.9% in the first quarter of 2023. The gross margin improvement was primarily due to the favorable effects of product mix (including lower royalty rates related to Keytruda and Gardasil/Gardasil 9 sales), foreign exchange and lower amortization of intangible assets, partially offset by higher restructuring costs and inventory write-offs.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses were nearly flat in the first quarter of 2024 primarily due to higher administrative costs, largely offset by lower promotional spending, reflecting the prioritization of spending on key growth products, and the favorable effect of foreign exchange.
Research and Development
Research and development (R&D) expenses declined 7% in the first quarter of 2024 primarily due to lower charges for business development transactions, which included a $656 million charge for the acquisition of Harpoon in the first quarter of 2024, compared with charges of $1.2 billion for the acquisition of Imago and $175 million for a license and collaboration agreement with Kelun-Biotech in the first quarter of 2023. The decline was partially offset by higher compensation and benefit costs, increased clinical development spending, and higher investments in discovery research and early drug development in the first quarter of 2024.
R&D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $2.4 billion and $2.1 billion for the first quarter of 2024 and 2023, respectively. Also included in R&D expenses are Animal Health research costs, upfront payments for collaboration and licensing agreements, charges for transactions accounted for as asset acquisitions (including the charges for the Harpoon and Imago acquisitions as noted above), and costs incurred by other divisions in support of R&D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $1.6 billion and $2.2 billion for the first quarter of 2024 and 2023, respectively.
Restructuring Costs
In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company expects to record charges of approximately $800 million in 2024 related to the 2024 Restructuring Program. The Company anticipates the actions under the 2024 Restructuring Program will result in cumulative annual net cost savings of approximately $750 million by the end of 2031.
In 2019, Merck approved a global restructuring program (2019 Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate
- 32 -

footprint. The actions under the 2019 Restructuring Program were substantially complete at the end of 2023 and, as of January 1, 2024, any remaining activities are now being accounted for as part of the 2024 Restructuring Program.
Restructuring costs, primarily representing separation and other costs associated with these restructuring activities, were $123 million and $67 million for the first quarter of 2024 and 2023, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for involuntary headcount reductions that were probable and could be reasonably estimated. Other expenses in Restructuring costs include facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in Cost of sales, Selling, general and administrative expenses and Research and development costs. The Company recorded aggregate pretax costs of $246 million and $97 million in the first quarter of 2024 and 2023, respectively, related to restructuring program activities (see Note 4 to the condensed consolidated financial statements).
Other (Income) Expense, Net
Other (income) expense, net, was $33 million of income in the first quarter of 2024 compared with $89 million of expense in the first quarter of 2023. The favorability was primarily due to a $572.5 million charge in 2023 related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 7 to the condensed consolidated financial statements), partially offset by lower income from investments in equity securities and higher interest expense in 2024.
For details on the components of Other (income) expense, net, see Note 10 to the condensed consolidated financial statements.
Segment Profits
 Three Months Ended
March 31,
($ in millions)20242023
Pharmaceutical segment profits$10,904 $9,140 
Animal Health segment profits555 566 
Other(5,789)(6,056)
Income Before Taxes$5,670 $3,650 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&A and R&D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&D expenses incurred by MRL, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition- and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements.
Pharmaceutical segment profits grew 19% in the first quarter of 2024 primarily due to higher sales, partially offset by higher administrative and promotional costs, as well as the unfavorable effect of foreign exchange. Animal Health segment profits declined 2% in the first quarter of 2024 reflecting higher production costs, increased administrative and promotional costs, as well as the unfavorable effect of foreign exchange.
Taxes on Income
The effective income tax rate of 15.9% for the first quarter of 2024 reflects a 1.6 percentage point unfavorable discrete impact of a charge for the acquisition of Harpoon for which no tax benefit was recognized. The effective income tax rate of 22.6% for the first quarter of 2023 reflects a 5.5 percentage point unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized.
While many jurisdictions in which Merck operates have adopted the global minimum tax provision of the Organisation for Economic Co-operation and Development (OECD) Pillar 2, effective for tax years beginning in January 2024, the Company anticipates there will be a reduced impact to its 2024 tax rate due to the accounting for the tax effects of intercompany transactions. The Company expects the impact of the global minimum tax will increase its tax rate to a greater extent in 2025 and thereafter. Also, in the event that the provision of the Tax Cuts and Jobs Act of 2017 requiring capitalization and amortization of R&D expenses for tax purposes is repealed along the lines recently proposed in the Tax Relief for American Families and
- 33 -

Workers Act of 2024, the Company will again be able to realize the benefit of U.S. R&D expenses as incurred but expects no material impact to its effective income tax rate.
Non-GAAP Income and Non-GAAP EPS
Non-GAAP income and non-GAAP EPS are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items. These excluded items are significant components in understanding and assessing financial performance.
Non-GAAP income and non-GAAP EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP).
A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:
Three Months Ended
March 31,
($ in millions except per share amounts)20242023
Income before taxes as reported under GAAP$5,670 $3,650 
Increase (decrease) for excluded items:
Acquisition- and divestiture-related costs496 590 
Restructuring costs246 97 
Income from investments in equity securities, net(116)(429)
Other items:
Charge for Zetia antitrust litigation settlements— 573 
Non-GAAP income before taxes6,296 4,481 
Income tax provision as reported under GAAP903 825 
Estimated tax benefit on excluded items (1)
109 88 
Non-GAAP income tax provision1,012 913 
Non-GAAP net income
5,284 3,568 
Less: Net income attributable to noncontrolling interests as reported under GAAP5 4 
Non-GAAP net income attributable to Merck & Co., Inc.
$5,279 $3,564 
EPS assuming dilution as reported under GAAP (2)
$1.87 $1.11 
EPS difference0.20 0.29 
Non-GAAP EPS assuming dilution (2)
$2.07 $1.40 
(1)    The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
(2)    GAAP and non-GAAP EPS were negatively affected in the first quarter of 2024 and 2023 by $0.26 per share and $0.52 per share, respectively, of charges for certain upfront payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions.
Acquisition- and Divestiture-Related Costs
Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.
Restructuring Costs
Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 4 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related
- 34 -

costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.
Income and Losses from Investments in Equity Securities
Non-GAAP income and non-GAAP EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Certain Other Items
Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2023 is a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 7 to the condensed consolidated financial statements).
Research and Development Update
The Company currently has several candidates under regulatory review in the U.S. and internationally.
MK-1022, patritumab deruxtecan, a potential first-in-class HER3 directed DXd antibody drug conjugate (ADC), is under priority review by the FDA for the treatment of adult patients with locally advanced or metastatic EGFR-mutated NSCLC previously treated with two or more systemic therapies. The Biologics License Application (BLA) is based on the primary results from the HERTHENA-Lung01 pivotal Phase 2 trial and data results presented at the IASLC 2023 World Conference on Lung Cancer, which were simultaneously published in the Journal of Clinical Oncology. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 26, 2024 for the BLA. The priority review follows receipt of Breakthrough Therapy designation granted by the FDA in December 2021. The BLA is being reviewed under the Real-Time Oncology Review program. Patritumab deruxtecan (HER3-DXd) was discovered by Daiichi Sankyo and is being jointly developed by Daiichi Sankyo and Merck.
V116, the Company’s investigational 21-valent pneumococcal conjugate vaccine designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia in adults, is under priority review by the FDA. The BLA for V116 is supported by results from multiple Phase 3 clinical studies evaluating V116 in both vaccine-naïve and vaccine-experienced adult patient populations, including STRIDE-3, STRIDE-4, STRIDE-5 and STRIDE-6. The FDA set a PDUFA date of June 17, 2024. V116 was granted Breakthrough Therapy designation from the FDA for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. V116 is also under review in the EU.
MK-7962, Winrevair (sotatercept-csrk), Merck’s novel activin signaling inhibitor, is under review in the EU for the treatment of adult patients with PAH (WHO Group 1). The application is based on the results from the Phase 3 STELLAR trial. Winrevair was granted Priority Medicines (PRIME) scheme and Orphan Drug designation by the European Medicines Agency for the treatment of PAH.
MK-7264, gefapixant, is a non-narcotic, oral selective P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough in adults. In December 2023, the FDA issued a second Complete Response Letter (CRL) regarding the resubmission of Merck’s New Drug Application for gefapixant. In the CRL, the FDA concluded that Merck’s application did not meet substantial evidence of effectiveness for treating refractory chronic cough and unexplained chronic cough. The CRL was not related to the safety of gefapixant. Merck is reviewing the FDA’s feedback to determine next steps.
MK-3475, Keytruda, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These studies encompass more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.
Keytruda is under priority review by the FDA in combination with chemotherapy (carboplatin and paclitaxel), followed by Keytruda as a single agent for the treatment of patients with primary advanced or recurrent endometrial carcinoma, based on the KEYNOTE-868 trial. The FDA set a PDUFA date of June 21, 2024 for the supplemental BLA. KEYNOTE-868 is also under review in the EU and Japan.
In addition, Keytruda is under review in the EU and Japan in combination with Padcev (enfortumab vedotin-ejfv), an ADC, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma, based on the KEYNOTE-A39 trial that was conducted in collaboration with Seagen (now Pfizer Inc.) and Astellas.
Keytruda is also under review in the EU and Japan in combination with chemoradiotherapy for the treatment of patients with high-risk locally advanced cervical cancer, based on the KEYNOTE-A18 trial.
Keytruda is under review in Japan as part of a perioperative treatment regimen for certain patients with resectable stage II, IIIA or IIIB NSCLC based on the KEYNOTE-671 study. A perioperative treatment regimen includes treatment before surgery (neoadjuvant) and continued after surgery (adjuvant).
- 35 -

Additionally, Keytruda is under review in Japan in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, based on the KEYNOTE-859 trial.
Keytruda is also under review in Japan in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer, based on the KEYNOTE-966 trial.
Welireg is under review in the EU for the treatment of previously treated advanced RCC based on the LITEPARK-005 clinical trial and for the treatment of VHL disease based on the LITESPARK-004 clinical trial.
In March 2024, Merck announced that in the Phase 3 KEYLYNK-006 trial, Keytruda in combination with chemotherapy followed by Keytruda plus maintenance Lynparza did not meet the study’s pre-specified statistical criteria for overall survival or progression-free survival compared to Keytruda in combination with chemotherapy (pemetrexed plus carboplatin or cisplatin) followed by Keytruda plus maintenance chemotherapy (pemetrexed). A full evaluation of the data from this study is ongoing. Merck will work with investigators to share the results with the scientific community.
Also, the Company has discontinued development of MK-5475 in PAH but continues to study MK-5475 in PH associated with chronic obstructive pulmonary disease.
The chart below reflects the Company’s research pipeline as of May 1, 2024. Candidates shown in Phase 3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.
Phase 2
Cancer
MK-1022 (patritumab deruxtecan)(1)
Gastric
Melanoma
MK-1308 (quavonlimab)(2)
Non-Small-Cell Lung
MK-1308A (quavonlimab+pembrolizumab)
Colorectal
MK-2140 (zilovertamab vedotin)
Hematological Malignancies
MK-2400 (ifinatamab deruxtecan)(1)
Colorectal
Small-Cell Lung
MK-2870 (sacituzumab tirumotecan)(1)(3)
Neoplasm Malignant
MK-3475 Keytruda
Advanced Solid Tumors
Prostate
MK-3475A (pembrolizumab+hyaluronidase subcutaneous)
Cutaneous Squamous Cell
MK-4280 (favezelimab)(2)
    Non-Small-Cell Lung
MK-4280A (favezelimab+pembrolizumab)
Bladder
Cutaneous Squamous Cell
Endometrial
Esophageal
Melanoma
Renal Cell
MK-5890 (boserolimab)(2)
     Neoplasm Malignant



Cancer
MK-5909 (raludotatug deruxtecan)(1)
Ovarian
MK-6482 Welireg(3)
Endometrial
Esophageal
Hepatocellular
Prostate
Rare cancers
MK-7339 Lynparza(1)(3)
Advanced Solid Tumors
MK-7684A (vibostolimab+pembrolizumab)
Biliary
Bladder
Breast
Cervical
Colorectal
Endometrial
Esophageal
Gastric
Head and Neck
Hepatocellular
Ovarian
Prostate
Renal
V940(1)(2)
Cutaneous Squamous Cell
Bladder
Renal Cell
Cancer
MK-7902 Lenvima(1)(2)
Head and Neck
Dengue Fever Virus Vaccine
V181
HIV-1 Infection
MK-8591B (islatravir+MK-8507)(4)
MK-8591D (islatravir+lenacapavir)(1)(5)
HIV-1 Prevention
MK-8527
Nonalcoholic Steatohepatitis (NASH)
MK-6024 (efinopegdutide)
Pulmonary Hypertension-Chronic Obstructive Pulmonary Disease
MK-5475
Pulmonary Hypertension Due To Left Heart Disease
MK-7962 Winrevair
Schizophrenia
MK-8189(6)
Thrombosis
MK-2060
Vitiligo
MK-6194

- 36 -

Phase 3 (Phase 3 entry date)Under Review
Antiviral COVID-19
     MK-4482 Lagevrio (U.S.) (May 2021)(1)(7)
Cancer
MK-1022 (patritumab deruxtecan)(1)
     Non-Small-Cell Lung (May 2022) (EU)
MK-1026 (nemtabrutinib)
     Hematological Malignancies (March 2023)
MK-1308A (quavonlimab+pembrolizumab)
Renal Cell (April 2021)
MK-2870 (sacituzumab tirumotecan)(1)(3)
Breast (April 2024)
Endometrial (December 2023)
Non-Small-Cell Lung (November 2023)
MK-3475 Keytruda
Cutaneous Squamous Cell (August 2019) (EU)
Hepatocellular (May 2016) (EU)
Mesothelioma (May 2018)
Ovarian (December 2018)
Small-Cell Lung (May 2017)
MK-3475A (pembrolizumab+hyaluronidase subcutaneous)
Non-Small-Cell Lung (February 2023)
MK-3543 (bomedemstat)
Myeloproliferative Disorders (December 2023)
MK-4280A (favezelimab+pembrolizumab)
Colorectal (November 2021)
Hematological Malignancies (October 2022)
MK-5684 (opevesostat)(1)
Prostate (December 2023)
MK-7339 Lynparza(1)(2)
Non-Small-Cell Lung (June 2019)
Small-Cell Lung (December 2020)
MK-7684A (vibostolimab+pembrolizumab)
Melanoma (January 2023)
Non-Small-Cell Lung (April 2021)
Small-Cell Lung (March 2022)
MK-7902 Lenvima(1)(2)
Esophageal (July 2021)
Gastric (December 2020)
V940(1)(2)
Melanoma (July 2023)
Non-Small-Cell Lung (December 2023)
HIV-1 Infection
     MK-8591A (doravirine+islatravir) (February 2020)(5)
Hypercholesterolemia
MK-0616 (August 2023)
Respiratory Syncytial Virus
MK-1654 (clesrovimab) (November 2021)
Ulcerative Colitis
MK-7240 (tulisokibart) (October 2023)
New Molecular Entities
Cancer
MK-1022 (patritumab deruxtecan)(1)
Non-Small-Cell Lung (U.S.)
MK-6482 Welireg
Von Hippel-Lindau (VHL) Disease (EU)
Cough
MK-7264 (gefapixant) (U.S.)(8)
Pneumococcal Vaccine Adult
V116 (U.S.) (EU)
Pulmonary Arterial Hypertension
MK-7962 Winrevair (EU)





Certain Supplemental Filings
Cancer
MK-3475 Keytruda
• Primary Advanced or Recurrent Endometrial Carcinoma
(KEYNOTE-868) (U.S.) (EU) (JPN)
• First-Line Locally Advanced or Metastatic Urothelial Cancer
(KEYNOTE-A39) (EU) (JPN)
• High-Risk Locally Advanced Cervical Cancer
(KEYNOTE-A18) (EU) (JPN)
• Resectable Stage II, IIIA or IIIB NSCLC
(KEYNOTE-671) (JPN)
• First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer
(KEYNOTE-859) (JPN)
• First-Line Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
(KEYNOTE-966) (JPN)

  

MK-6482 Welireg
• Previously Treated Advanced Renal Cell Carcinoma
(LITESPARK-005) (EU)



Footnotes:
(1) Being developed in a collaboration.
(2) Being developed in combination with Keytruda.
(3) Being developed as monotherapy and/or in combination with Keytruda.
(4) On FDA clinical hold.
(5) On FDA partial clinical hold for higher doses than those used in current clinical trials.
(6) Phase 2b development costs are being co-funded.
(7) Available in the U.S. under Emergency Use Authorization.
(8) In December 2023, the FDA issued a CRL for the NDA for gefapixant. Merck is reviewing the FDA’s feedback to determine next steps.


Analysis of Liquidity and Capital Resources
($ in millions)March 31, 2024December 31, 2023
Cash and investments$5,899 $7,345 
Working capital6,346 6,474 
Total debt to total liabilities and equity32.3 %32.9 %
Cash provided by operating activities was $3.1 billion in the first three months of 2024 compared with $1.3 billion in the first three months of 2023 reflecting stronger operating performance. Cash provided by operating activities was reduced by milestone and option payments related to certain collaborations of $245 million and $115 million in the first three months of 2024 and 2023, respectively. Cash provided by operating activities continues to be the Company’s primary source of funds to finance operating needs, with excess cash generally serving as the primary source of funds to finance business development transactions, capital expenditures, dividends paid to shareholders and treasury stock purchases.
Cash used in investing activities was $1.4 billion in the first three months of 2024 compared with $2.4 billion in the first three months of 2023. The lower use of cash in investing activities was primarily due to lower cash used for acquisitions, lower purchases of securities and other investments, as well as lower capital expenditures, partially offset by higher proceeds from sales of securities and other investments.
Cash used in financing activities was $2.8 billion in the first three months of 2024 compared with $2.1 billion in the first three months of 2023. The higher use of cash in financing activities was primarily due to higher payments on debt and higher dividends paid to shareholders, partially offset by higher proceeds from the exercise of stock options and lower purchases of treasury stock.
- 37 -

The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.7 billion and $3.0 billion of accounts receivable at March 31, 2024 and December 31, 2023, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows.
In March 2024, the Company’s $750 million, 2.90% notes matured in accordance with their terms and were repaid.
Dividends paid to stockholders were $2.0 billion and $1.9 billion for the first three months of 2024 and 2023, respectively. In November 2023, Merck’s Board of Directors declared a quarterly dividend of $0.77 per share on the Company’s outstanding common stock for the first quarter of 2024 that was paid in January 2024. In January 2024, the Board of Directors declared a quarterly dividend of $0.77 per share on the Company’s outstanding common stock for the second quarter that was paid in April 2024.
In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. During the first three months of 2024, the Company purchased $122 million (1 million shares) of its common stock for its treasury under this program. As of March 31, 2024, the Company’s remaining share repurchase authorization was $3.6 billion.
The Company has a $6.0 billion credit facility that matures in May 2028. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Critical Accounting Estimates
The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended December 31, 2023 included in Merck’s Form 10‑K filed on February 26, 2024. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Merck’s Form 10-K. There have been no significant changes in the Company’s critical accounting estimates since December 31, 2023.
Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the Company’s 2023 Form 10-K filed on February 26, 2024.
Item 4. Controls and Procedures
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2024, the Company’s disclosure controls and procedures are effective. For the first quarter of 2024, there were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.
- 38 -

The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended December 31, 2023, filed on February 26, 2024, the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.
PART II - Other Information
Item 1. Legal Proceedings
The information called for by this Item is incorporated herein by reference to Note 7 included in Part I, Item 1, Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer purchases of equity securities for the three months ended March 31, 2024 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
($ in millions)
Period
Total Number
of Shares
Purchased (1)
Average Price
Paid Per
Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs (1)
January 1 - January 31
147,500$112.29147,500$3,684
February 1 - February 29
209,200$127.83209,200$3,658
March 1 - March 31
633,971$123.45633,971$3,579
Total990,671$122.71990,671
(1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury.
Item 5. Other Information
Insider Trading Arrangements
During the three months ended March 31, 2024, none of the Company’s directors or executive officers adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements.
- 39 -


Item 6. Exhibits
Number  Description
3.1—
3.2—
31.1 —
31.2 —
32.1 —
32.2 —
101.INS—XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH—XBRL Taxonomy Extension Schema Document.
101.CAL—XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF—XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB—XBRL Taxonomy Extension Label Linkbase Document.
101.PRE—XBRL Taxonomy Extension Presentation Linkbase Document.
104 —Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
- 40 -




Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 MERCK & CO., INC.
Date: May 3, 2024 /s/ Jennifer Zachary
 JENNIFER ZACHARY
 Executive Vice President and General Counsel
Date: May 3, 2024 
/s/ Dalton Smart
 
DALTON SMART
 Senior Vice President Finance - Global Controller
- 41 -
 EX-31.1 2 exhibit311-rule13ax14a15dx.htm EX-31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO Document

Exhibit 31.1
CERTIFICATION
I, Robert M. Davis, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 3, 2024
 
By:     /s/ Robert M. Davis
ROBERT M. DAVIS
Chairman, Chief Executive Officer and President

 EX-31.2 3 exhibit312-rule13ax14a15dx.htm EX-31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO Document

Exhibit 31.2
CERTIFICATION
I, Caroline Litchfield, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:   May 3, 2024
By:      /s/ Caroline Litchfield
CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer

 EX-32.1 4 exhibit321-section1350cert.htm EX-32.1 SECTION 1350 CERTIFICATION OF CEO Document

Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
 
 
 
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 3, 2024
/s/ Robert M. Davis
Name:
Title:		ROBERT M. DAVIS
Chairman, Chief Executive Officer and President



 EX-32.2 5 exhibit322-section1350cert.htm EX-32.2 SECTION 1350 CERTIFICATION OF CFO Document

Exhibit 32.2
Section 1350
Certification of Chief Financial Officer



Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 3, 2024
/s/ Caroline Litchfield
Name:
Title:		CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer




 EX-101.SCH 6 mrk-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Pension and Other Postretirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Other (Income) Expense, Net link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Other (Income) Expense, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Collaborative Arrangements - AstraZeneca PLC (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Collaborative Arrangements - Bayer AG (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Collaborative Arrangements - Daiicho Sankyo - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Collaborative Arrangements - Daiicho Sankyo (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Collaborative Arrangements - Moderna, Inc. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Collaborative Arrangements - Moderna, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Restructuring - Activities by Program (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Other (Income) Expense, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Segment Reporting - Sales from Products (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mrk-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 mrk-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 mrk-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Less: Net Income Attributable to Noncontrolling Interests Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Latin America Latin America [Member] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Daiichi Sankyo Daiichi Sankyo [Member] Daiichi Sankyo Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and development Research and Development Expense Underlying Security Market Price Change Underlying Security Market Price Change, Percent Revenue related to the sale of the marketing rights Proceeds from Sale of Intangible Assets Delstrigo Delstrigo [Member] Delstrigo Amount of Pretax Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Sales from Products Revenue from External Customers by Products and Services [Table Text Block] Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Charge for the acquisition of Imago BioSciences, Inc. Research and Development Asset Acquired Other than Through Business Combination, Writeoff Aggregate upfront payments due upon execution in collaborative arrangement Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Accrued and other current liabilities Other Current Liabilities [Member] Payment to acquire business Payments to Acquire Businesses, Gross Information on Investments in Debt and Equity Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Deferred Income Taxes Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Currency options Foreign Exchange Option [Member] Patritumab Deruxtecan And Raludotatug Deruxtecan Patritumab Deruxtecan And Raludotatug Deruxtecan [Member] Patritumab Deruxtecan And Raludotatug Deruxtecan Segment Reporting [Abstract] Segment Reporting [Abstract] Trade accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Income Statement Effects of Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Corporate notes and bonds Corporate Debt Securities [Member] Purchases of securities and other investments Payments to Acquire Investments Loss contingency, pending claims Loss Contingency, Pending Claims, Number Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Lagevrio Lagevrio [Member] Lagevrio Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Curtailments Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Equity Equity [Text Block] Geographical [Axis] Geographical [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] International Foreign Plan [Member] Income Taxes Income Tax Disclosure [Text Block] Number of Interest Rate Swaps Held Number of Interest Rate Derivatives Held Current Liabilities Liabilities, Current [Abstract] Bayer AG Bayer AG [Member] Bayer AG [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Dividends paid to stockholders Payments of Ordinary Dividends, Common Stock Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) Earnings Per Share, Diluted Gross amounts recognized in the consolidated balance sheet, liability Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable (net of allowance for doubtful accounts of $80 in 2024 and $88 in 2023) Accounts Receivable, after Allowance for Credit Loss, Current Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member] Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Net unrealized gain (loss) on derivatives, net of reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Treasury stock (in shares) Treasury stock, beginning balance (in shares) Treasury stock, ending balance (in shares) Treasury Stock, Common, Shares Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Other comprehensive income (loss) before reclassification adjustments, pretax Other Comprehensive Income (Loss), before Reclassifications, before Tax Legal defense costs reserve Estimated Litigation Liability Litigation Case [Axis] Litigation Case [Axis] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Trading Symbol Trading Symbol U.S. government and agency securities US Government Agencies Debt Securities [Member] Restructuring Plan [Domain] Restructuring Plan [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Legal Defense Costs Legal Defense Costs [Member] Legal Defense Costs [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net Income Attributable to Merck & Co., Inc. Net Income Attributable to Merck & Co., Inc. Net (loss) income attributable to Merck & Co., Inc. Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Derivative Contract [Domain] Derivative Contract [Domain] Increase to pension liabilities due to remeasurement Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Sales discounts Sales Discounts Sales Discounts Liabilities and Equity Liabilities and Equity [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] AstraZeneca AstraZeneca [Member] AstraZeneca [Member] Proceeds from sales of securities and other investments Proceeds from Sale and Maturity of Other Investments Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Merck & Co., Inc. Stockholders’ Equity Equity, Attributable to Parent [Abstract] Debt securities, unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Acquisition of Imago BioSciences, Inc., net of cash acquired Payments to Acquire Business Two, Net of Cash Acquired Amount of gain (loss) recognized in OCI on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Total Inventory, Gross Other Intangible Assets Other Intangible Assets [Member] Calculations of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of Goods and Services Sold Service cost Defined Benefit Plan, Service Cost Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Litigation Status [Domain] Litigation Status [Domain] Inventory, noncurrent Schedule of Inventory, Noncurrent [Table Text Block] Executive Category: Executive Category [Axis] Foreign exchange contracts Foreign Exchange Contract [Member] Accounts Receivable Factoring Collections Accounts Receivable Factoring Collections [Member] Accounts Receivable Factoring Collections Level 1 Fair Value, Inputs, Level 1 [Member] Benefit plan net (loss) gain and prior service (cost) credit, net of amortization Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Name Measure Name Patents Patents [Member] Short-term investments Marketable Securities, Current Name Forgone Recovery, Individual Name Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Financial Instruments Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Consolidated Sales by Geographic Area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Decrease to LIFO cost Inventory, LIFO Reserve Asset Acquisition [Domain] Asset Acquisition [Domain] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Animal Health Animal Health segment Animal Health segment [Member] Animal Health segment [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Total pretax restructuring costs Expenses Restructuring and Related Cost, Incurred Cost Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Forecast Forecast [Member] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Alliance revenue - Koselugo Alliance revenue - Koselugo [Member] Alliance revenue - Koselugo Legal Costs Legal Costs, Policy [Policy Text Block] Cash dividends declared on common stock (in dollars per share) Common Stock, Dividends, Per Share, Declared Derivative, notional amount U.S dollar notional amount Derivative, Notional Amount Selling, general and administrative Selling, General and Administrative Expenses [Member] Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Measurement Frequency [Axis] Measurement Frequency [Axis] Sales based royalty percentage Collaborative Arrangement, Rights And Obligations, Royalty Percentage Collaborative Arrangement, Rights And Obligations, Royalty Percentage Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Depreciation Retirement Benefits [Abstract] Retirement Benefits [Abstract] Reclassification adjustments, pretax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Discontinued Operations, Disposed of by Means Other than Sale, Spinoff Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member] Common shares issuable (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Harpoon Therapeutics, Inc. Harpoon Therapeutics, Inc. [Member] Harpoon Therapeutics, Inc. Income taxes payable Accrued Income Taxes, Current Sales Revenues Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Cash collateral received, liability Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Domestic Plan Domestic Plan [Member] Sanofi Pasteur Sanofi Pasteur [Member] Sanofi Pasteur [Member] Research and development Research and Development Expense [Member] Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Litigation Status [Axis] Litigation Status [Axis] Restructuring reserve, beginning balance Restructuring reserve, ending balance Restructuring Reserve Januvia Januvia [Member] Januvia [Member] . Award Type Award Type [Axis] Antidilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Document Quarterly Report Document Quarterly Report Revenue from collaborative arrangement Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Interest expense Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Trading Arrangement: Trading Arrangement [Axis] Contingent consideration, measurement input, discount rate Business Combination, Contingent Consideration, Liability, Measurement Input PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Eligible future contingent development-related payments (up to) Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Aggregate upfront payments due upon lapse of time in collaborative arrangement Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time RotaTeq Rotateq [Member] RotaTeq [Member] Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Finite-lived intangible assets Finite-Lived Intangible Assets, Net Recently Issued Accounting Standard Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Organon & Co. Organon & Co. [Member] Organon & Co. Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets) Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets) Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Restructuring Program, 2024 Restructuring Program, 2024 [Member] Restructuring Program, 2024 Fair value of loans payable and long-term debt, including current portion Debt Instrument, Fair Value Disclosure Other pharmaceutical Other Pharmaceutical [Member] Other pharmaceutical. Interest income Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock, issued (in shares) Common stock, beginning balance (in shares) Common stock, ending balance (in shares) Common Stock, Shares, Issued Tax benefit resulting from acquisition charge Tax Benefit Resulting From Acquisition Charge Tax Benefit Resulting From Acquisition Charge Less treasury stock, at cost: 1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023 Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Total assets Assets, Fair Value Disclosure Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) before reclassification adjustments, net of taxes Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Employee Stock Option Employee Stock Option [Member] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Belsomra Belsomra [Member] Belsomra [Member] Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Pneumovax 23 Pneumovax 23 [Member] Pneumovax 23[Member]. Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Other Proceeds from (Payments for) Other Financing Activities Cumulative costs since program inception Restructuring and Related Cost, Cost Incurred to Date Maximum Maximum [Member] Comprehensive Income Attributable to Merck & Co., Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Charges Related to Restructuring Program Activities by Type of Cost Restructuring and Related Costs [Table Text Block] Cash equivalents Cash Equivalents, at Carrying Value Summary of Interest Rate Swaps Held Schedule of Interest Rate Derivatives [Table Text Block] Document Type Document Type 0.500% Notes due 2024 0.500% Notes due 2024 [Member] 0.500% Notes due 2024 [Member] Alliance revenue - Lenvima Lenvima [Member] Lenvima [Member] Maximum aggregate contingent milestone payments, per product, in collaborative arrangement Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product Tabular List, Table Tabular List [Table Text Block] Currency Swap Currency Swap [Member] Europe, Middle East and Africa EMEA [Member] Entity Address, Address Line One Entity Address, Address Line One Treasury stock shares purchased Treasury Stock, Value, Acquired, Cost Method Investments Marketable Securities, Noncurrent Dr. Scholl's Dr. Scholl's [Member] Dr. Scholl's Period of continuing involvement after disposal Discontinued Operation, Period of Continuing Involvement after Disposal Foreign Exchange Future Foreign Exchange Future [Member] Number of jurisdictions remaining Disposal Group, Including Discontinued Operation, Under Interim Operating Agreement, Number Of Jurisdiction Disposal Group, Including Discontinued Operation, Under Interim Operating Agreement, Number Of Jurisdiction 1.875% Notes due 2026 1.875% Notes due 2026 [Member] 1.875% Notes due 2026 [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other Other Noncash Income (Expense) Stockholders Equity [Line Items] Stockholders Equity [Line Items] [Line Items] for Stockholders Equity [Table] Business Acquisition [Axis] Business Acquisition [Axis] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Subsequent Event Subsequent Event [Member] Derivative [Table] Derivative [Table] Restructuring costs Restructuring Charges [Member] Accrued and other current liabilities Other Liabilities, Current Income Statement [Abstract] Income Statement [Abstract] Inventory [Line Items] Inventory [Line Items] Costs, Expenses and Other Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Isentress/Isentress HD Isentress/Isentress HD [Member] Isentress/Isentress HD [Member]. Raw materials and work in process Inventory, Work in Process and Raw Materials, Excluding Supplies Inventory, Work in Process and Raw Materials, Excluding Supplies Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Research and development expense (credit) Research and Development Expense (Credit) Research and Development Expense (Credit) Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Pifeltro Pifeltro [Member] Pifeltro Charges and Spending Relating to Restructuring Activities by Program Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Tax Other Comprehensive Income (Loss) before Reclassifications, Tax Related Party, Type [Domain] Related Party, Type [Domain] Share-based compensation plans and other (in shares) Stockholders' Equity, Other Shares Fair value of derivative, liability Derivative Liability Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Inventory [Table] Inventory [Table] Inventory [Table] Operating Segments Operating Segments Operating Segments [Member] Licenses and Other Licenses and Other [Member] Licenses and Other Dividends payable Dividends Payable, Current Other current assets Other Assets, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Financial Instruments Financial Instruments Disclosure [Text Block] Entity Tax Identification Number Entity Tax Identification Number Debt, carrying amount Debt, Long-Term and Short-Term, Combined Amount Inventories (excludes inventories of $3,413 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6) Inventories Inventory, Net Number of antibody drug conjugates obtained right and obligations Collaborative Arrangement, Rights And Obligations, Number Of Antibody Drug Conjugates Collaborative Arrangement, Rights And Obligations, Number Of Antibody Drug Conjugates Recognized as: Recognized As [Abstract] Recognized as. Imago Bio Sciences, Inc. Imago Bio Sciences, Inc. [Member] Imago Bio Sciences, Inc. Statistical Measurement [Axis] Statistical Measurement [Axis] Inventories classified in Other assets Other Assets Inventory, Noncurrent Financial Instrument Financial Instrument [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Purchases of treasury stock Payments for Repurchase of Common Stock Net changes in assets and liabilities Increase (Decrease) in Operating Capital Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Raludotatug Deruxtecan Raludotatug Deruxtecan [Member] Raludotatug Deruxtecan Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Other (Income) Expense, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Schedule of Equity Schedule of Stockholders Equity [Table Text Block] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Loss related to litigation settlement Charge for Zetia antitrust litigation settlements Gain (Loss) Related to Litigation Settlement Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Elanco Animal Health Incorporated Aqua Business Elanco Animal Health Incorporated Aqua Business [Member] Elanco Animal Health Incorporated Aqua Business Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Par Value of Debt Debt Instrument, Face Amount Noxafil Noxafil [Member] Noxafil [Member]. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current Assets Assets, Current [Abstract] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Stock investment in counterparty Collaborative Arrangement, Stock Investment In Counterparty Collaborative Arrangement, Stock Investment In Counterparty Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Partial settlement charge Defined Benefit Plan, Plan Assets, Payment for Settlement Disposal Group Name [Domain] Disposal Group Name [Domain] Interest cost Defined Benefit Plan, Interest Cost Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] PEO PEO [Member] Share-based compensation plans and other Stockholders' Equity, Other Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Pension and Other Postretirement Benefit Plans Retirement Benefits [Text Block] ProQuad/M-M-R II/Varivax ProQuad MMR II Varivax [Member] ProQuad/M-M-R II/Varivax [Member]. Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Moderna, Inc. Moderna, Inc. [Member] Moderna, Inc. Gross amounts recognized in the consolidated balance sheet, asset Derivative Asset, Subject to Master Netting Arrangement, before Offset Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis Offsetting Assets And Liabilities [Table Text Block] Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis. Net Cash Used in Investing Activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Publicly traded equity securities, fair value Publicly traded equity securities Equity Securities, FV-NI, Current Net Income Attributable to Merck & Co., Inc., basic Net Income (Loss) Available to Common Stockholders, Basic Increase in Sales as a result of AOCL reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Estimate of cumulative pre tax costs that will be noncash Estimate Of Cumulative Pre Tax Costs That Will Be Noncash Estimate of cumulative pre tax costs that will be noncash. Inventory, current Schedule of Inventory, Current [Table Text Block] Loss contingency, claims settled Loss Contingency, Claims Settled, Number Interest rate swap contracts Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Simponi Simponi [Member] Simponi [Member]. Total debt and publicly traded equity securities, fair value Debt Securities and Equity Securities, FV-NI Debt Securities and Equity Securities, FV-NI Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Restructuring Program, 2019 Restructuring Program, 2019 [Member] Restructuring Program, 2019 Regulatory milestone payments Collaborative Arrangement, Rights and Obligations, Milestone Payments Regulatory Collaborative Arrangement, Rights and Obligations, Milestone Payments Regulatory Liabilities Liabilities Net amounts, asset Derivative Asset, Subject to Master Netting Arrangement, after Offset Asset Acquisition [Axis] Asset Acquisition [Axis] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-cash activity Restructuring Reserve, Increase (Decrease) Noncash Activity Noncash activity affecting the restructuring reserve, including accelerated depreciation. Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Other, net Other Nonoperating Income Expense, Other Other nonoperating income and expense items not separately disclosed. Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Related Party Transaction [Domain] Related Party Transaction [Domain] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Keytruda Keytruda [Member] Keytruda [Member] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Loss contingency, trial period Loss Contingency, Trial Period Loss Contingency, Trial Period Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023 Common Stock, Value, Issued China CHINA Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Alliance revenue - Adempas/Verquvo Alliance revenue - Adempas/Verquvo [Member] Alliance revenue - Adempas/Verquvo Hedged Liability, Statement of Financial Position [Extensible Enumeration] Hedged Liability, Statement of Financial Position [Extensible Enumeration] Senior Notes Senior Notes [Member] Total current assets Other current assets Assets, Current Number of antibody drug conjugates terminated with collaborative partner Collaborative Arrangement, Rights And Obligations, Terminated, Number Of Antibody Drug Conjugates Collaborative Arrangement, Rights And Obligations, Terminated, Number Of Antibody Drug Conjugates Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Loss contingency, number of patents allegedly infringed Loss Contingency, Patents Allegedly Infringed, Number Contingent consideration Fair value, beginning balance Fair value, ending balance Business Combination, Contingent Consideration, Liability Publicly traded equity securities Equity Securities [Member] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Sales-Based Milestones Sales-Based Milestones [Member] Sales-Based Milestones [Member] Litigation Case [Domain] Litigation Case [Domain] Equity Funds Equity Funds [Member] Amortization Amortization Amortization Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Restructuring Type [Axis] Restructuring Type [Axis] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Japan JAPAN Current Fiscal Year End Date Current Fiscal Year End Date Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement, percentage Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage Refundable upfront payments in collaborative arrangement Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments Manufacturing and Supply Agreements Manufacturing And Supply Agreements [Member] Manufacturing And Supply Agreements PEO Name PEO Name Commercial and Other Litigation Commercial and Other Litigation [Member] Commercial and Other Litigation Asia Pacific (other than China and Japan) Asia Pacific [Member] Changes in AOCI by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Investments Investments Restricted cash Restricted Cash, Current Other Postretirement Benefit Plans Other Postretirement Benefits Plan [Member] Lynparza Lynparza [Member] Lynparza [Member] Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Current liability Business Combination, Contingent Consideration, Liability, Current Class of Stock [Axis] Class of Stock [Axis] Entities [Table] Entities [Table] Pretax net unrealized gain on derivatives maturing within the next 12 months estimated to be reclassified from AOCI to sales Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Total current and noncurrent inventories Inventory Net And Inventory Noncurrent Total of current and noncurrent inventories. Corporate, Non-Segment Corporate, Non-Segment Corporate, Non-Segment [Member] Amortization of unrecognized prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Zetia antitrust litigation Zetia antitrust litigation [Member] Zetia antitrust litigation [Member] Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Acquisitions, Divestitures, Research Collaborations and Licensing Agreements Acquisitions Research Collaborations And License Agreements [Text Block] Information related to acquisitions, divestitures, research collaborations and license agreements. Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Information [Line Items] Entity Information [Line Items] Business Combination and Asset Acquisition [Abstract] Total Merck & Co., Inc. stockholders’ equity Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Commercial paper Commercial Paper [Member] 1.375% Notes due 2036 1.375% Notes due 2036 [Member] 1.375% Notes due 2036 [Member] Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Probable contingent payments Collaborative Arrangement, Rights and Obligations, Probable Contingent Payments Collaborative Arrangement, Rights and Obligations, Probable Contingent Payments Unrealized gains recognized on investments in equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Alliance Revenue - Reblozyl Alliance Revenue - Reblozyl [Member] Alliance Revenue - Reblozyl Restricted cash Restricted Cash and Cash Equivalents Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Income Before Taxes Profits Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Other (Income) Expense, Net Other Income and Other Expense Disclosure [Text Block] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Cumulative unrealized losses on investments Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Derivatives Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Restructuring Restructuring and Related Activities Disclosure [Text Block] Hedging Designation [Domain] Hedging Designation [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Ridgeback Biotherapeutics LP Ridgeback Biotherapeutics LP [Member] Ridgeback Biotherapeutics LP Entity Emerging Growth Company Entity Emerging Growth Company Total Costs, Expenses and Other Costs Expenses And Other Total of cost of sales, operating expenses and nonoperating income or expense. Supplies Other Inventory, Supplies, Gross Other Intangibles, Net Intangible Assets, Net (Excluding Goodwill) Other Assets Other Noncurrent Assets [Member] Finished goods Inventory, Finished Goods, Gross Unfavorable discrete impact on tax rate Effective Income Tax Rate Reconciliation, Unfavorable Discrete Impact, Percent Effective Income Tax Rate Reconciliation, Unfavorable Discrete Impact, Percent Disposal Group Classification [Domain] Disposal Group Classification [Domain] Location and Amount of Pretax Gains and Losses of Derivatives Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Royalty rate Royalty Rate, Percentage Royalty Rate, Percentage Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Share-based compensation Share-Based Payment Arrangement, Noncash Expense Contingent proceeds collaborative arrangement Collaborative Arrangement, Rights and Obligations, Contingent Milestone Proceeds Collaborative Arrangement, Rights and Obligations, Contingent Milestone Proceeds Common Stock ($0.50 par value)   Common Stock Common Stock [Member] Debt securities, available-for-sale, noncurrent Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Earnings Per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Information About the Changes in Liabilities for Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Other Other Countries [Member] Other Countries [Member] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total equity Equity, beginning balance Equity, ending balance Equity, Including Portion Attributable to Noncontrolling Interest Collaboration Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Inventory [Domain] Inventory [Domain] Minimum Minimum [Member] Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,620 in 2024 and $18,266 in 2023 Property, Plant and Equipment, Net Basis of Presentation Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Other comprehensive income (loss), net of taxes Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Amount of Derivative Pretax (Gain) Loss Recognized in Income Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Cash dividends declared on common stock Dividends, Common Stock, Cash Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Total liabilities Liabilities, Fair Value Disclosure Exchange losses Gain (Loss), Foreign Currency Transaction, before Tax Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Bristol Myers Squibb Company Bristol Myers Squibb Company [Member] Bristol Myers Squibb Company Equity securities held through ownership interest in investments funds Publicly traded equity securities Equity Securities, FV-NI, Noncurrent Other current assets Other Current Assets [Member] Net Income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Cash Used in Financing Activities Net Cash Provided by (Used in) Financing Activities Retirement Plan Type [Axis] Retirement Plan Type [Axis] Termination benefits Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits Contingencies Commitments and Contingencies Disclosure [Text Block] Other Payments for (Proceeds from) Other Investing Activities Retained Earnings Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Reconciliation of Segment Profits to Income before Taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Liabilities and Equity Liabilities and Equity Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost Other Assets Other Assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) Earnings Per Share, Basic Prevymis Prevymis [Member] Prevymis [Member] Verquvo Verquvo [Member] Verquvo Eligible future contingent sales-based milestone payments (up to) Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Ifinatamab Deruxtecan Ifinatamab Deruxtecan [Member] Ifinatamab Deruxtecan 2.500% Notes due 2034 2.500% Notes due 2034 [Member] 2.500% Notes due 2034 [Member] Net Income Attributable to Merck & Co., Inc., diluted Net Income (Loss) Available to Common Stockholders, Diluted Expected restructuring and related cost Restructuring and Related Cost, Expected Cost Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Pending Litigation Pending Litigation [Member] Other noncurrent liabilities Liabilities, Noncurrent Net assets acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Restructuring costs Restructuring costs Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Unrealized losses recognized on investments in equity securities without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Termination Date Trading Arrangement Termination Date Common stock, authorized (shares) Common Stock, Shares Authorized Debt securities, fair value Investments Debt Securities, Available-for-Sale Carrying Amount of Hedged Liabilities Hedged Liability, Fair Value Hedge Eligible future contingent regulatory milestone payments (up to) Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt securities, unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Euro-denominated notes Euro-dominated Notes [Member] Euro-dominated Notes [Member] Effect of Net Investment Hedges on OCI and the Consolidated Statement of Operations Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Income from investments in equity securities, net Equity Securities, FV-NI, Gain (Loss) Royalty rate, deduction Royalty Rate, Deduction, Percentage Royalty Rate, Deduction, Percentage Derivative Instrument [Axis] Derivative Instrument [Axis] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Tax Reclassification from AOCI, Current Period, Tax Derivative [Line Items] Derivative [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Charge for the acquisition of Harpoon Therapeutics, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two Award Timing Disclosures [Line Items] Bridion Bridion [Member] Bridion [Member]. Compensation Amount Outstanding Recovery Compensation Amount Patritumab Deruxtecan Patritumab Deruxtecan [Member] Patritumab Deruxtecan Cash collateral received from counterparties Cash collateral received, asset Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Eisai Eisai [Member] Eisai [Member] Welireg Welireg [Member] Welireg Inventory [Axis] Inventory [Axis] Fair value of derivative, asset Derivative Asset Deferred income taxes Deferred Income Tax Expense (Benefit) Int’l International [Member] International [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Restructuring Plan [Axis] Restructuring Plan [Axis] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Loss contingency, number of plaintiffs Loss Contingency, Number of Plaintiffs Maximum average period of maturities of contracts in years (less than) Derivative, Average Remaining Maturity Loans payable and current portion of long-term debt Debt, Current Insider Trading Arrangements [Line Items] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Pharmaceutical Pharmaceutical segment Pharmaceutical segment [Member] Pharmaceutical segment. Related Party, Type [Axis] Related Party, Type [Axis] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Asset acquisition, transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost 4.50% Notes Due 2033 4.50% Notes Due 2033 [Member] 4.50% Notes Due 2033 Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Unrealized net gains (losses) Equity Securities, FV-NI, Unrealized Gain (Loss) Adjustment to Compensation, Amount Adjustment to Compensation Amount Changes in estimated fair value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Cost of sales Cost of Sales [Member] Separation Costs Employee Severance [Member] Noncontrolling Interests Equity, Attributable to Noncontrolling Interest Vaxneuvance Vaxneuvance [Member] Vaxneuvance (Payments) receipts, net Payments for Restructuring Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Disposal Group Name [Axis] Disposal Group Name [Axis] Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Sales Sales [Member] Payments on debt Repayments of Long-Term Debt  Treasury Stock Treasury Stock, Common [Member] Inventories Produced in Preparation for Product Launches Inventories Produced in Preparation for Product Launches [Member] Inventories Produced in Preparation for Product Launches [Member] Entity Central Index Key Entity Central Index Key Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Liabilities Liabilities, Fair Value Disclosure [Abstract] Amount of gain recognized in Other (income) expense, net on derivatives Derivative, Gain (Loss) on Derivative, Net Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Taxes on Income Income Tax Expense (Benefit) Non-US Non-US [Member] Derivatives Designated as Hedging Instruments Designated as Hedging Instrument [Member] Net periodic defined benefit plan (credit) cost other than service cost Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Number of operating segments Number of Operating Segments Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Other Exit Costs Other Restructuring [Member] Name Trading Arrangement, Individual Name Reclassification adjustments, net of taxes Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Gardasil/Gardasil 9 Gardasil/Gardasil 9 [Member] Gardasil/Gardasil 9 [Member]. Other comprehensive income (loss), net of taxes Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Companion Animal Companion Animal [Member] Companion Animal [Member] Stockholders' equity before deduction for treasury stock Stockholders' Equity before Treasury Stock Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventories Inventory Disclosure [Text Block] Remicade Remicade [Member] Remicade [Member]. Stockholders Equity [Table] Stockholders Equity [Table] Stockholders Equity [Table] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Net loss (gain) amortization Defined Benefit Plan, Amortization of Gain (Loss) Janumet Janumet [Member] Janumet [Member]. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Acquisition of Harpoon Therapeutics, Inc., net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Licensing Agreements Licensing Agreements [Member] Interest Paid Interest Paid, Excluding Capitalized Interest, Operating Activities Assets Assets, Fair Value Disclosure [Abstract] Treasury stock shares purchased (in shares) Treasury Stock, Shares, Acquired Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Amounts Recorded on Balance Sheet Related to Fair Value Hedges Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Zerbaxa Zerbaxa [Member] Zerbaxa [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Dificid Dificid [Member] Dificid Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Long-Term Debt Long-Term Debt, Excluding Current Maturities Number of interest rate swaps Derivative, Number of Instruments Held Average common shares outstanding assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Interest rate contracts Interest Rate Contract [Member] Increase in hedge revenue Increase (Decrease) In Hedge Revenue Increase (Decrease) In Hedge Revenue Accelerated Depreciation Accelerated Depreciation [Member] Accelerated Depreciation [Member] Adempas Adempas [Member] Adempas Capital expenditures Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Other paid-in capital Additional Paid in Capital, Common Stock Other Paid-In Capital Additional Paid-in Capital [Member] Alliance revenue - Lynparza Alliance revenue - Lynparza [Member] Alliance revenue - Lynparza [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total Assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Livestock Livestock [Member] Livestock [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Sales-based milestone payments Collaborative Arrangement, Rights and Obligations, Milestone Payments Sales-Based Collaborative Arrangement, Rights and Obligations, Milestone Payments Sales-Based U.S. United States UNITED STATES Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Other unallocated, net Segment Reporting Unallocated Other Expenses Net Other net expenses not allocated to segments. Segment Reconciling Items Segment Reconciling Items [Member] Upfront payment made to collaborative partner Collaborative Arrangement, Rights And Obligations, Upfront Payment Due Upon Execution Collaborative Arrangement, Rights And Obligations, Upfront Payment Due Upon Execution Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Inventories Not Expected to be Sold Within One Year Inventory Not Expected to be Sold Within One Year [Member] Inventory Not Expected to be Sold Within One Year [Member] Other Noncurrent Liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Other (income) expense, net Other Nonoperating Income (Expense) [Member] Consideration transferred, asset acquisition Asset Acquisition, Consideration Transferred Pension Plans Pension Plan [Member] Segment Reporting Segment Reporting Disclosure [Text Block] Net Decrease in Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Januvia/Janumet Januvia/Janumet [Member] Januvia/Janumet Securities, fair value, which are subject to a contractual sale restriction Equity Security, FV-NI, Contractual Sale Restriction Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Scenario [Axis] Scenario [Axis] Entity Current Reporting Status Entity Current Reporting Status 4.50% note due 2033 4.50% note due 2033 [Member] 4.50% note due 2033 Factored accounts receivable Accounts Receivable, Sale Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Net amounts, liability Derivative Liability, Subject to Master Netting Arrangement, after Offset Prepaid Expense and Other Assets Prepaid Expense and Other Assets Loss contingency, number of motion for summary judgments Loss Contingency, Motion for Summary Judgment, Number Loss Contingency, Motion for Summary Judgment, Number Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Cumulative unrealized gains on investments Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Other Comprehensive Loss Net of Taxes: Other Comprehensive Income (Loss), Net of Tax [Abstract] Scenario [Domain] Scenario [Domain] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Type of Restructuring [Domain] Type of Restructuring [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Non- controlling Interests Noncontrolling Interest [Member] EX-101.PRE 10 mrk-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page - shares
 3 Months Ended
Mar. 31, 2024
Apr. 30, 2024
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 1-6571  
Entity Registrant Name Merck & Co., Inc.  
Entity Incorporation, State or Country Code NJ  
Entity Tax Identification Number 22-1918501  
Entity Address, Address Line One 126 East Lincoln Avenue  
Entity Address, City or Town Rahway  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07065  
City Area Code (908)  
Local Phone Number 740-4000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   2,532,806,307
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0000310158  
Current Fiscal Year End Date --12-31  
Common Stock ($0.50 par value)    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock ($0.50 par value)  
Trading Symbol MRK  
Security Exchange Name NYSE  
0.500% Notes due 2024    
Entity Information [Line Items]    
Title of 12(b) Security 0.500% Notes due 2024  
Trading Symbol MRK 24  
Security Exchange Name NYSE  
1.875% Notes due 2026    
Entity Information [Line Items]    
Title of 12(b) Security 1.875% Notes due 2026  
Trading Symbol MRK/26  
Security Exchange Name NYSE  
2.500% Notes due 2034    
Entity Information [Line Items]    
Title of 12(b) Security 2.500% Notes due 2034  
Trading Symbol MRK/34  
Security Exchange Name NYSE  
1.375% Notes due 2036    
Entity Information [Line Items]    
Title of 12(b) Security 1.375% Notes due 2036  
Trading Symbol MRK 36A  
Security Exchange Name NYSE  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Sales $ 15,775 $ 14,487
Costs, Expenses and Other    
Cost of sales 3,540 3,926
Selling, general and administrative 2,483 2,479
Research and development 3,992 4,276
Restructuring costs 123 67
Other (income) expense, net (33) 89
Total Costs, Expenses and Other 10,105 10,837
Income Before Taxes 5,670 3,650
Taxes on Income 903 825
Net Income 4,767 2,825
Less: Net Income Attributable to Noncontrolling Interests 5 4
Net Income Attributable to Merck & Co., Inc. $ 4,762 $ 2,821
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.88 $ 1.11
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.87 $ 1.11
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net Income Attributable to Merck & Co., Inc. $ 4,762 $ 2,821
Other Comprehensive Loss Net of Taxes:    
Net unrealized gain (loss) on derivatives, net of reclassifications 130 (133)
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization (5) (50)
Cumulative translation adjustment (238) 68
Other comprehensive income (loss), net of taxes (113) (115)
Comprehensive Income Attributable to Merck & Co., Inc. $ 4,649 $ 2,706
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents $ 5,579 $ 6,841
Short-term investments 40 252
Accounts receivable (net of allowance for doubtful accounts of $80 in 2024 and $88 in 2023) 11,366 10,349
Inventories (excludes inventories of $3,413 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6) 6,510 6,358
Other current assets 7,950 8,368
Total current assets 31,445 32,168
Investments 280 252
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,620 in 2024 and $18,266 in 2023 23,045 23,051
Goodwill 21,181 21,197
Other Intangibles, Net 17,572 18,011
Other Assets 12,326 11,996
Total Assets 105,849 106,675
Current Liabilities    
Loans payable and current portion of long-term debt 3,077 1,372
Trade accounts payable 3,514 3,922
Accrued and other current liabilities 14,102 15,766
Income taxes payable 2,398 2,649
Dividends payable 2,008 1,985
Total current liabilities 25,099 25,694
Long-Term Debt 31,142 33,683
Deferred Income Taxes 922 871
Other Noncurrent Liabilities 8,262 8,792
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023 1,788 1,788
Other paid-in capital 44,598 44,509
Retained earnings 56,697 53,895
Accumulated other comprehensive loss (5,274) (5,161)
Stockholders' equity before deduction for treasury stock 97,809 95,031
Less treasury stock, at cost: 1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023 57,445 57,450
Total Merck & Co., Inc. stockholders’ equity 40,364 37,581
Noncontrolling Interests 60 54
Total equity 40,424 37,635
Liabilities and Equity $ 105,849 $ 106,675
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 80 $ 88
Inventories classified in Other assets 3,413 3,348
Accumulated depreciation $ 18,620 $ 18,266
Common stock, par value (in dollars per share) $ 0.50 $ 0.50
Common stock, authorized (shares) 6,500,000,000 6,500,000,000
Common stock, issued (in shares) 3,577,103,522 3,577,103,522
Treasury stock (in shares) 1,044,402,655 1,045,470,249
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash Flows from Operating Activities    
Net income $ 4,767 $ 2,825
Adjustments to reconcile net income to net cash provided by operating activities:    
Amortization 473 543
Depreciation 511 448
Income from investments in equity securities, net (143) (450)
Charge for the acquisition of Harpoon Therapeutics, Inc. 656 0
Charge for the acquisition of Imago BioSciences, Inc. 0 1,192
Deferred income taxes (51) (277)
Share-based compensation 176 145
Other 83 (197)
Net changes in assets and liabilities (3,382) (2,890)
Net Cash Provided by Operating Activities 3,090 1,339
Cash Flows from Investing Activities    
Capital expenditures (861) (1,007)
Purchases of securities and other investments (15) (562)
Proceeds from sales of securities and other investments 260 500
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired (746) 0
Acquisition of Imago BioSciences, Inc., net of cash acquired 0 (1,327)
Other (14) 37
Net Cash Used in Investing Activities (1,376) (2,359)
Cash Flows from Financing Activities    
Payments on debt (751) (1)
Dividends paid to stockholders (1,950) (1,853)
Purchases of treasury stock (122) (149)
Proceeds from exercise of stock options 87 30
Other (78) (81)
Net Cash Used in Financing Activities (2,814) (2,054)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (138) 87
Net Decrease in Cash, Cash Equivalents and Restricted Cash (1,238) (2,987)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets) 6,909 12,773
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets) $ 5,671 $ 9,786
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Statement of Cash Flows [Abstract]        
Restricted cash $ 92 $ 68 $ 79 $ 79
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2024.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Recently Issued Accounting Standards Not Yet Adopted
In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The amended guidance is effective prospectively for all joint ventures with a formation date on or after January 1, 2025, however existing joint ventures have the option to apply the guidance retrospectively. Early adoption is permitted for both interim and annual periods. The Company anticipates there will be no impact to its consolidated financial statements upon adoption.
In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses. The guidance is effective for annual periods beginning in 2024, and interim periods beginning in 2025. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.
In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. Early adoption is permitted. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements Acquisitions, Divestitures, Research Collaborations and Licensing Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments; expense reimbursements or payments to the third party; milestone, royalty or profit share arrangements contingent upon the occurrence of certain future events linked to the success of the asset in development; and can also include option and continuation payments. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
2024 Transactions
In March 2024, Merck acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases, for $765 million and also incurred $56 million of transaction costs. Harpoon’s lead candidate, MK-6070 (formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small-cell lung cancer (SCLC) and neuroendocrine tumors. MK-6070 is currently being evaluated as monotherapy in a Phase 1/2 clinical trial in certain patients with advanced cancers associated with expression of DLL3. The study is also evaluating MK-6070 in combination with atezolizumab in certain patients with SCLC. The transaction was accounted for as an asset acquisition since MK-6070 represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $165 million, as well as a charge of $656 million to Research and development expenses in the first quarter of 2024 related to the transaction. There are no future contingent payments associated with the acquisition.
In February 2024, Merck entered into a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (Elanco) for $1.3 billion in cash. The Elanco aqua business to be acquired consists of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. Upon closing, the acquisition will broaden Animal Health’s aqua portfolio with products, such as Clynav, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic sea lice treatment. This acquisition also brings a portfolio of water treatment products for warm water production, complementing Animal Health’s warm water vaccine portfolio. In addition to these products, the DNA-based vaccine
technology that is a part of the business has the potential to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. The acquisition is expected to be completed by mid-2024, subject to approvals from regulatory authorities and other customary closing conditions. The transaction will be accounted for as a business combination.
2023 Transactions
In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded as a charge to Research and development expenses in the first quarter of 2023. In October 2023, Merck notified Kelun-Biotech it was terminating two of the seven candidates under the agreement. Subsequently, in April 2024, Merck notified Kelun-Biotech it was terminating an additional candidate under the agreement. Kelun-Biotech remains eligible to receive future contingent payments aggregating up to $600 million in development-related payments, $1.6 billion in regulatory milestones, and $3.1 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all remaining candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech shares in January 2023.
In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate, bomedemstat MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. A Phase 3 clinical trial evaluating bomedemstat for the treatment of certain patients with essential thrombocythemia is underway. The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as a charge of $1.2 billion to Research and development expenses in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
Spin-Off of Organon & Co.
In connection with the 2021 spin-off of Organon & Co. (Organon), Merck and Organon entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck continued to market, import and distribute such products on behalf of Organon until such time as the relevant licenses and permits transferred to Organon, with Organon receiving all of the economic benefits and burdens of such activities. As of March 31, 2024, only one jurisdiction remains under an interim operating agreement. Additionally, Merck and Organon entered into a number of manufacturing and supply agreements (MSAs) with terms ranging from four years to ten years. The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $107 million and $94 million and related cost of sales of $110 million and $107 million for the first quarter of 2024 and 2023, respectively. The amounts due from Organon for all spin-off related agreements were $462 million and $632 million at March 31, 2024 and December 31, 2023, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $193 million and $598 million at March 31, 2024 and December 31, 2023, respectively, and are included in Accrued and other current liabilities.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements
 3 Months Ended
Mar. 31, 2024
Collaborative Arrangements [Abstract]  
Collaborative Arrangements Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca PLC
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca are developing and commercializing Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at March 31, 2024) and a corresponding increase to the intangible asset related to Lynparza. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. Lynparza received regulatory approvals triggering capitalized milestone payments from Merck to AstraZeneca of $245 million and $105 million in the first quarter of 2024 and 2023, respectively (each of which had been previously accrued for). Potential future regulatory milestone payments of $650 million remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.4 billion at March 31, 2024 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Lynparza$292 $275 
Alliance revenue - Koselugo38 23 
Total alliance revenue$330 $298 
Cost of sales (1)
82 70 
Selling, general and administrative39 47 
Research and development20 21 
($ in millions)March 31, 2024December 31, 2023
Receivables from AstraZeneca included in Other current assets
$334 $341 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
617 256 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
— 600 
(1)    Represents amortization of capitalized milestone payments.
(2)    Includes accrued milestone payments.
Eisai Co., Ltd.
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai are developing and commercializing Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a $125 million sales-based milestone payment from Merck to Eisai. Similarly, in the third quarter of 2023 an additional $125 million sales-based milestone payment to Eisai was deemed by the Company to be probable of payment. Accordingly, Merck recorded $250 million of liabilities for these payments (of which $125 million was subsequently paid in the second quarter of 2023 and $125 million remained accrued at March 31, 2024) and corresponding increases to the intangible asset related to Lenvima. Merck also recognized $72 million and $81 million of cumulative amortization catch-up expense related to the recognition of these milestones in the first and third quarters of 2023, respectively. Potential future sales-based milestone payments of $2.3 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $623 million at March 31, 2024 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Lenvima$255 $232 
Cost of sales (1)
60 126 
Selling, general and administrative39 51 
Research and development8 39 
($ in millions)March 31, 2024December 31, 2023
Receivables from Eisai included in Other current assets
$255 $226 
Payables to Eisai included in Accrued and other current liabilities (2)
125 125 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.
(2)    Represents an accrued milestone payment.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat) and Verquvo (vericiguat). The two companies have implemented a joint development and commercialization strategy. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. There are no sales-based milestone payments remaining under this collaboration.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $483 million and $49 million, respectively, at March 31, 2024 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Adempas/Verquvo$98 $99 
Net sales of Adempas recorded by Merck70 59 
Net sales of Verquvo recorded by Merck5 7 
Total sales$173 $165 
Cost of sales (1)
62 57 
Selling, general and administrative33 33 
Research and development28 25 
($ in millions)March 31, 2024December 31, 2023
Receivables from Bayer included in Other current assets
$155 $156 
Payables to Bayer included in Accrued and other current liabilities
74 80 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Ridgeback Biotherapeutics LP
In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, Lagevrio has since received multiple additional authorizations.
Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Net sales of Lagevrio recorded by Merck
$350 $392 
Cost of sales (1)
191 221 
Selling, general and administrative
16 27 
Research and development
(5)16 
($ in millions)March 31, 2024December 31, 2023
Payables to Ridgeback included in Accrued and other current liabilities (2)
$160 $113 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Daiichi Sankyo
In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments. The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.
Under the terms of the agreement, Merck made payments to Daiichi Sankyo totaling $4.0 billion in 2023. These payments included $1.0 billion ($500 million each for patritumab deruxtecan and ifinatamab deruxtecan) which may be refundable on a pro-rated basis in the event of early termination of development with respect to either program. In addition, the agreement provides for a continuation payment of $750 million related to patritumab deruxtecan due from Merck in October 2024 and a continuation payment of $750 million related to raludotatug deruxtecan due from Merck in October 2025. If Merck does not make the continuation payments on the dates noted for either patritumab deruxtecan and/or raludotatug deruxtecan, the rights for the applicable program will revert to Daiichi Sankyo and the non-refundable upfront payments already paid will be retained by Daiichi Sankyo. The agreement also provides for contingent payments from Merck to Daiichi Sankyo of up to an additional $5.5 billion for each DXd ADC upon the successful achievement of certain sales-based milestones. In conjunction with this transaction, Merck recorded an aggregate pretax charge of $5.5 billion to Research and development expenses in the fourth quarter of 2023 for the $4.0 billion of upfront payments and the $1.5 billion of continuation payments.
Merck and Daiichi Sankyo will equally share research and development costs, except for raludotatug deruxtecan, where Merck will be responsible for 75% of the first $2.0 billion of research and development expenses. Merck includes its share of development costs associated with the collaboration as part of Research and development expenses. Following regulatory approval, Daiichi Sankyo will generally record sales worldwide (Daiichi Sankyo will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights and Merck will receive a 5% sales-based royalty. Merck will record its share of product sales, net of cost of sales and commercialization costs, as alliance revenue.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Selling, general and administrative $3 $— 
Research and development
69 — 
($ in millions)March 31, 2024December 31, 2023
Payables to Daiichi Sankyo included in Accrued and other current liabilities
$817 $800 
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities
750 750 
Moderna, Inc.
In 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna). V940 (mRNA-4157) is currently being evaluated in combination with Keytruda in multiple Phase 3 clinical trials. Merck and Moderna will share costs and any profits equally under this worldwide collaboration. Merck records its share of development costs associated with the collaboration as part of Research and development expenses. Any reimbursements received from Moderna for research and development expenses are recognized as reductions to Research and development costs. Merck has also capitalized certain of the shared costs, which aggregated $110 million at March 31, 2024 and will be amortized over the assets’ estimated useful lives.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Selling, general and administrative $2 $1 
Research and development
69 26 
($ in millions)March 31, 2024December 31, 2023
Payables to Moderna included in Accrued and other current liabilities
$72 $63 
Bristol-Myers Squibb Company
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Alliance revenue related to this collaboration, consisting of royalties (recorded within Sales) was $71 million and $43 million in the first quarter of 2024 and 2023, respectively.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company recorded total pretax costs of $246 million in the first quarter of 2024 related to the 2024 Restructuring Program, bringing total cumulative pretax costs incurred through March 31, 2024 to $436 million.
In 2019, Merck approved a global restructuring program (2019 Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The Company recorded total pretax costs of $97 million in the first quarter of 2023 related to the 2019 Restructuring Program. The actions under the 2019 Restructuring Program were substantially complete at the end of 2023 and, as of January 1, 2024, any remaining activities are now being accounted for as part of the 2024 Restructuring Program.
For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to the restructuring programs by type of cost:
 Three Months Ended March 31, 2024
($ in millions)
Accelerated Depreciation
Separation Costs
Other Exit Costs
Total
2024 Restructuring Program
Cost of sales$65 $— $51 $116 
Selling, general and administrative— — 5 5 
Research and development— — 2 2 
Restructuring costs— 92 31 123 
$65 $92 $89 $246 
 Three Months Ended March 31, 2023
($ in millions)
Accelerated Depreciation
Separation Costs
Other Exit Costs
Total
2019 Restructuring Program
Cost of sales$21 $— $8 $29 
Selling, general and administrative— — 1 1 
Restructuring costs— 41 26 67 
$21 $41 $35 $97 
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.
Other exit costs in 2024 and 2023 include asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 9) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2024:
($ in millions)
Accelerated Depreciation
Separation
Costs
Other Exit Costs
Total
Restructuring reserves January 1, 2024
$— $681 $31 $712 
Expenses65 92 89 246 
(Payments) receipts, net— (67)(32)(99)
Non-cash activity(65)— (58)(123)
Restructuring reserves March 31, 2024
$— $706 $30 $736 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and foreign exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated Other Comprehensive Loss (AOCL) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of foreign exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of foreign exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the foreign exchange rate and the cost of the hedging instrument (primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi). The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in foreign exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Condensed Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended March 31,Three Months Ended March 31,
($ in millions)2024202320242023
Net Investment Hedging Relationships
Foreign exchange contracts$(2)$1 $— $1 
Euro-denominated notes(62)52 — — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.
At March 31, 2024, the Company was a party to four pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of a portion of fixed-rate notes as detailed in the table below.
March 31, 2024
($ in millions)
Par Value of Debt
Number of Interest Rate Swaps Held
Total Swap Notional Amount
4.50% notes due 2033
$1,500 4 $1,000 
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark Secured Overnight Financing Rate (SOFR) swap rate. The fair value changes in the notes attributable to changes in the SOFR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. In April 2024, the Company entered into two additional interest rate swaps with notional amounts of $250 million each also related to its 4.50% notes due 2033.
The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged Liabilities
Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount
($ in millions)
March 31, 2024December 31, 2023March 31, 2024December 31, 2023
Balance Sheet Caption
Long-Term Debt
$1,026 $1,056 $26 $56 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  March 31, 2024December 31, 2023
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption
Interest rate swap contracts
Other Assets
$27 $— $1,000 $57 $— $1,000 
Foreign exchange contractsOther current assets175 — 9,082 106 — 6,138 
Foreign exchange contractsOther Assets32 — 2,062 26 — 1,929 
Foreign exchange contractsAccrued and other current liabilities— 10 1,076 — 76 3,680 
Foreign exchange contractsOther Noncurrent Liabilities— 1 204 — 1 7 
  234 11 13,424 189 77 12,754 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets121 — 9,428 153 — 9,693 
Foreign exchange contractsOther Assets2 — 43 — — — 
Foreign exchange contractsAccrued and other current liabilities— 154 9,282 — 162 8,104 
Foreign exchange contractsOther Noncurrent Liabilities— 2 43 — — — 
  123 156 18,796 153 162 17,797 
  $357 $167 $32,220 $342 $239 $30,551 
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 March 31, 2024December 31, 2023
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$357 $167 $342 $239 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(111)(111)(215)(215)
Cash collateral received
(58)— (3)— 
Net amounts$188 $56 $124 $24 
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended March 31,
($ in millions)202420232024202320242023
Financial Statement Caption in which Effects of Fair Value or Cash Flow
Hedges are Recorded
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$15,775 $14,487 $(33)$89 $(113)$(115)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items— — (30)— — — 
Derivatives designated as hedging instruments— — 30 — — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain (loss) recognized in OCI on derivatives
— — — — 209 (66)
Increase in Sales as a result of AOCL reclassifications
44 101 — — (44)(101)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — — (1)— — 
Amount of loss recognized in OCI on derivatives
— — — — — (1)
(1)    Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended March 31,
($ in millions)20242023
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$65 $13 
Foreign exchange contracts (2)
Sales(10)2 
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)    These derivative contracts serve as economic hedges of forecasted transactions.
At March 31, 2024, the Company estimates $113 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual foreign exchange rates at maturity.
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 March 31, 2024December 31, 2023
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
Commercial paper$40 $— $— $40 $252 $— $— $252 
U.S. government and agency securities77 — — 77 72 — — 72 
Corporate notes and bonds— — — — 13 — — 13 
Total debt securities$117 $— $— $117 $337 $— $— $337 
Publicly traded equity securities (1)
908 764 
Total debt and publicly traded equity securities$1,025 $1,101 
(1)    Unrealized net gains of $143 million were recorded in Other (income) expense, net in the first quarter of 2024 on equity securities still held at March 31, 2024. Unrealized net gains of $338 million were recorded in Other (income) expense, net in the first quarter of 2023 on equity securities still held at March 31, 2023.
At March 31, 2024 and March 31, 2023, the Company also had $851 million and $942 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During the first quarter of 2024, the Company recorded unrealized gains of $4 million and unrealized losses of $5 million related to certain of these equity investments still held at March 31, 2024. During the first quarter of 2023, the Company recorded unrealized gains of $1 million and unrealized losses of $21 million related to certain of these equity investments still held at March 31, 2023. Cumulative unrealized gains and cumulative unrealized losses based on observable
price changes for investments in equity investments without readily determinable fair values still held at March 31, 2024 were $297 million and $69 million, respectively.
At March 31, 2024 and March 31, 2023, the Company also had $396 million and $725 million, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. Losses (gains) recorded in Other (income) expense, net relating to these investment funds were $2 million and $(132) million for the first quarter of 2024 and 2023, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)March 31, 2024December 31, 2023
Assets
Investments
Commercial paper$— $40 $— $40 $— $252 $— $252 
Publicly traded equity securities280 — — 280 252 — — 252 
 280 40 — 320 252 252 — 504 
Other assets (1)
U.S. government and agency securities77 — — 77 72 — — 72 
Corporate notes and bonds— — — — 13 — — 13 
Publicly traded equity securities (2)
628 — — 628 512 — — 512 
705 — — 705 597 — — 597 
Derivative assets (3)
Forward exchange contracts— 204 — 204 — 202 — 202 
Purchased currency options— 126 — 126 — 83 — 83 
Interest rate swaps
— 27 — 27 — 57 — 57 
 — 357 — 357 — 342 — 342 
Total assets$985 $397 $— $1,382 $849 $594 $— $1,443 
Liabilities
Other liabilities
Contingent consideration$— $— $226 $226 $— $— $354 $354 
Derivative liabilities (3)
Forward exchange contracts— 149 — 149 — 239 — 239 
Written currency options— 18 — 18 — — — — 
— 167 — 167 — 239 — 239 
Total liabilities$— $167 $226 $393 $— $239 $354 $593 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    Balance at March 31, 2024 includes securities with a fair value of $266 million, which are subject to a contractual sale restriction that expires in July 2024.
(3)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of March 31, 2024 and December 31, 2023, Cash and cash equivalents included $4.6 billion and $6.0 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions)20242023
Fair value January 1$354 $456 
Changes in estimated fair value (1)
(2)14 
Payments(126)(117)
Fair value March 31 (2)
$226 $353 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    Balance at March 31, 2024, includes $133 million of current liabilities, all of which relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows.
The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at March 31, 2024, was $30.4 billion compared with a carrying value of $34.2 billion and at December 31, 2023, was $32.0 billion compared with a carrying value of $35.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers, distributors and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.7 billion and $3.0 billion of accounts receivable as of March 31, 2024 and December 31, 2023, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions, generally within thirty days after receipt. As of March 31, 2024 and December 31, 2023, the Company had collected $43 million and $44 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets and the related obligation to remit the cash within Accrued and other current liabilities. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $58 million and $3 million at March 31, 2024 and December 31, 2023, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of:
($ in millions)March 31, 2024December 31, 2023
Finished goods$1,902 $1,954 
Raw materials and work in process8,366 8,037 
Supplies276 277 
Total10,544 10,268 
Decrease to LIFO cost(621)(562)
 $9,923 $9,706 
Recognized as:
Inventories$6,510 $6,358 
Other Assets3,413 3,348 
Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At both March 31, 2024 and December 31, 2023, these amounts included $2.6 billion of inventories not expected to be sold within one year. In addition, these amounts included $861 million and $790 million at March 31, 2024 and December 31, 2023, respectively, of inventories produced in preparation for product launches.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Generally, for product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Dr. Scholl’s Foot Powder
Merck is a defendant in product liability lawsuits in the U.S. arising from consumers’ alleged exposure to talc in Dr. Scholl’s foot powder, which Merck acquired through its merger with Schering-Plough Corporation and sold as part of the divestiture of Merck’s consumer care business to Bayer in 2014. In these actions, plaintiffs allege that they were exposed to asbestos-contaminated talc and developed mesothelioma as a result. As of March 31, 2024, approximately 275 cases were pending against Merck in various state courts.
Gardasil/Gardasil 9
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of March 31, 2024, approximately 190 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the U.S. Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. In February 2024, the multidistrict litigation was reassigned to Judge Kenneth D. Bell. There are fewer than 15 product liability cases pending outside the U.S.
Governmental Proceedings
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, Merck Sharp & Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) were defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.
As previously disclosed, in April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck agreed to pay $572.5 million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs’ claims, which was recorded as an expense in the Company’s financial results in the first quarter of 2023. In October 2023, the court granted final approval of the indirect purchaser class settlement.
In 2020 and 2021, United Healthcare Services, Inc. (United Healthcare), Humana Inc. (Humana), Centene Corporation and others (Centene), and Kaiser Foundation Health Plan, Inc. (Kaiser) (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases were transferred to the Eastern District of Virginia to proceed with the Zetia MDL.
In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. In December 2023, prior to a decision on the motion to dismiss, the U.S. Judicial Panel on Multidistrict Litigation remanded the four Insurer Plaintiff cases to the transferor courts in the Northern District of California (Kaiser), the District of Minnesota (United Healthcare), and the District of New Jersey (Humana and Centene). On March 15, 2024, the Merck Defendants filed motions to dismiss the Humana and Centene cases.
Qui Tam Litigation
As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company’s M-M-R II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In July 2023, the court denied relators’ motion for summary judgment, granted two of the Company’s motions for summary judgment, and denied the Company’s remaining motions for summary judgment as moot. The court entered judgment in favor of the Company and dismissed relators’ amended complaint in full with prejudice. Relators have appealed that decision. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the M-M-R II vaccine, which charge that the Company misrepresented the efficacy of the M-M-R II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In the antitrust case, the court granted the Company’s motion for summary judgment as to plaintiffs’ state law claims and denied the motion as to plaintiffs’ antitrust claim. The Company has appealed the antitrust decision.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.
Bridion — As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies had filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey were consolidated. The West Virginia case was jointly dismissed with prejudice in August 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action stipulated to infringement of the asserted claims and withdrew all remaining claims and defenses other than a defense seeking to shorten the patent term extension (PTE) of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial in December 2022 on this remaining PTE calculation defense.
As previously disclosed, in June 2023, the U.S. District Court for the District of New Jersey ruled in Merck’s favor. The court held that Merck’s calculation of PTE for the sugammadex patent covering the compound is not invalid and that the U.S. Patent & Trademark Office correctly granted a full five-year extension. This ruling affirms and validates Merck’s U.S. patent protection for Bridion through at least January 2026. Also in June 2023, the U.S. District Court for the District of New Jersey issued a final judgment prohibiting the FDA from approving any of the pending or tentatively approved generic applications until January 27, 2026, except for any subsequent agreements between defendants and Merck or further order by the court.
In July 2023, defendants filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit. The appeal is currently pending.
While the New Jersey action was pending, the Company settled with five generic companies providing that these generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric exclusivity.
On February 5, 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Hikma Pharmaceuticals USA Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell a generic version of Bridion Injection. On March 15, 2024, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Hikma, postponing FDA approval of the Hikma generic drug for 30 months or until expiration of the sugammadex patent (January 27, 2026) and any potentially applicable pediatric exclusivity or an adverse court decision, if any, whichever may occur earlier. Expiration of the patent, and any potentially applicable pediatric exclusivity, will occur earlier than expiry of the 30-month stay.
Januvia, Janumet, Janumet XR — As previously disclosed, the FDA granted pediatric exclusivity with respect to Januvia (sitagliptin), Janumet (sitagliptin/metformin HCI), and Janumet XR (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent).
As previously disclosed, beginning in 2019, a number of generic drug companies filed ANDAs seeking approval of generic forms of Januvia and Janumet along with paragraph IV certifications challenging the validity of the 2027 salt/polymorph patent. The Company responded by filing infringement suits which have all been settled. The Company has settled with a total of 26 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the market in the U.S. in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in July 2026 or earlier under certain circumstances.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of a form of sitagliptin that is a different form than that used in Januvia. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product.
In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA’s Orange Book for Janumet will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Janumet. In November 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl Extended Release tablets. In January 2024, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable version containing a different form of sitagliptin than that used in Janumet XR.
As a result of these settlement agreements related to the later expiring 2027 salt/polymorph patent directed to the specific sitagliptin salt form of the products, the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although Zydus has received FDA approval for a non-automatically substitutable form of sitagliptin that differs from the form in the Company’s sitagliptin products.
Supplementary Protection Certificates (SPCs) for Janumet expired in April 2023 for the majority of European countries. Prior to expiration, generic companies sought revocation of the Janumet SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the Janumet SPCs in Europe, for which an oral hearing was held in March 2023 and an Advocate General Opinion is expected in June 2024 with a decision later in 2024. If the CJEU renders a decision that negatively impacts the validity of the Janumet SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the Janumet SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the Janumet SPC.
In October 2023, the Company filed a patent infringement lawsuit against Sawai Pharmaceuticals Co., Ltd. and Medisa Shinyaku Co., Ltd (collectively, Defendants) in the Tokyo District Court seeking an injunction to stop the manufacture, sale and offer for sale of the Defendants’ sitagliptin dihydrogen phosphate product, while the Company’s patents and patent term extensions are in force. The lawsuit is in response to the Defendants’ application for marketing authorization to sell a generic sitagliptin dihydrogen phosphate product, in the anhydrate form, which was approved on August 15, 2023. Merck asserts that the Defendants’ activity infringes a patent term extension associated with Merck’s patent directed to the sitagliptin compound patent.
Keytruda — As previously disclosed, in November 2022, the Company filed a complaint against The Johns Hopkins University (JHU) in the U.S. District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name Keytruda. Merck and JHU partnered to design and conduct a clinical study administering Keytruda to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract, declaratory judgment of noninfringement, and promissory estoppel. JHU answered the complaint in April and May 2023, denying Merck’s claims, and counterclaiming for willful infringement of nine issued U.S. patents, including a demand for damages. Between November 30, 2023, and March 13, 2024, the Company filed inter partes review petitions with the United States Patent & Trademark Office Patent Trial and Appeal Board, challenging the validity of all nine patents asserted in the case.
Lynparza — In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey/Delaware against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.
In December 2023, AstraZeneca Pharmaceuticals LP received a second Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Sandoz Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Sandoz. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2026 or until an adverse court decision, if any, whichever may occur earlier.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials; and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March 31, 2024 and December 31, 2023 of approximately $220 million and $210 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Equity
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Equity Equity
Three Months Ended March 31,
   Common StockOther
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		 Treasury StockNon-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 2023
3,577 $1,788 $44,379 $61,081 $(4,768)1,039 $(56,489)$67 $46,058 
Net income attributable to Merck & Co., Inc.— — — 2,821 — — — — 2,821 
Other comprehensive loss, net of taxes— — — — (115)— — — (115)
Cash dividends declared on common stock ($0.73 per share)
— — — (1,863)— — — — (1,863)
Treasury stock shares purchased— — — — — 1 (149)— (149)
Share-based compensation plans and other— — 88 — — — 61 — 149 
Net income attributable to noncontrolling interests— — — — — — — 4 4 
Balance at March 31, 20233,577 $1,788 $44,467 $62,039 $(4,883)1,040 $(56,577)$71 $46,905 
Balance at January 1, 2024
3,577 $1,788 $44,509 $53,895 $(5,161)1,045 $(57,450)$54 $37,635 
Net income attributable to Merck & Co., Inc.— — — 4,762 — — — — 4,762 
Other comprehensive loss, net of taxes
— — — — (113)— — — (113)
Cash dividends declared on common stock ($0.77 per share)
— — — (1,960)— — — — (1,960)
Treasury stock shares purchased— — — — — 1 (122)— (122)
Share-based compensation plans and other— — 89 — — (2)127 1 217 
Net income attributable to noncontrolling interests— — — — — — — 5 5 
Balance at March 31, 20243,577 $1,788 $44,598 $56,697 $(5,274)1,044 $(57,445)$60 $40,424 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pension and Other Postretirement Benefit Plans
 3 Months Ended
Mar. 31, 2024
Retirement Benefits [Abstract]  
Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: 
  Three Months Ended
March 31,
20242023
($ in millions)U.S.InternationalU.S.International
Service cost$86 $61 $76 $49 
Interest cost134 74 133 74 
Expected return on plan assets(207)(139)(187)(128)
Amortization of unrecognized prior service credit
— (3)— (3)
Net loss (gain) amortization
10 1 — (1)
Termination benefits3 — — — 
Curtailments— — 2 — 
Settlements— — 21 — 
 $26 $(6)$45 $(9)
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
March 31,
($ in millions)20242023
Service cost$8 $8 
Interest cost14 16 
Expected return on plan assets(20)(16)
Amortization of unrecognized prior service credit(11)(12)
Net gain amortization(12)(11)
 $(21)$(15)
In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of $21 million in the first quarter of 2023. This partial settlement triggered a remeasurement of some of the Company’s U.S. pension plans. The remeasurement, which was calculated using discount rates and asset values as of March 31, 2023, resulted in a net increase of $44 million to net pension liabilities and also resulted in a related adjustment to AOCL.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 10), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement related to restructuring actions.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other (Income) Expense, Net
 3 Months Ended
Mar. 31, 2024
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
March 31,
($ in millions)20242023
Interest income$(73)$(112)
Interest expense303 242 
Exchange losses83 61 
Income from investments in equity securities, net (1)
(143)(450)
Net periodic defined benefit plan (credit) cost other than service cost(160)(115)
Other, net(43)463 
 $(33)$89 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
Other, net (as reflected in the table above) in the first three months of 2023 includes a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 7).
Interest paid for the three months ended March 31, 2024 and 2023 was $217 million and $208 million, respectively.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The effective income tax rate of 15.9% for the first quarter of 2024 reflects a 1.6 percentage point unfavorable discrete impact of a charge for the acquisition of Harpoon for which no tax benefit was recognized. The effective income tax rate of 22.6% for the first quarter of 2023 reflects a 5.5 percentage point unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized.
The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the Tax Cuts and Jobs Act of 2017. If the IRS disagrees with the Company’s transition tax position, it may result in a significant tax liability. The statute of limitations for assessments with respect to the 2019 and 2020 federal return years will expire in June and October of 2024, respectively, unless extended.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
March 31,
($ and shares in millions except per share amounts)20242023
Net Income Attributable to Merck & Co., Inc.$4,762 $2,821 
Average common shares outstanding2,533 2,538 
Common shares issuable (1)
11 13 
Average common shares outstanding assuming dilution 2,544 2,551 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders$1.88 $1.11 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$1.87 $1.11 
(1)    Issuable primarily under share-based compensation plans.
For the first quarter of 2024 and 2023, 3 million and 1 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computations of earnings per common share assuming dilution because the effect would have been antidilutive.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Comprehensive Income (Loss)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Other Comprehensive Income (Loss) Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended March 31,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance January 1, 2023, net of taxes
$73 $(2,408)$(2,433)$(4,768)
Other comprehensive income (loss) before reclassification adjustments, pretax(66)(47)79 (34)
Tax14 2 (20)(4)
Other comprehensive income (loss) before reclassification adjustments, net of taxes(52)(45)59 (38)
Reclassification adjustments, pretax(102)
(1)
(7)
(2)
9 (100)
Tax21 2 — 23 
Reclassification adjustments, net of taxes(81)

(5)

9 (77)
Other comprehensive income (loss), net of taxes(133)(50)68 (115)
Balance March 31, 2023, net of taxes
$(60)$(2,458)$(2,365)$(4,883)
Balance January 1, 2024, net of taxes
$(24)$(2,793)$(2,344)$(5,161)
Other comprehensive income (loss) before reclassification adjustments, pretax209 5 (225)(11)
Tax(44)(4)(13)(61)
Other comprehensive income (loss) before reclassification adjustments, net of taxes165 1 (238)(72)
Reclassification adjustments, pretax(44)
(1)
(15)
(2)
— (59)
Tax9 9 — 18 
Reclassification adjustments, net of taxes(35)

(6)

— (41)
Other comprehensive income (loss), net of taxes130 (5)(238)(113)
Balance March 31, 2024, net of taxes
$106 $(2,798)$(2,582)$(5,274)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 9).
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Reporting
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
Sales of the Company’s products were as follows:
Three Months Ended March 31,
20242023
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$4,119 $2,828 $6,947 $3,485 $2,310 $5,795 
Alliance revenue-Lynparza (1)
135 157 292 142 133 275 
Alliance revenue-Lenvima (1)
173 82 255 153 79 232 
Welireg77 7 85 41 1 42 
Alliance revenue-Reblozyl (2)
58 12 71 30 12 43 
Vaccines
Gardasil/Gardasil 9
488 1,761 2,249 416 1,556 1,972 
ProQuad/M-M-R II/Varivax
438 133 570 421 107 528 
Vaxneuvance161 58 219 94 13 106 
RotaTeq149 67 216 180 117 297 
Pneumovax 23
6 55 61 40 56 96 
Hospital Acute Care
Bridion329 111 440 276 210 487 
Prevymis74 100 174 54 75 129 
Dificid68 5 73 62 3 65 
Zerbaxa33 23 56 27 23 50 
Noxafil8 48 56 14 46 60 
Cardiovascular
Alliance revenue-Adempas/Verquvo (3)
90 8 98 83 16 99 
Adempas— 70 70 — 59 59 
Virology
Lagevrio45 305 350 (2)394 392 
Isentress/Isentress HD
50 61 111 52 71 123 
Delstrigo
12 44 56 11 33 44 
Pifeltro
29 13 42 24 10 34 
Neuroscience
Belsomra15 32 46 16 40 56 
Immunology
Simponi— 184 184 — 180 180 
Remicade— 39 39 — 51 51 
Diabetes
Januvia183 236 419 271 280 551 
Janumet39 212 251 56 272 329 
Other pharmaceutical (4)
157 419 576 171 457 626 
Total Pharmaceutical segment sales6,936 7,070 14,006 6,117 6,604 12,721 
Animal Health:
Livestock166 683 850 174 676 849 
Companion Animal308 354 661 308 334 642 
Total Animal Health segment sales474 1,037 1,511 482 1,010 1,491 
Total segment sales7,410 8,107 15,517 6,599 7,614 14,212 
Other (5)
68 190 258 60 214 275 
 $7,478 $8,297 $15,775 $6,659 $7,828 $14,487 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue for Reblozyl represents royalties (see Note 3).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $54 million and $99 million for the three months ended March 31, 2024 and 2023, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2024 and 2023 also includes $61 million and $51 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.2 billion and $3.1 billion for the three months ended March 31, 2024 and 2023, respectively.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
March 31,
($ in millions)20242023
United States$7,478 $6,659 
Europe, Middle East and Africa3,563 3,303 
China1,772 1,715 
Japan821 758 
Latin America796 661 
Asia Pacific (other than China and Japan)724 846 
Other621 545 
 $15,775 $14,487 
A reconciliation of segment profits to Income Before Taxes is as follows:
 Three Months Ended
March 31,
($ in millions)20242023
Segment profits:
Pharmaceutical segment$10,904 $9,140 
Animal Health segment555 566 
Total segment profits11,459 9,706 
Other profits146 164 
Unallocated:
Interest income73 112 
Interest expense(303)(242)
Amortization(473)(543)
Depreciation(452)(398)
Research and development(3,851)(4,147)
Restructuring costs(123)(67)
Charge for Zetia antitrust litigation settlements— (573)
Other unallocated, net(806)(362)
 $5,670 $3,650 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and amortization of purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits (losses) related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net Income Attributable to Merck & Co., Inc. $ 4,762 $ 2,821
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation (Policies)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2024.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Recently Issued Accounting Standard Not Yet Adopted
Recently Issued Accounting Standards Not Yet Adopted
In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The amended guidance is effective prospectively for all joint ventures with a formation date on or after January 1, 2025, however existing joint ventures have the option to apply the guidance retrospectively. Early adoption is permitted for both interim and annual periods. The Company anticipates there will be no impact to its consolidated financial statements upon adoption.
In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses. The guidance is effective for annual periods beginning in 2024, and interim periods beginning in 2025. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.
In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. Early adoption is permitted. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.
Legal Costs Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements (Tables)
 3 Months Ended
Mar. 31, 2024
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Lynparza$292 $275 
Alliance revenue - Koselugo38 23 
Total alliance revenue$330 $298 
Cost of sales (1)
82 70 
Selling, general and administrative39 47 
Research and development20 21 
($ in millions)March 31, 2024December 31, 2023
Receivables from AstraZeneca included in Other current assets
$334 $341 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
617 256 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
— 600 
(1)    Represents amortization of capitalized milestone payments.
(2)    Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Lenvima$255 $232 
Cost of sales (1)
60 126 
Selling, general and administrative39 51 
Research and development8 39 
($ in millions)March 31, 2024December 31, 2023
Receivables from Eisai included in Other current assets
$255 $226 
Payables to Eisai included in Accrued and other current liabilities (2)
125 125 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.
(2)    Represents an accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Adempas/Verquvo$98 $99 
Net sales of Adempas recorded by Merck70 59 
Net sales of Verquvo recorded by Merck5 7 
Total sales$173 $165 
Cost of sales (1)
62 57 
Selling, general and administrative33 33 
Research and development28 25 
($ in millions)March 31, 2024December 31, 2023
Receivables from Bayer included in Other current assets
$155 $156 
Payables to Bayer included in Accrued and other current liabilities
74 80 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Net sales of Lagevrio recorded by Merck
$350 $392 
Cost of sales (1)
191 221 
Selling, general and administrative
16 27 
Research and development
(5)16 
($ in millions)March 31, 2024December 31, 2023
Payables to Ridgeback included in Accrued and other current liabilities (2)
$160 $113 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Selling, general and administrative $3 $— 
Research and development
69 — 
($ in millions)March 31, 2024December 31, 2023
Payables to Daiichi Sankyo included in Accrued and other current liabilities
$817 $800 
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities
750 750 
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Selling, general and administrative $2 $1 
Research and development
69 26 
($ in millions)March 31, 2024December 31, 2023
Payables to Moderna included in Accrued and other current liabilities
$72 $63 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring (Tables)
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Charges Related to Restructuring Program Activities by Type of Cost
The following tables summarize the charges related to the restructuring programs by type of cost:
 Three Months Ended March 31, 2024
($ in millions)
Accelerated Depreciation
Separation Costs
Other Exit Costs
Total
2024 Restructuring Program
Cost of sales$65 $— $51 $116 
Selling, general and administrative— — 5 5 
Research and development— — 2 2 
Restructuring costs— 92 31 123 
$65 $92 $89 $246 
 Three Months Ended March 31, 2023
($ in millions)
Accelerated Depreciation
Separation Costs
Other Exit Costs
Total
2019 Restructuring Program
Cost of sales$21 $— $8 $29 
Selling, general and administrative— — 1 1 
Restructuring costs— 41 26 67 
$21 $41 $35 $97 
Charges and Spending Relating to Restructuring Activities by Program
The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2024:
($ in millions)
Accelerated Depreciation
Separation
Costs
Other Exit Costs
Total
Restructuring reserves January 1, 2024
$— $681 $31 $712 
Expenses65 92 89 246 
(Payments) receipts, net— (67)(32)(99)
Non-cash activity(65)— (58)(123)
Restructuring reserves March 31, 2024
$— $706 $30 $736 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments (Tables)
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Effect of Net Investment Hedges on OCI and the Consolidated Statement of Operations
The effects of the Company’s net investment hedges on OCI and the Condensed Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended March 31,Three Months Ended March 31,
($ in millions)2024202320242023
Net Investment Hedging Relationships
Foreign exchange contracts$(2)$1 $— $1 
Euro-denominated notes(62)52 — — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Summary of Interest Rate Swaps Held
At March 31, 2024, the Company was a party to four pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of a portion of fixed-rate notes as detailed in the table below.
March 31, 2024
($ in millions)
Par Value of Debt
Number of Interest Rate Swaps Held
Total Swap Notional Amount
4.50% notes due 2033
$1,500 4 $1,000 
Amounts Recorded on Balance Sheet Related to Fair Value Hedges
The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged Liabilities
Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount
($ in millions)
March 31, 2024December 31, 2023March 31, 2024December 31, 2023
Balance Sheet Caption
Long-Term Debt
$1,026 $1,056 $26 $56 
Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  March 31, 2024December 31, 2023
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption
Interest rate swap contracts
Other Assets
$27 $— $1,000 $57 $— $1,000 
Foreign exchange contractsOther current assets175 — 9,082 106 — 6,138 
Foreign exchange contractsOther Assets32 — 2,062 26 — 1,929 
Foreign exchange contractsAccrued and other current liabilities— 10 1,076 — 76 3,680 
Foreign exchange contractsOther Noncurrent Liabilities— 1 204 — 1 7 
  234 11 13,424 189 77 12,754 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets121 — 9,428 153 — 9,693 
Foreign exchange contractsOther Assets2 — 43 — — — 
Foreign exchange contractsAccrued and other current liabilities— 154 9,282 — 162 8,104 
Foreign exchange contractsOther Noncurrent Liabilities— 2 43 — — — 
  123 156 18,796 153 162 17,797 
  $357 $167 $32,220 $342 $239 $30,551 
Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 March 31, 2024December 31, 2023
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$357 $167 $342 $239 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(111)(111)(215)(215)
Cash collateral received
(58)— (3)— 
Net amounts$188 $56 $124 $24 
Location and Amount of Pretax Gains and Losses of Derivatives
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended March 31,
($ in millions)202420232024202320242023
Financial Statement Caption in which Effects of Fair Value or Cash Flow
Hedges are Recorded
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$15,775 $14,487 $(33)$89 $(113)$(115)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items— — (30)— — — 
Derivatives designated as hedging instruments— — 30 — — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain (loss) recognized in OCI on derivatives
— — — — 209 (66)
Increase in Sales as a result of AOCL reclassifications
44 101 — — (44)(101)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — — (1)— — 
Amount of loss recognized in OCI on derivatives
— — — — — (1)
(1)    Interest expense is a component of Other (income) expense, net.
Income Statement Effects of Derivatives Not Designated as Hedging Instruments
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended March 31,
($ in millions)20242023
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$65 $13 
Foreign exchange contracts (2)
Sales(10)2 
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)    These derivative contracts serve as economic hedges of forecasted transactions.
Information on Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 March 31, 2024December 31, 2023
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
Commercial paper$40 $— $— $40 $252 $— $— $252 
U.S. government and agency securities77 — — 77 72 — — 72 
Corporate notes and bonds— — — — 13 — — 13 
Total debt securities$117 $— $— $117 $337 $— $— $337 
Publicly traded equity securities (1)
908 764 
Total debt and publicly traded equity securities$1,025 $1,101 
(1)    Unrealized net gains of $143 million were recorded in Other (income) expense, net in the first quarter of 2024 on equity securities still held at March 31, 2024. Unrealized net gains of $338 million were recorded in Other (income) expense, net in the first quarter of 2023 on equity securities still held at March 31, 2023.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)March 31, 2024December 31, 2023
Assets
Investments
Commercial paper$— $40 $— $40 $— $252 $— $252 
Publicly traded equity securities280 — — 280 252 — — 252 
 280 40 — 320 252 252 — 504 
Other assets (1)
U.S. government and agency securities77 — — 77 72 — — 72 
Corporate notes and bonds— — — — 13 — — 13 
Publicly traded equity securities (2)
628 — — 628 512 — — 512 
705 — — 705 597 — — 597 
Derivative assets (3)
Forward exchange contracts— 204 — 204 — 202 — 202 
Purchased currency options— 126 — 126 — 83 — 83 
Interest rate swaps
— 27 — 27 — 57 — 57 
 — 357 — 357 — 342 — 342 
Total assets$985 $397 $— $1,382 $849 $594 $— $1,443 
Liabilities
Other liabilities
Contingent consideration$— $— $226 $226 $— $— $354 $354 
Derivative liabilities (3)
Forward exchange contracts— 149 — 149 — 239 — 239 
Written currency options— 18 — 18 — — — — 
— 167 — 167 — 239 — 239 
Total liabilities$— $167 $226 $393 $— $239 $354 $593 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    Balance at March 31, 2024 includes securities with a fair value of $266 million, which are subject to a contractual sale restriction that expires in July 2024.
(3)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
Information About the Changes in Liabilities for Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions)20242023
Fair value January 1$354 $456 
Changes in estimated fair value (1)
(2)14 
Payments(126)(117)
Fair value March 31 (2)
$226 $353 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    Balance at March 31, 2024, includes $133 million of current liabilities, all of which relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories (Tables)
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Inventory, current
Inventories consisted of:
($ in millions)March 31, 2024December 31, 2023
Finished goods$1,902 $1,954 
Raw materials and work in process8,366 8,037 
Supplies276 277 
Total10,544 10,268 
Decrease to LIFO cost(621)(562)
 $9,923 $9,706 
Recognized as:
Inventories$6,510 $6,358 
Other Assets3,413 3,348 
Inventory, noncurrent
Inventories consisted of:
($ in millions)March 31, 2024December 31, 2023
Finished goods$1,902 $1,954 
Raw materials and work in process8,366 8,037 
Supplies276 277 
Total10,544 10,268 
Decrease to LIFO cost(621)(562)
 $9,923 $9,706 
Recognized as:
Inventories$6,510 $6,358 
Other Assets3,413 3,348 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Equity (Tables)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Equity
Three Months Ended March 31,
   Common StockOther
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		 Treasury StockNon-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 2023
3,577 $1,788 $44,379 $61,081 $(4,768)1,039 $(56,489)$67 $46,058 
Net income attributable to Merck & Co., Inc.— — — 2,821 — — — — 2,821 
Other comprehensive loss, net of taxes— — — — (115)— — — (115)
Cash dividends declared on common stock ($0.73 per share)
— — — (1,863)— — — — (1,863)
Treasury stock shares purchased— — — — — 1 (149)— (149)
Share-based compensation plans and other— — 88 — — — 61 — 149 
Net income attributable to noncontrolling interests— — — — — — — 4 4 
Balance at March 31, 20233,577 $1,788 $44,467 $62,039 $(4,883)1,040 $(56,577)$71 $46,905 
Balance at January 1, 2024
3,577 $1,788 $44,509 $53,895 $(5,161)1,045 $(57,450)$54 $37,635 
Net income attributable to Merck & Co., Inc.— — — 4,762 — — — — 4,762 
Other comprehensive loss, net of taxes
— — — — (113)— — — (113)
Cash dividends declared on common stock ($0.77 per share)
— — — (1,960)— — — — (1,960)
Treasury stock shares purchased— — — — — 1 (122)— (122)
Share-based compensation plans and other— — 89 — — (2)127 1 217 
Net income attributable to noncontrolling interests— — — — — — — 5 5 
Balance at March 31, 20243,577 $1,788 $44,598 $56,697 $(5,274)1,044 $(57,445)$60 $40,424 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pension and Other Postretirement Benefit Plans (Tables)
 3 Months Ended
Mar. 31, 2024
Pension Plans  
Defined Benefit Plan Disclosure [Line Items]  
Net Benefit Costs
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: 
  Three Months Ended
March 31,
20242023
($ in millions)U.S.InternationalU.S.International
Service cost$86 $61 $76 $49 
Interest cost134 74 133 74 
Expected return on plan assets(207)(139)(187)(128)
Amortization of unrecognized prior service credit
— (3)— (3)
Net loss (gain) amortization
10 1 — (1)
Termination benefits3 — — — 
Curtailments— — 2 — 
Settlements— — 21 — 
 $26 $(6)$45 $(9)
Other Postretirement Benefit Plans  
Defined Benefit Plan Disclosure [Line Items]  
Net Benefit Costs
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
March 31,
($ in millions)20242023
Service cost$8 $8 
Interest cost14 16 
Expected return on plan assets(20)(16)
Amortization of unrecognized prior service credit(11)(12)
Net gain amortization(12)(11)
 $(21)$(15)
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other (Income) Expense, Net (Tables)
 3 Months Ended
Mar. 31, 2024
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
March 31,
($ in millions)20242023
Interest income$(73)$(112)
Interest expense303 242 
Exchange losses83 61 
Income from investments in equity securities, net (1)
(143)(450)
Net periodic defined benefit plan (credit) cost other than service cost(160)(115)
Other, net(43)463 
 $(33)$89 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Calculations of Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
March 31,
($ and shares in millions except per share amounts)20242023
Net Income Attributable to Merck & Co., Inc.$4,762 $2,821 
Average common shares outstanding2,533 2,538 
Common shares issuable (1)
11 13 
Average common shares outstanding assuming dilution 2,544 2,551 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders$1.88 $1.11 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$1.87 $1.11 
(1)    Issuable primarily under share-based compensation plans.
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Comprehensive Income (Loss) (Tables)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Changes in AOCI by Component
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended March 31,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance January 1, 2023, net of taxes
$73 $(2,408)$(2,433)$(4,768)
Other comprehensive income (loss) before reclassification adjustments, pretax(66)(47)79 (34)
Tax14 2 (20)(4)
Other comprehensive income (loss) before reclassification adjustments, net of taxes(52)(45)59 (38)
Reclassification adjustments, pretax(102)
(1)
(7)
(2)
9 (100)
Tax21 2 — 23 
Reclassification adjustments, net of taxes(81)

(5)

9 (77)
Other comprehensive income (loss), net of taxes(133)(50)68 (115)
Balance March 31, 2023, net of taxes
$(60)$(2,458)$(2,365)$(4,883)
Balance January 1, 2024, net of taxes
$(24)$(2,793)$(2,344)$(5,161)
Other comprehensive income (loss) before reclassification adjustments, pretax209 5 (225)(11)
Tax(44)(4)(13)(61)
Other comprehensive income (loss) before reclassification adjustments, net of taxes165 1 (238)(72)
Reclassification adjustments, pretax(44)
(1)
(15)
(2)
— (59)
Tax9 9 — 18 
Reclassification adjustments, net of taxes(35)

(6)

— (41)
Other comprehensive income (loss), net of taxes130 (5)(238)(113)
Balance March 31, 2024, net of taxes
$106 $(2,798)$(2,582)$(5,274)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 9).
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Sales from Products
Sales of the Company’s products were as follows:
Three Months Ended March 31,
20242023
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$4,119 $2,828 $6,947 $3,485 $2,310 $5,795 
Alliance revenue-Lynparza (1)
135 157 292 142 133 275 
Alliance revenue-Lenvima (1)
173 82 255 153 79 232 
Welireg77 7 85 41 1 42 
Alliance revenue-Reblozyl (2)
58 12 71 30 12 43 
Vaccines
Gardasil/Gardasil 9
488 1,761 2,249 416 1,556 1,972 
ProQuad/M-M-R II/Varivax
438 133 570 421 107 528 
Vaxneuvance161 58 219 94 13 106 
RotaTeq149 67 216 180 117 297 
Pneumovax 23
6 55 61 40 56 96 
Hospital Acute Care
Bridion329 111 440 276 210 487 
Prevymis74 100 174 54 75 129 
Dificid68 5 73 62 3 65 
Zerbaxa33 23 56 27 23 50 
Noxafil8 48 56 14 46 60 
Cardiovascular
Alliance revenue-Adempas/Verquvo (3)
90 8 98 83 16 99 
Adempas— 70 70 — 59 59 
Virology
Lagevrio45 305 350 (2)394 392 
Isentress/Isentress HD
50 61 111 52 71 123 
Delstrigo
12 44 56 11 33 44 
Pifeltro
29 13 42 24 10 34 
Neuroscience
Belsomra15 32 46 16 40 56 
Immunology
Simponi— 184 184 — 180 180 
Remicade— 39 39 — 51 51 
Diabetes
Januvia183 236 419 271 280 551 
Janumet39 212 251 56 272 329 
Other pharmaceutical (4)
157 419 576 171 457 626 
Total Pharmaceutical segment sales6,936 7,070 14,006 6,117 6,604 12,721 
Animal Health:
Livestock166 683 850 174 676 849 
Companion Animal308 354 661 308 334 642 
Total Animal Health segment sales474 1,037 1,511 482 1,010 1,491 
Total segment sales7,410 8,107 15,517 6,599 7,614 14,212 
Other (5)
68 190 258 60 214 275 
 $7,478 $8,297 $15,775 $6,659 $7,828 $14,487 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue for Reblozyl represents royalties (see Note 3).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $54 million and $99 million for the three months ended March 31, 2024 and 2023, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2024 and 2023 also includes $61 million and $51 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Consolidated Sales by Geographic Area
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
March 31,
($ in millions)20242023
United States$7,478 $6,659 
Europe, Middle East and Africa3,563 3,303 
China1,772 1,715 
Japan821 758 
Latin America796 661 
Asia Pacific (other than China and Japan)724 846 
Other621 545 
 $15,775 $14,487 
Reconciliation of Segment Profits to Income before Taxes
A reconciliation of segment profits to Income Before Taxes is as follows:
 Three Months Ended
March 31,
($ in millions)20242023
Segment profits:
Pharmaceutical segment$10,904 $9,140 
Animal Health segment555 566 
Total segment profits11,459 9,706 
Other profits146 164 
Unallocated:
Interest income73 112 
Interest expense(303)(242)
Amortization(473)(543)
Depreciation(452)(398)
Research and development(3,851)(4,147)
Restructuring costs(123)(67)
Charge for Zetia antitrust litigation settlements— (573)
Other unallocated, net(806)(362)
 $5,670 $3,650 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details)
$ in Millions
 1 Months Ended 2 Months Ended 3 Months Ended
Jun. 02, 2021
Mar. 31, 2024
USD ($)
jurisdiction
Jan. 31, 2023
USD ($)
Jul. 31, 2024
USD ($)
Mar. 31, 2024
USD ($)
jurisdiction
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Oct. 31, 2023
USD ($)
candidate
Feb. 28, 2023
candidate
Business Acquisition [Line Items]                  
Research and development         $ 3,992 $ 4,276      
Sales         15,775 14,487      
Cost of sales         3,540 3,926      
Other current assets   $ 7,950     7,950   $ 8,368    
Accrued and other current liabilities   14,102     14,102   15,766    
Related Party                  
Business Acquisition [Line Items]                  
Other current assets   462     462   632    
Accrued and other current liabilities   $ 193     193   $ 598    
Manufacturing and Supply Agreements | Related Party                  
Business Acquisition [Line Items]                  
Sales         107 94      
Cost of sales         $ 110 107      
Minimum | Manufacturing and Supply Agreements | Related Party                  
Business Acquisition [Line Items]                  
Period of continuing involvement after disposal 4 years                
Maximum | Manufacturing and Supply Agreements | Related Party                  
Business Acquisition [Line Items]                  
Period of continuing involvement after disposal 10 years                
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Organon & Co.                  
Business Acquisition [Line Items]                  
Number of jurisdictions remaining | jurisdiction   1     1        
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                  
Business Acquisition [Line Items]                  
Number of antibody drug conjugates obtained right and obligations | candidate                 7
Upfront payment made to collaborative partner           175      
Number of antibody drug conjugates terminated with collaborative partner | candidate               2  
Eligible future contingent development-related payments (up to)               $ 600  
Eligible future contingent regulatory milestone payments (up to)               1,600  
Eligible future contingent sales-based milestone payments (up to)               $ 3,100  
Stock investment in counterparty     $ 100            
Elanco Animal Health Incorporated Aqua Business | Forecast                  
Business Acquisition [Line Items]                  
Payment to acquire business       $ 1,300          
Harpoon Therapeutics, Inc.                  
Business Acquisition [Line Items]                  
Consideration transferred, asset acquisition   $ 765              
Asset acquisition, transaction costs   56              
Net assets acquired   $ 165              
Research and development         $ 656        
Imago Bio Sciences, Inc.                  
Business Acquisition [Line Items]                  
Consideration transferred, asset acquisition     1,350            
Asset acquisition, transaction costs     60            
Net assets acquired     $ 219            
Research and development           $ 1,200      
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) - Lynparza - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2022
Other Intangible Assets | Licenses and Other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets $ 1,400    
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Probable contingent payments     $ 600
Liabilities     $ 600
Eligible future contingent sales-based milestone payments (up to) 2,100    
Regulatory milestone payments 245 $ 105  
Eligible future contingent regulatory milestone payments (up to) $ 650    
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales $ 3,540 $ 3,926  
Selling, general and administrative 2,483 2,479  
Research and development 3,992 4,276  
Other current assets 31,445   $ 32,168
Accrued and other current liabilities 14,102   15,766
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 330 298  
Cost of sales 82 70  
Selling, general and administrative 39 47  
Research and development 20 21  
Other current assets 334   341
Accrued and other current liabilities 617   256
Other noncurrent liabilities 0   $ 600
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 292 275  
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement $ 38 $ 23  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Mar. 31, 2024
Alliance revenue - Lenvima | Other Intangible Assets | Licenses and Other        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Finite-lived intangible assets       $ 623
Eisai        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Amortization of intangible assets $ 81   $ 72  
Eisai | Alliance revenue - Lenvima | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Probable contingent payments 125   $ 125  
Liabilities $ 250     125
Sales-based milestone payments   $ 125    
Eligible future contingent sales-based milestone payments (up to)       $ 2,300
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - Eisai Co., Ltd. (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Cost of sales $ 3,540   $ 3,926  
Selling, general and administrative 2,483   2,479  
Research and development 3,992   4,276  
Other current assets 31,445     $ 32,168
Accrued and other current liabilities 14,102     15,766
Eisai        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Amortization of intangible assets   $ 81 72  
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue from collaborative arrangement 255   232  
Cost of sales 60   126  
Selling, general and administrative 39   51  
Research and development 8   $ 39  
Other current assets 255     226
Accrued and other current liabilities $ 125     $ 125
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - Bayer AG (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 15,775 $ 14,487  
Cost of sales 3,540 3,926  
Selling, general and administrative 2,483 2,479  
Research and development 3,992 4,276  
Other current assets 31,445   $ 32,168
Accrued and other current liabilities 14,102   15,766
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Eligible future contingent sales-based milestone payments (up to) 0    
Revenue from collaborative arrangement 98 99  
Sales 173 165  
Cost of sales 62 57  
Selling, general and administrative 33 33  
Research and development 28 25  
Other current assets 155   156
Accrued and other current liabilities 74   $ 80
Adempas | Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 70 59  
Adempas | Other Intangible Assets | Licenses and Other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets 483    
Verquvo | Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 5 $ 7  
Verquvo | Other Intangible Assets | Licenses and Other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets $ 49    
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 15,775 $ 14,487  
Cost of sales 3,540 3,926  
Selling, general and administrative 2,483 2,479  
Accrued and other current liabilities 14,102   $ 15,766
Ridgeback Biotherapeutics LP | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 191 221  
Selling, general and administrative 16 27  
Research and development expense (credit) (5) 16  
Accrued and other current liabilities 160   $ 113
Ridgeback Biotherapeutics LP | Lagevrio | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 350 $ 392  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - Daiicho Sankyo - Narrative (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Oct. 31, 2023
USD ($)
candidate
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development $ 3,992   $ 4,276  
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of antibody drug conjugates obtained right and obligations | candidate       3
Aggregate upfront payments due upon execution in collaborative arrangement       $ 4,000
Refundable upfront payments in collaborative arrangement       1,000
Maximum aggregate contingent milestone payments, per product, in collaborative arrangement       $ 5,500
Research and development $ 69 $ 5,500 $ 0  
Sales based royalty percentage       5.00%
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Ifinatamab Deruxtecan        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Refundable upfront payments in collaborative arrangement       $ 500
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Patritumab Deruxtecan        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Refundable upfront payments in collaborative arrangement       500
Aggregate upfront payments due upon lapse of time in collaborative arrangement       750
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Raludotatug Deruxtecan        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Aggregate upfront payments due upon lapse of time in collaborative arrangement       $ 750
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement, percentage       75.00%
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement       $ 2,000
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Patritumab Deruxtecan And Raludotatug Deruxtecan        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Aggregate upfront payments due upon lapse of time in collaborative arrangement   $ 1,500    
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - Daiicho Sankyo (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative $ 2,483   $ 2,479
Research and development 3,992   4,276
Accrued and other current liabilities 14,102 $ 15,766  
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 3   0
Research and development 69 5,500 $ 0
Accrued and other current liabilities 817 800  
Other noncurrent liabilities $ 750 $ 750  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - Moderna, Inc. - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Research and development $ 3,992 $ 4,276
Moderna, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Research and development 69 $ 26
Prepaid Expense and Other Assets $ 110  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - Moderna, Inc. (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative $ 2,483 $ 2,479  
Research and development 3,992 4,276  
Accrued and other current liabilities 14,102   $ 15,766
Moderna, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 2 1  
Research and development 69 $ 26  
Accrued and other current liabilities $ 72   $ 63
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details) - Bristol Myers Squibb Company - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Licensing Agreements    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Royalty rate, deduction 0.50  
Licensing Agreements | Sales-Based Milestones    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Contingent proceeds collaborative arrangement $ 80  
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Revenue from collaborative arrangement $ 71 $ 43
Minimum | Licensing Agreements    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Royalty rate 20.00%  
Maximum | Licensing Agreements    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Royalty rate 24.00%  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs $ 246  
Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Expected restructuring and related cost $ 4,000  
Estimate of cumulative pre tax costs that will be noncash 60.00%  
Total pretax restructuring costs $ 246  
Cumulative costs since program inception $ 436  
Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   $ 97
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring - Charges Activities by Type of Cost (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs $ 246  
Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 246  
Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   $ 97
Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 65  
Accelerated Depreciation | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 65  
Accelerated Depreciation | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   21
Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 92  
Separation Costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 92  
Separation Costs | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   41
Other Exit Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 89  
Other Exit Costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 89  
Other Exit Costs | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   35
Cost of sales | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 116  
Cost of sales | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   29
Cost of sales | Accelerated Depreciation | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 65  
Cost of sales | Accelerated Depreciation | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   21
Cost of sales | Separation Costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0  
Cost of sales | Separation Costs | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   0
Cost of sales | Other Exit Costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 51  
Cost of sales | Other Exit Costs | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   8
Selling, general and administrative | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 5  
Selling, general and administrative | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   1
Selling, general and administrative | Accelerated Depreciation | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0  
Selling, general and administrative | Accelerated Depreciation | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   0
Selling, general and administrative | Separation Costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0  
Selling, general and administrative | Separation Costs | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   0
Selling, general and administrative | Other Exit Costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 5  
Selling, general and administrative | Other Exit Costs | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   1
Research and development | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 2  
Research and development | Accelerated Depreciation | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0  
Research and development | Separation Costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0  
Research and development | Other Exit Costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 2  
Restructuring costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 123  
Restructuring costs | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   67
Restructuring costs | Accelerated Depreciation | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0  
Restructuring costs | Accelerated Depreciation | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   0
Restructuring costs | Separation Costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 92  
Restructuring costs | Separation Costs | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   41
Restructuring costs | Other Exit Costs | Restructuring Program, 2024    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs $ 31  
Restructuring costs | Other Exit Costs | Restructuring Program, 2019    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   $ 26
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring - Activities by Program (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Restructuring Reserve [Roll Forward]  
Restructuring reserve, beginning balance $ 712
Expenses 246
(Payments) receipts, net (99)
Non-cash activity (123)
Restructuring reserve, ending balance 736
Accelerated Depreciation  
Restructuring Reserve [Roll Forward]  
Restructuring reserve, beginning balance 0
Expenses 65
(Payments) receipts, net 0
Non-cash activity (65)
Restructuring reserve, ending balance 0
Separation Costs  
Restructuring Reserve [Roll Forward]  
Restructuring reserve, beginning balance 681
Expenses 92
(Payments) receipts, net (67)
Non-cash activity 0
Restructuring reserve, ending balance 706
Other Exit Costs  
Restructuring Reserve [Roll Forward]  
Restructuring reserve, beginning balance 31
Expenses 89
(Payments) receipts, net (32)
Non-cash activity (58)
Restructuring reserve, ending balance $ 30
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Narrative (Details)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Apr. 30, 2024
USD ($)
interest_rate_swap
Derivative [Line Items]        
Derivative, notional amount $ 32,220   $ 30,551  
Pretax net unrealized gain on derivatives maturing within the next 12 months estimated to be reclassified from AOCI to sales 113      
Equity investments without readily determinable fair values 851 $ 942    
Unrealized gains recognized on investments in equity securities without readily determinable fair value 4 1    
Unrealized losses recognized on investments in equity securities without readily determinable fair values 5 21    
Cumulative unrealized gains on investments 297      
Cumulative unrealized losses on investments 69      
Income from investments in equity securities, net (143) (450)    
Fair value of loans payable and long-term debt, including current portion 30,400   32,000  
Debt, carrying amount 34,200   35,100  
Factored accounts receivable 2,700   3,000  
Cash collateral received from counterparties 58   3  
Equity Funds        
Derivative [Line Items]        
Equity securities held through ownership interest in investments funds 396 725    
Income from investments in equity securities, net 2 $ (132)    
Accounts Receivable Factoring Collections        
Derivative [Line Items]        
Restricted cash $ 43   44  
Senior Notes | 4.50% Notes Due 2033        
Derivative [Line Items]        
Stated interest rate 4.50%      
Level 2        
Derivative [Line Items]        
Cash equivalents $ 4,600   6,000  
Interest rate swap contracts | Subsequent Event        
Derivative [Line Items]        
Number of interest rate swaps | interest_rate_swap       2
Interest rate swap contracts | 4.50% note due 2033        
Derivative [Line Items]        
Derivative, notional amount 1,000      
Interest rate swap contracts | 4.50% note due 2033 | Subsequent Event        
Derivative [Line Items]        
Derivative, notional amount       $ 250
Derivatives Designated as Hedging Instruments        
Derivative [Line Items]        
Derivative, notional amount 13,424   12,754  
Derivatives Designated as Hedging Instruments | Interest rate swap contracts        
Derivative [Line Items]        
Derivative, notional amount 1,000   1,000  
Derivatives Not Designated as Hedging Instruments        
Derivative [Line Items]        
Derivative, notional amount $ 18,796   $ 17,797  
Maximum | Derivatives Designated as Hedging Instruments        
Derivative [Line Items]        
Maximum average period of maturities of contracts in years (less than) 2 years      
Maximum | Derivatives Not Designated as Hedging Instruments        
Derivative [Line Items]        
Maximum average period of maturities of contracts in years (less than) 6 months      
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Foreign exchange contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income $ (2) $ 1
Foreign exchange contracts | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing 0 1
Euro-denominated notes    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (62) 52
Euro-denominated notes | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing $ 0 $ 0
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Summary of Interest Rate Swaps Held (Details)
Mar. 31, 2024
USD ($)
interest_rate_swap
Dec. 31, 2023
USD ($)
Derivative [Line Items]    
U.S dollar notional amount $ 32,220,000,000 $ 30,551,000,000
Senior Notes | 4.50% Notes Due 2033    
Derivative [Line Items]    
Stated interest rate 4.50%  
Interest rate swap contracts | 4.50% note due 2033    
Derivative [Line Items]    
Par Value of Debt $ 1,500,000,000  
Number of Interest Rate Swaps Held | interest_rate_swap 4  
U.S dollar notional amount $ 1,000,000,000  
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Hedged Liability, Statement of Financial Position [Extensible Enumeration] Long-Term Debt Long-Term Debt
Carrying Amount of Hedged Liabilities $ 1,026 $ 1,056
Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount $ 26 $ 56
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset $ 357 $ 342
Fair value of derivative, liability 167 239
U.S dollar notional amount 32,220 30,551
Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 234 189
Fair value of derivative, liability 11 77
U.S dollar notional amount 13,424 12,754
Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 123 153
Fair value of derivative, liability 156 162
U.S dollar notional amount 18,796 17,797
Interest rate swap contracts | Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset $ 27 $ 57
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
U.S dollar notional amount $ 1,000 $ 1,000
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset $ 32 $ 26
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
U.S dollar notional amount $ 2,062 $ 1,929
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset $ 175 $ 106
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
U.S dollar notional amount $ 9,082 $ 6,138
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, liability $ 10 $ 76
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
U.S dollar notional amount $ 1,076 $ 3,680
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, liability $ 1 $ 1
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
U.S dollar notional amount $ 204 $ 7
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset $ 2 $ 0
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
U.S dollar notional amount $ 43 $ 0
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset $ 121 $ 153
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
U.S dollar notional amount $ 9,428 $ 9,693
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, liability $ 154 $ 162
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
U.S dollar notional amount $ 9,282 $ 8,104
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, liability $ 2 $ 0
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
U.S dollar notional amount $ 43 $ 0
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross amounts recognized in the consolidated balance sheet, asset $ 357 $ 342
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset (111) (215)
Cash collateral received, asset (58) (3)
Net amounts, asset 188 124
Gross amounts recognized in the consolidated balance sheet, liability 167 239
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability (111) (215)
Cash collateral received, liability 0 0
Net amounts, liability $ 56 $ 24
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]    
Sales $ 15,775 $ 14,487
Other (income) expense, net (33) 89
Other comprehensive income (loss) $ (113) $ (115)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other (income) expense, net Other (income) expense, net
Interest rate swap contracts | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge $ (30) $ 0
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 30 0
Foreign exchange contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain (loss) recognized in OCI on derivatives 209 (66)
Increase in Sales as a result of AOCL reclassifications (44) (101)
Foreign exchange contracts | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest    
Derivative Instruments, Gain (Loss) [Line Items]    
Sales 44 101
Interest rate contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain (loss) recognized in OCI on derivatives 0 (1)
Amount of gain recognized in Other (income) expense, net on derivatives $ 0 $ (1)
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Currency Swap | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ 65 $ 13
Foreign Exchange Future | Sales    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ (10) $ 2
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Information on Available-for-sale Investments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost $ 117   $ 337
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value 117   337
Publicly traded equity securities, fair value 908   764
Total debt and publicly traded equity securities, fair value 1,025   1,101
Unrealized net gains (losses) 143 $ 338  
Commercial paper      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 40   252
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value 40   252
U.S. government and agency securities      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 77   72
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value 77   72
Corporate notes and bonds      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 0   13
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value $ 0   $ 13
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Assets        
Investments $ 117 $ 337    
Publicly traded equity securities 908 764    
Other Assets 12,326 11,996    
Fair value of derivative, asset 357 342    
Liabilities        
Contingent consideration 226 354 $ 353 $ 456
Fair value of derivative, liability 167 239    
Commercial paper        
Assets        
Investments 40 252    
U.S. government and agency securities        
Assets        
Investments 77 72    
Corporate notes and bonds        
Assets        
Investments 0 13    
Fair Value, Measurements, Recurring        
Assets        
Investments 320 504    
Other Assets 705 597    
Fair value of derivative, asset 357 342    
Total assets 1,382 1,443    
Liabilities        
Contingent consideration 226 354    
Fair value of derivative, liability 167 239    
Total liabilities 393 593    
Fair Value, Measurements, Recurring | Foreign exchange contracts        
Assets        
Fair value of derivative, asset 204 202    
Liabilities        
Fair value of derivative, liability 149 239    
Fair Value, Measurements, Recurring | Currency options        
Assets        
Fair value of derivative, asset 126 83    
Liabilities        
Fair value of derivative, liability 18 0    
Fair Value, Measurements, Recurring | Interest rate swap contracts        
Assets        
Fair value of derivative, asset 27 57    
Fair Value, Measurements, Recurring | Level 1        
Assets        
Investments 280 252    
Other Assets 705 597    
Fair value of derivative, asset 0 0    
Total assets 985 849    
Liabilities        
Contingent consideration 0 0    
Fair value of derivative, liability 0 0    
Total liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts        
Assets        
Fair value of derivative, asset 0 0    
Liabilities        
Fair value of derivative, liability 0 0    
Fair Value, Measurements, Recurring | Level 1 | Currency options        
Assets        
Fair value of derivative, asset 0 0    
Liabilities        
Fair value of derivative, liability 0 0    
Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts        
Assets        
Fair value of derivative, asset 0 0    
Fair Value, Measurements, Recurring | Level 2        
Assets        
Investments 40 252    
Other Assets 0 0    
Fair value of derivative, asset 357 342    
Total assets 397 594    
Liabilities        
Contingent consideration 0 0    
Fair value of derivative, liability 167 239    
Total liabilities 167 239    
Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts        
Assets        
Fair value of derivative, asset 204 202    
Liabilities        
Fair value of derivative, liability 149 239    
Fair Value, Measurements, Recurring | Level 2 | Currency options        
Assets        
Fair value of derivative, asset 126 83    
Liabilities        
Fair value of derivative, liability 18 0    
Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts        
Assets        
Fair value of derivative, asset 27 57    
Fair Value, Measurements, Recurring | Level 3        
Assets        
Investments 0 0    
Other Assets 0 0    
Fair value of derivative, asset 0 0    
Total assets 0 0    
Liabilities        
Contingent consideration 226 354    
Fair value of derivative, liability 0 0    
Total liabilities 226 354    
Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts        
Assets        
Fair value of derivative, asset 0 0    
Liabilities        
Fair value of derivative, liability 0 0    
Fair Value, Measurements, Recurring | Level 3 | Currency options        
Assets        
Fair value of derivative, asset 0 0    
Liabilities        
Fair value of derivative, liability 0 0    
Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts        
Assets        
Fair value of derivative, asset 0 0    
Fair Value, Measurements, Recurring | Commercial paper        
Assets        
Investments 40 252    
Fair Value, Measurements, Recurring | Commercial paper | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Commercial paper | Level 2        
Assets        
Investments 40 252    
Fair Value, Measurements, Recurring | Commercial paper | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | U.S. government and agency securities        
Assets        
Debt securities, available-for-sale, noncurrent 77 72    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 1        
Assets        
Debt securities, available-for-sale, noncurrent 77 72    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 2        
Assets        
Debt securities, available-for-sale, noncurrent 0 0    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 3        
Assets        
Debt securities, available-for-sale, noncurrent 0 0    
Fair Value, Measurements, Recurring | Corporate notes and bonds        
Assets        
Debt securities, available-for-sale, noncurrent 0 13    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 1        
Assets        
Debt securities, available-for-sale, noncurrent 0 13    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 2        
Assets        
Debt securities, available-for-sale, noncurrent 0 0    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 3        
Assets        
Debt securities, available-for-sale, noncurrent 0 0    
Fair Value, Measurements, Recurring | Publicly traded equity securities        
Assets        
Publicly traded equity securities 280 252    
Publicly traded equity securities 628 512    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 1        
Assets        
Publicly traded equity securities 280 252    
Publicly traded equity securities 628 512    
Liabilities        
Securities, fair value, which are subject to a contractual sale restriction 266      
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 2        
Assets        
Publicly traded equity securities 0 0    
Publicly traded equity securities 0 0    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 3        
Assets        
Publicly traded equity securities 0 0    
Publicly traded equity securities $ 0 $ 0    
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair value, beginning balance $ 354 $ 456
Changes in estimated fair value (2) 14
Payments (126) (117)
Fair value, ending balance 226 $ 353
Sanofi Pasteur    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Current liability $ 133  
Contingent consideration, measurement input, discount rate 0.115  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Finished goods $ 1,902 $ 1,954
Raw materials and work in process 8,366 8,037
Supplies 276 277
Total 10,544 10,268
Decrease to LIFO cost (621) (562)
Total current and noncurrent inventories 9,923 9,706
Recognized as:    
Inventories 6,510 6,358
Other Assets $ 3,413 $ 3,348
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories - Narrative (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Inventory [Line Items]    
Inventories classified in Other assets $ 3,413 $ 3,348
Inventories Not Expected to be Sold Within One Year    
Inventory [Line Items]    
Inventories classified in Other assets 2,600 2,600
Inventories Produced in Preparation for Product Launches    
Inventory [Line Items]    
Inventories classified in Other assets $ 861 $ 790
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contingencies (Details)
$ in Millions
 3 Months Ended
Apr. 13, 2023
patent
Dec. 19, 2022
Mar. 31, 2024
USD ($)
case
employee
company
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Jul. 27, 2023
motion_for_summary_judgment
Pending Litigation | Commercial and Other Litigation            
Loss Contingencies [Line Items]            
Loss contingency, pending claims     2      
Loss contingency, number of plaintiffs | employee     2      
Loss contingency, number of motion for summary judgments | motion_for_summary_judgment           2
Legal Defense Costs            
Loss Contingencies [Line Items]            
Legal defense costs reserve | $     $ 220.0   $ 210.0  
Zetia antitrust litigation            
Loss Contingencies [Line Items]            
Loss related to litigation settlement | $       $ 572.5    
Gardasil/Gardasil 9 | Pending Litigation | U.S.            
Loss Contingencies [Line Items]            
Loss contingency, pending claims     190      
Gardasil/Gardasil 9 | Pending Litigation | Non-US            
Loss Contingencies [Line Items]            
Loss contingency, pending claims     15      
Bridion | Patents            
Loss Contingencies [Line Items]            
Loss contingency, claims settled | company     5      
Bridion | Patents | Pending Litigation            
Loss Contingencies [Line Items]            
Loss contingency, pending claims | company     2      
Loss contingency, trial period   1 day        
Keytruda | Patents | Pending Litigation            
Loss Contingencies [Line Items]            
Loss contingency, number of patents allegedly infringed | patent 9          
Dr. Scholl's | Pending Litigation | U.S.            
Loss Contingencies [Line Items]            
Loss contingency, pending claims     275      
Januvia/Janumet            
Loss Contingencies [Line Items]            
Loss contingency, claims settled     26      
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Common stock, beginning balance (in shares) 3,577,103,522  
Treasury stock, beginning balance (in shares) 1,045,470,249  
Equity, beginning balance $ 37,635 $ 46,058
Net (loss) income attributable to Merck & Co., Inc. 4,762 2,821
Other comprehensive income (loss), net of taxes (113) (115)
Cash dividends declared on common stock (1,960) (1,863)
Treasury stock shares purchased (122) (149)
Share-based compensation plans and other 217 149
Net income attributable to noncontrolling interests $ 5 4
Common stock, ending balance (in shares) 3,577,103,522  
Treasury stock, ending balance (in shares) 1,044,402,655  
Equity, ending balance $ 40,424 $ 46,905
Cash dividends declared on common stock (in dollars per share) $ 0.77 $ 0.73
  Common Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Common stock, beginning balance (in shares) 3,577,000,000 3,577,000,000
Equity, beginning balance $ 1,788 $ 1,788
Common stock, ending balance (in shares) 3,577,000,000 3,577,000,000
Equity, ending balance $ 1,788 $ 1,788
Other Paid-In Capital    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance 44,509 44,379
Share-based compensation plans and other 89 88
Equity, ending balance 44,598 44,467
Retained Earnings    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance 53,895 61,081
Net (loss) income attributable to Merck & Co., Inc. 4,762 2,821
Cash dividends declared on common stock (1,960) (1,863)
Equity, ending balance 56,697 62,039
Accumulated Other Comprehensive Loss    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance (5,161) (4,768)
Other comprehensive income (loss), net of taxes (113) (115)
Equity, ending balance $ (5,274) $ (4,883)
 Treasury Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Treasury stock, beginning balance (in shares) 1,045,000,000 1,039,000,000
Equity, beginning balance $ (57,450) $ (56,489)
Treasury stock shares purchased (in shares) 1,000,000 1,000,000
Treasury stock shares purchased $ (122) $ (149)
Share-based compensation plans and other (in shares) (2,000,000) 0
Share-based compensation plans and other $ 127 $ 61
Treasury stock, ending balance (in shares) 1,044,000,000 1,040,000,000
Equity, ending balance $ (57,445) $ (56,577)
Non- controlling Interests    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance 54 67
Share-based compensation plans and other 1  
Net income attributable to noncontrolling interests 5 4
Equity, ending balance $ 60 $ 71
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Other Postretirement Benefit Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost $ 8 $ 8
Interest cost 14 16
Expected return on plan assets (20) (16)
Amortization of unrecognized prior service credit (11) (12)
Net loss (gain) amortization (12) (11)
Net periodic benefit cost (21) (15)
U.S. | Pension Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost 86 76
Interest cost 134 133
Expected return on plan assets (207) (187)
Amortization of unrecognized prior service credit 0 0
Net loss (gain) amortization 10 0
Termination benefits 3 0
Curtailments 0 2
Settlements 0 21
Net periodic benefit cost 26 45
International | Pension Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost 61 49
Interest cost 74 74
Expected return on plan assets (139) (128)
Amortization of unrecognized prior service credit (3) (3)
Net loss (gain) amortization 1 (1)
Termination benefits 0 0
Curtailments 0 0
Settlements 0 0
Net periodic benefit cost $ (6) $ (9)
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pension and Other Postretirement Benefit Plans - Narrative (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2023
USD ($)
Retirement Benefits [Abstract]  
Partial settlement charge $ 21
Increase to pension liabilities due to remeasurement $ 44
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Other Income and Expenses [Abstract]    
Interest income $ (73) $ (112)
Interest expense 303 242
Exchange losses 83 61
Income from investments in equity securities, net (143) (450)
Net periodic defined benefit plan (credit) cost other than service cost (160) (115)
Other, net (43) 463
Other (income) expense, net $ (33) $ 89
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other (Income) Expense, Net - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Loss Contingencies [Line Items]    
Interest Paid $ 217.0 $ 208.0
Zetia antitrust litigation    
Loss Contingencies [Line Items]    
Loss related to litigation settlement   $ 572.5
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Effective income tax rate 15.90% 22.60%
Unfavorable discrete impact on tax rate 1.60% 5.50%
Tax benefit resulting from acquisition charge $ 0 $ 0
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Net Income Attributable to Merck & Co., Inc., basic $ 4,762 $ 2,821
Net Income Attributable to Merck & Co., Inc., diluted $ 4,762 $ 2,821
Average common shares outstanding (in shares) 2,533 2,538
Common shares issuable (in shares) 11 13
Average common shares outstanding assuming dilution (in shares) 2,544 2,551
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.88 $ 1.11
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.87 $ 1.11
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share - Narrative (Details) - shares
shares in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Antidilutive shares (in shares) 3 1
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance $ 37,635 $ 46,058
Other comprehensive income (loss), net of taxes (113) (115)
Equity, ending balance 40,424 46,905
Derivatives    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance (24) 73
Other comprehensive income (loss) before reclassification adjustments, pretax 209 (66)
Tax (44) 14
Other comprehensive income (loss) before reclassification adjustments, net of taxes 165 (52)
Reclassification adjustments, pretax (44) (102)
Tax 9 21
Reclassification adjustments, net of taxes (35) (81)
Other comprehensive income (loss), net of taxes 130 (133)
Equity, ending balance 106 (60)
Employee Benefit Plans    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance (2,793) (2,408)
Other comprehensive income (loss) before reclassification adjustments, pretax 5 (47)
Tax (4) 2
Other comprehensive income (loss) before reclassification adjustments, net of taxes 1 (45)
Reclassification adjustments, pretax (15) (7)
Tax 9 2
Reclassification adjustments, net of taxes (6) (5)
Other comprehensive income (loss), net of taxes (5) (50)
Equity, ending balance (2,798) (2,458)
Foreign Currency Translation Adjustment    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance (2,344) (2,433)
Other comprehensive income (loss) before reclassification adjustments, pretax (225) 79
Tax (13) (20)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (238) 59
Reclassification adjustments, pretax 0 9
Tax 0 0
Reclassification adjustments, net of taxes 0 9
Other comprehensive income (loss), net of taxes (238) 68
Equity, ending balance (2,582) (2,365)
Accumulated Other Comprehensive Loss    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance (5,161) (4,768)
Other comprehensive income (loss) before reclassification adjustments, pretax (11) (34)
Tax (61) (4)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (72) (38)
Reclassification adjustments, pretax (59) (100)
Tax 18 23
Reclassification adjustments, net of taxes (41) (77)
Other comprehensive income (loss), net of taxes (113) (115)
Equity, ending balance $ (5,274) $ (4,883)
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Reporting - Narrative (Details)
$ in Billions
 3 Months Ended
Mar. 31, 2024
USD ($)
segment
Mar. 31, 2023
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 2  
Sales discounts | $ $ 3.2 $ 3.1
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Reporting - Sales from Products (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Sales $ 15,775 $ 14,487
Increase in hedge revenue 54 99
Revenue related to the sale of the marketing rights 61 51
U.S.    
Segment Reporting Information [Line Items]    
Sales 7,478 6,659
Int’l    
Segment Reporting Information [Line Items]    
Sales 8,297 7,828
Operating Segments    
Segment Reporting Information [Line Items]    
Sales 15,517 14,212
Operating Segments | U.S.    
Segment Reporting Information [Line Items]    
Sales 7,410 6,599
Operating Segments | Int’l    
Segment Reporting Information [Line Items]    
Sales 8,107 7,614
Corporate, Non-Segment    
Segment Reporting Information [Line Items]    
Sales 258 275
Corporate, Non-Segment | U.S.    
Segment Reporting Information [Line Items]    
Sales 68 60
Corporate, Non-Segment | Int’l    
Segment Reporting Information [Line Items]    
Sales 190 214
Pharmaceutical | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 14,006 12,721
Pharmaceutical | Operating Segments | U.S.    
Segment Reporting Information [Line Items]    
Sales 6,936 6,117
Pharmaceutical | Operating Segments | Int’l    
Segment Reporting Information [Line Items]    
Sales 7,070 6,604
Pharmaceutical | Operating Segments | Keytruda    
Segment Reporting Information [Line Items]    
Sales 6,947 5,795
Pharmaceutical | Operating Segments | Keytruda | U.S.    
Segment Reporting Information [Line Items]    
Sales 4,119 3,485
Pharmaceutical | Operating Segments | Keytruda | Int’l    
Segment Reporting Information [Line Items]    
Sales 2,828 2,310
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza    
Segment Reporting Information [Line Items]    
Sales 292 275
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S.    
Segment Reporting Information [Line Items]    
Sales 135 142
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l    
Segment Reporting Information [Line Items]    
Sales 157 133
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima    
Segment Reporting Information [Line Items]    
Sales 255 232
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S.    
Segment Reporting Information [Line Items]    
Sales 173 153
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l    
Segment Reporting Information [Line Items]    
Sales 82 79
Pharmaceutical | Operating Segments | Welireg    
Segment Reporting Information [Line Items]    
Sales 85 42
Pharmaceutical | Operating Segments | Welireg | U.S.    
Segment Reporting Information [Line Items]    
Sales 77 41
Pharmaceutical | Operating Segments | Welireg | Int’l    
Segment Reporting Information [Line Items]    
Sales 7 1
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl    
Segment Reporting Information [Line Items]    
Sales 71 43
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S.    
Segment Reporting Information [Line Items]    
Sales 58 30
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l    
Segment Reporting Information [Line Items]    
Sales 12 12
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9    
Segment Reporting Information [Line Items]    
Sales 2,249 1,972
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S.    
Segment Reporting Information [Line Items]    
Sales 488 416
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l    
Segment Reporting Information [Line Items]    
Sales 1,761 1,556
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax    
Segment Reporting Information [Line Items]    
Sales 570 528
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S.    
Segment Reporting Information [Line Items]    
Sales 438 421
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l    
Segment Reporting Information [Line Items]    
Sales 133 107
Pharmaceutical | Operating Segments | Vaxneuvance    
Segment Reporting Information [Line Items]    
Sales 219 106
Pharmaceutical | Operating Segments | Vaxneuvance | U.S.    
Segment Reporting Information [Line Items]    
Sales 161 94
Pharmaceutical | Operating Segments | Vaxneuvance | Int’l    
Segment Reporting Information [Line Items]    
Sales 58 13
Pharmaceutical | Operating Segments | RotaTeq    
Segment Reporting Information [Line Items]    
Sales 216 297
Pharmaceutical | Operating Segments | RotaTeq | U.S.    
Segment Reporting Information [Line Items]    
Sales 149 180
Pharmaceutical | Operating Segments | RotaTeq | Int’l    
Segment Reporting Information [Line Items]    
Sales 67 117
Pharmaceutical | Operating Segments | Pneumovax 23    
Segment Reporting Information [Line Items]    
Sales 61 96
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S.    
Segment Reporting Information [Line Items]    
Sales 6 40
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l    
Segment Reporting Information [Line Items]    
Sales 55 56
Pharmaceutical | Operating Segments | Bridion    
Segment Reporting Information [Line Items]    
Sales 440 487
Pharmaceutical | Operating Segments | Bridion | U.S.    
Segment Reporting Information [Line Items]    
Sales 329 276
Pharmaceutical | Operating Segments | Bridion | Int’l    
Segment Reporting Information [Line Items]    
Sales 111 210
Pharmaceutical | Operating Segments | Prevymis    
Segment Reporting Information [Line Items]    
Sales 174 129
Pharmaceutical | Operating Segments | Prevymis | U.S.    
Segment Reporting Information [Line Items]    
Sales 74 54
Pharmaceutical | Operating Segments | Prevymis | Int’l    
Segment Reporting Information [Line Items]    
Sales 100 75
Pharmaceutical | Operating Segments | Dificid    
Segment Reporting Information [Line Items]    
Sales 73 65
Pharmaceutical | Operating Segments | Dificid | U.S.    
Segment Reporting Information [Line Items]    
Sales 68 62
Pharmaceutical | Operating Segments | Dificid | Int’l    
Segment Reporting Information [Line Items]    
Sales 5 3
Pharmaceutical | Operating Segments | Zerbaxa    
Segment Reporting Information [Line Items]    
Sales 56 50
Pharmaceutical | Operating Segments | Zerbaxa | U.S.    
Segment Reporting Information [Line Items]    
Sales 33 27
Pharmaceutical | Operating Segments | Zerbaxa | Int’l    
Segment Reporting Information [Line Items]    
Sales 23 23
Pharmaceutical | Operating Segments | Noxafil    
Segment Reporting Information [Line Items]    
Sales 56 60
Pharmaceutical | Operating Segments | Noxafil | U.S.    
Segment Reporting Information [Line Items]    
Sales 8 14
Pharmaceutical | Operating Segments | Noxafil | Int’l    
Segment Reporting Information [Line Items]    
Sales 48 46
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo    
Segment Reporting Information [Line Items]    
Sales 98 99
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S.    
Segment Reporting Information [Line Items]    
Sales 90 83
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l    
Segment Reporting Information [Line Items]    
Sales 8 16
Pharmaceutical | Operating Segments | Adempas    
Segment Reporting Information [Line Items]    
Sales 70 59
Pharmaceutical | Operating Segments | Adempas | U.S.    
Segment Reporting Information [Line Items]    
Sales 0 0
Pharmaceutical | Operating Segments | Adempas | Int’l    
Segment Reporting Information [Line Items]    
Sales 70 59
Pharmaceutical | Operating Segments | Lagevrio    
Segment Reporting Information [Line Items]    
Sales 350 392
Pharmaceutical | Operating Segments | Lagevrio | U.S.    
Segment Reporting Information [Line Items]    
Sales 45 (2)
Pharmaceutical | Operating Segments | Lagevrio | Int’l    
Segment Reporting Information [Line Items]    
Sales 305 394
Pharmaceutical | Operating Segments | Isentress/Isentress HD    
Segment Reporting Information [Line Items]    
Sales 111 123
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S.    
Segment Reporting Information [Line Items]    
Sales 50 52
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l    
Segment Reporting Information [Line Items]    
Sales 61 71
Pharmaceutical | Operating Segments | Delstrigo    
Segment Reporting Information [Line Items]    
Sales 56 44
Pharmaceutical | Operating Segments | Delstrigo | U.S.    
Segment Reporting Information [Line Items]    
Sales 12 11
Pharmaceutical | Operating Segments | Delstrigo | Int’l    
Segment Reporting Information [Line Items]    
Sales 44 33
Pharmaceutical | Operating Segments | Pifeltro    
Segment Reporting Information [Line Items]    
Sales 42 34
Pharmaceutical | Operating Segments | Pifeltro | U.S.    
Segment Reporting Information [Line Items]    
Sales 29 24
Pharmaceutical | Operating Segments | Pifeltro | Int’l    
Segment Reporting Information [Line Items]    
Sales 13 10
Pharmaceutical | Operating Segments | Belsomra    
Segment Reporting Information [Line Items]    
Sales 46 56
Pharmaceutical | Operating Segments | Belsomra | U.S.    
Segment Reporting Information [Line Items]    
Sales 15 16
Pharmaceutical | Operating Segments | Belsomra | Int’l    
Segment Reporting Information [Line Items]    
Sales 32 40
Pharmaceutical | Operating Segments | Simponi    
Segment Reporting Information [Line Items]    
Sales 184 180
Pharmaceutical | Operating Segments | Simponi | U.S.    
Segment Reporting Information [Line Items]    
Sales 0 0
Pharmaceutical | Operating Segments | Simponi | Int’l    
Segment Reporting Information [Line Items]    
Sales 184 180
Pharmaceutical | Operating Segments | Remicade    
Segment Reporting Information [Line Items]    
Sales 39 51
Pharmaceutical | Operating Segments | Remicade | U.S.    
Segment Reporting Information [Line Items]    
Sales 0 0
Pharmaceutical | Operating Segments | Remicade | Int’l    
Segment Reporting Information [Line Items]    
Sales 39 51
Pharmaceutical | Operating Segments | Januvia    
Segment Reporting Information [Line Items]    
Sales 419 551
Pharmaceutical | Operating Segments | Januvia | U.S.    
Segment Reporting Information [Line Items]    
Sales 183 271
Pharmaceutical | Operating Segments | Januvia | Int’l    
Segment Reporting Information [Line Items]    
Sales 236 280
Pharmaceutical | Operating Segments | Janumet    
Segment Reporting Information [Line Items]    
Sales 251 329
Pharmaceutical | Operating Segments | Janumet | U.S.    
Segment Reporting Information [Line Items]    
Sales 39 56
Pharmaceutical | Operating Segments | Janumet | Int’l    
Segment Reporting Information [Line Items]    
Sales 212 272
Pharmaceutical | Operating Segments | Other pharmaceutical    
Segment Reporting Information [Line Items]    
Sales 576 626
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S.    
Segment Reporting Information [Line Items]    
Sales 157 171
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l    
Segment Reporting Information [Line Items]    
Sales 419 457
Animal Health | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 1,511 1,491
Animal Health | Operating Segments | U.S.    
Segment Reporting Information [Line Items]    
Sales 474 482
Animal Health | Operating Segments | Int’l    
Segment Reporting Information [Line Items]    
Sales 1,037 1,010
Animal Health | Operating Segments | Livestock    
Segment Reporting Information [Line Items]    
Sales 850 849
Animal Health | Operating Segments | Livestock | U.S.    
Segment Reporting Information [Line Items]    
Sales 166 174
Animal Health | Operating Segments | Livestock | Int’l    
Segment Reporting Information [Line Items]    
Sales 683 676
Animal Health | Operating Segments | Companion Animal    
Segment Reporting Information [Line Items]    
Sales 661 642
Animal Health | Operating Segments | Companion Animal | U.S.    
Segment Reporting Information [Line Items]    
Sales 308 308
Animal Health | Operating Segments | Companion Animal | Int’l    
Segment Reporting Information [Line Items]    
Sales $ 354 $ 334
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Reporting - Consolidated Sales by Geographic Area (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue from External Customer [Line Items]    
Sales $ 15,775 $ 14,487
United States    
Revenue from External Customer [Line Items]    
Sales 7,478 6,659
Europe, Middle East and Africa    
Revenue from External Customer [Line Items]    
Sales 3,563 3,303
China    
Revenue from External Customer [Line Items]    
Sales 1,772 1,715
Japan    
Revenue from External Customer [Line Items]    
Sales 821 758
Latin America    
Revenue from External Customer [Line Items]    
Sales 796 661
Asia Pacific (other than China and Japan)    
Revenue from External Customer [Line Items]    
Sales 724 846
Other    
Revenue from External Customer [Line Items]    
Sales $ 621 $ 545
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Profits $ 5,670 $ 3,650
Interest income 73 112
Interest expense (303) (242)
Amortization (473) (543)
Depreciation (511) (448)
Research and development (3,992) (4,276)
Restructuring costs (123) (67)
Operating Segments    
Segment Reporting Information [Line Items]    
Profits 11,459 9,706
Operating Segments | Pharmaceutical segment    
Segment Reporting Information [Line Items]    
Profits 10,904 9,140
Operating Segments | Animal Health segment    
Segment Reporting Information [Line Items]    
Profits 555 566
Corporate, Non-Segment    
Segment Reporting Information [Line Items]    
Profits 146 164
Segment Reconciling Items    
Segment Reporting Information [Line Items]    
Interest income 73 112
Interest expense (303) (242)
Amortization (473) (543)
Depreciation (452) (398)
Research and development (3,851) (4,147)
Restructuring costs (123) (67)
Charge for Zetia antitrust litigation settlements 0 (573)
Other unallocated, net $ (806) $ (362)
EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
  •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mrk-20240331_htm.xml IDEA: XBRL DOCUMENT 0000310158 2024-01-01 2024-03-31 0000310158 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000310158 mrk:A0.500Notesdue2024Member 2024-01-01 2024-03-31 0000310158 mrk:A1.875Notesdue2026Member 2024-01-01 2024-03-31 0000310158 mrk:A2.500Notesdue2034Member 2024-01-01 2024-03-31 0000310158 mrk:A1.375Notesdue2036Member 2024-01-01 2024-03-31 0000310158 2024-04-30 0000310158 2023-01-01 2023-03-31 0000310158 2024-03-31 0000310158 2023-12-31 0000310158 2022-12-31 0000310158 2023-03-31 0000310158 mrk:HarpoonTherapeuticsInc.Member 2024-03-01 2024-03-31 0000310158 mrk:HarpoonTherapeuticsInc.Member 2024-01-01 2024-03-31 0000310158 srt:ScenarioForecastMember mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember 2024-06-01 2024-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-02-28 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-03-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-31 0000310158 mrk:ImagoBioSciencesIncMember 2023-01-01 2023-01-31 0000310158 mrk:ImagoBioSciencesIncMember 2023-01-01 2023-03-31 0000310158 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember mrk:OrganonCo.Member 2024-03-31 0000310158 srt:MinimumMember mrk:ManufacturingAndSupplyAgreementsMember us-gaap:RelatedPartyMember 2021-06-02 2021-06-02 0000310158 srt:MaximumMember mrk:ManufacturingAndSupplyAgreementsMember us-gaap:RelatedPartyMember 2021-06-02 2021-06-02 0000310158 mrk:ManufacturingAndSupplyAgreementsMember us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0000310158 mrk:ManufacturingAndSupplyAgreementsMember us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0000310158 us-gaap:RelatedPartyMember 2024-03-31 0000310158 us-gaap:RelatedPartyMember 2023-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:LynparzaMember us-gaap:OtherIntangibleAssetsMember mrk:LicensesAndOtherMember 2024-03-31 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-07-01 2023-09-30 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-09-30 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-04-01 2023-06-30 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-03-31 0000310158 mrk:EisaiMember 2023-01-01 2023-03-31 0000310158 mrk:EisaiMember 2023-07-01 2023-09-30 0000310158 mrk:LenvimaMember us-gaap:OtherIntangibleAssetsMember mrk:LicensesAndOtherMember 2024-03-31 0000310158 mrk:EisaiMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:EisaiMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:EisaiMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-03-31 0000310158 mrk:EisaiMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-03-31 0000310158 mrk:AdempasMember us-gaap:OtherIntangibleAssetsMember mrk:LicensesAndOtherMember 2024-03-31 0000310158 mrk:VerquvoMember us-gaap:OtherIntangibleAssetsMember mrk:LicensesAndOtherMember 2024-03-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0000310158 mrk:DaiichiSankyoMember mrk:IfinatamabDeruxtecanMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0000310158 mrk:DaiichiSankyoMember mrk:PatritumabDeruxtecanMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0000310158 mrk:DaiichiSankyoMember mrk:RaludotatugDeruxtecanMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-01 2023-12-31 0000310158 mrk:DaiichiSankyoMember mrk:PatritumabDeruxtecanAndRaludotatugDeruxtecanMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-03-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:ModernaInc.Member us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-03-31 0000310158 mrk:ModernaInc.Member us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:ModernaInc.Member us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:ModernaInc.Member us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:BristolMyersSquibbCompanyMember srt:MinimumMember us-gaap:LicensingAgreementsMember 2024-01-01 2024-03-31 0000310158 mrk:BristolMyersSquibbCompanyMember srt:MaximumMember us-gaap:LicensingAgreementsMember 2024-01-01 2024-03-31 0000310158 mrk:BristolMyersSquibbCompanyMember us-gaap:LicensingAgreementsMember 2024-01-01 2024-03-31 0000310158 mrk:BristolMyersSquibbCompanyMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2024-01-01 2024-03-31 0000310158 mrk:BristolMyersSquibbCompanyMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-03-31 0000310158 mrk:BristolMyersSquibbCompanyMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:RestructuringProgram2024Member 2024-03-31 0000310158 mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:CostOfSalesMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:RestructuringChargesMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2024-01-01 2024-03-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:CostOfSalesMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:RestructuringChargesMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2023-01-01 2023-03-31 0000310158 mrk:AcceleratedDepreciationMember 2023-12-31 0000310158 us-gaap:EmployeeSeveranceMember 2023-12-31 0000310158 us-gaap:OtherRestructuringMember 2023-12-31 0000310158 mrk:AcceleratedDepreciationMember 2024-01-01 2024-03-31 0000310158 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-03-31 0000310158 us-gaap:OtherRestructuringMember 2024-01-01 2024-03-31 0000310158 mrk:AcceleratedDepreciationMember 2024-03-31 0000310158 us-gaap:EmployeeSeveranceMember 2024-03-31 0000310158 us-gaap:OtherRestructuringMember 2024-03-31 0000310158 srt:MaximumMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-03-31 0000310158 srt:MaximumMember us-gaap:NondesignatedMember 2024-01-01 2024-03-31 0000310158 us-gaap:ForeignExchangeContractMember 2024-01-01 2024-03-31 0000310158 us-gaap:ForeignExchangeContractMember 2023-01-01 2023-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-03-31 0000310158 mrk:EurodominatedNotesMember 2024-01-01 2024-03-31 0000310158 mrk:EurodominatedNotesMember 2023-01-01 2023-03-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-03-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-03-31 0000310158 us-gaap:InterestRateSwapMember mrk:A450NoteDue2033Member 2024-03-31 0000310158 mrk:A450NotesDue2033Member us-gaap:SeniorNotesMember 2024-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:SubsequentEventMember 2024-04-30 0000310158 us-gaap:InterestRateSwapMember mrk:A450NoteDue2033Member us-gaap:SubsequentEventMember 2024-04-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000310158 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-03-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000310158 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000310158 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-03-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-03-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-03-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000310158 us-gaap:NondesignatedMember 2024-03-31 0000310158 us-gaap:NondesignatedMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-01-01 2024-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-01-01 2023-03-31 0000310158 us-gaap:InterestRateContractMember 2024-01-01 2024-03-31 0000310158 us-gaap:InterestRateContractMember 2023-01-01 2023-03-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-03-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-03-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2024-01-01 2024-03-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2023-01-01 2023-03-31 0000310158 us-gaap:CommercialPaperMember 2024-03-31 0000310158 us-gaap:CommercialPaperMember 2023-12-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:EquityFundsMember 2024-03-31 0000310158 us-gaap:EquityFundsMember 2023-03-31 0000310158 us-gaap:EquityFundsMember 2024-01-01 2024-03-31 0000310158 us-gaap:EquityFundsMember 2023-01-01 2023-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member 2024-03-31 0000310158 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000310158 mrk:SanofiPasteurMember 2024-03-31 0000310158 2023-01-01 2023-12-31 0000310158 mrk:AccountsReceivableFactoringCollectionsMember 2024-03-31 0000310158 mrk:AccountsReceivableFactoringCollectionsMember 2023-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2023-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2024-03-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2024-03-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2023-12-31 0000310158 mrk:Dr.SchollsMember country:US us-gaap:PendingLitigationMember 2024-03-31 0000310158 mrk:GardasilGardasil9Member country:US us-gaap:PendingLitigationMember 2024-03-31 0000310158 mrk:GardasilGardasil9Member us-gaap:NonUsMember us-gaap:PendingLitigationMember 2024-03-31 0000310158 mrk:ZetiaantitrustlitigationMember 2023-01-01 2023-03-31 0000310158 us-gaap:PendingLitigationMember mrk:CommercialAndOtherLitigationMember 2024-01-01 2024-03-31 0000310158 us-gaap:PendingLitigationMember mrk:CommercialAndOtherLitigationMember 2023-07-27 0000310158 us-gaap:PendingLitigationMember mrk:CommercialAndOtherLitigationMember 2024-03-31 0000310158 us-gaap:PatentsMember mrk:BridionMember us-gaap:PendingLitigationMember 2022-12-19 2022-12-19 0000310158 us-gaap:PatentsMember mrk:BridionMember 2024-01-01 2024-03-31 0000310158 us-gaap:PatentsMember mrk:BridionMember us-gaap:PendingLitigationMember 2024-03-31 0000310158 mrk:JanuviaJanumetMember 2024-01-01 2024-03-31 0000310158 us-gaap:PatentsMember mrk:KeytrudaMember us-gaap:PendingLitigationMember 2023-04-13 2023-04-13 0000310158 mrk:LegalDefenseCostsMember 2024-03-31 0000310158 mrk:LegalDefenseCostsMember 2023-12-31 0000310158 us-gaap:CommonStockMember 2022-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000310158 us-gaap:RetainedEarningsMember 2022-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2022-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2022-12-31 0000310158 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000310158 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000310158 us-gaap:CommonStockMember 2023-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000310158 us-gaap:RetainedEarningsMember 2023-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000310158 us-gaap:TreasuryStockCommonMember 2023-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2023-03-31 0000310158 us-gaap:CommonStockMember 2023-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000310158 us-gaap:RetainedEarningsMember 2023-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2023-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2023-12-31 0000310158 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000310158 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000310158 us-gaap:CommonStockMember 2024-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000310158 us-gaap:RetainedEarningsMember 2024-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000310158 us-gaap:TreasuryStockCommonMember 2024-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2024-03-31 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalMember country:US mrk:AnimalHealthsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalMember country:US mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2024-01-01 2024-03-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2024-01-01 2024-03-31 0000310158 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-03-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2023-01-01 2023-03-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2023-01-01 2023-03-31 0000310158 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000310158 country:US 2024-01-01 2024-03-31 0000310158 mrk:InternationalMember 2024-01-01 2024-03-31 0000310158 country:US 2023-01-01 2023-03-31 0000310158 mrk:InternationalMember 2023-01-01 2023-03-31 0000310158 us-gaap:EMEAMember 2024-01-01 2024-03-31 0000310158 us-gaap:EMEAMember 2023-01-01 2023-03-31 0000310158 country:CN 2024-01-01 2024-03-31 0000310158 country:CN 2023-01-01 2023-03-31 0000310158 country:JP 2024-01-01 2024-03-31 0000310158 country:JP 2023-01-01 2023-03-31 0000310158 srt:LatinAmericaMember 2024-01-01 2024-03-31 0000310158 srt:LatinAmericaMember 2023-01-01 2023-03-31 0000310158 srt:AsiaPacificMember 2024-01-01 2024-03-31 0000310158 srt:AsiaPacificMember 2023-01-01 2023-03-31 0000310158 mrk:OtherCountriesMember 2024-01-01 2024-03-31 0000310158 mrk:OtherCountriesMember 2023-01-01 2023-03-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2024-01-01 2024-03-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-03-31 shares iso4217:USD iso4217:USD shares mrk:candidate mrk:jurisdiction pure mrk:interest_rate_swap mrk:case mrk:employee mrk:motion_for_summary_judgment mrk:company mrk:patent mrk:segment false 2024 Q1 0000310158 --12-31 http://fasb.org/us-gaap/2023#LongTermDebtNoncurrent http://fasb.org/us-gaap/2023#LongTermDebtNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense 10-Q true 2024-03-31 false 1-6571 Merck & Co., Inc. NJ 22-1918501 126 East Lincoln Avenue Rahway NJ 07065 (908) 740-4000 Common Stock ($0.50 par value) MRK NYSE 0.500% Notes due 2024 MRK 24 NYSE 1.875% Notes due 2026 MRK/26 NYSE 2.500% Notes due 2034 MRK/34 NYSE 1.375% Notes due 2036 MRK 36A NYSE Yes Yes Large Accelerated Filer false false false 2532806307 15775000000 14487000000 3540000000 3926000000 2483000000 2479000000 3992000000 4276000000 123000000 67000000 33000000 -89000000 10105000000 10837000000 5670000000 3650000000 903000000 825000000 4767000000 2825000000 5000000 4000000 4762000000 2821000000 1.88 1.11 1.87 1.11 4762000000 2821000000 130000000 -133000000 5000000 50000000 -238000000 68000000 -113000000 -115000000 4649000000 2706000000 5579000000 6841000000 40000000 252000000 80000000 88000000 11366000000 10349000000 3413000000 3348000000 6510000000 6358000000 7950000000 8368000000 31445000000 32168000000 280000000 252000000 18620000000 18266000000 23045000000 23051000000 21181000000 21197000000 17572000000 18011000000 12326000000 11996000000 105849000000 106675000000 3077000000 1372000000 3514000000 3922000000 14102000000 15766000000 2398000000 2649000000 2008000000 1985000000 25099000000 25694000000 31142000000 33683000000 922000000 871000000 8262000000 8792000000 0.50 0.50 6500000000 6500000000 3577103522 3577103522 1788000000 1788000000 44598000000 44509000000 56697000000 53895000000 -5274000000 -5161000000 97809000000 95031000000 1044402655 1045470249 57445000000 57450000000 40364000000 37581000000 60000000 54000000 40424000000 37635000000 105849000000 106675000000 4767000000 2825000000 473000000 543000000 511000000 448000000 143000000 450000000 656000000 0 0 1192000000 -51000000 -277000000 176000000 145000000 -83000000 197000000 3382000000 2890000000 3090000000 1339000000 861000000 1007000000 15000000 562000000 260000000 500000000 746000000 0 0 1327000000 14000000 -37000000 -1376000000 -2359000000 751000000 1000000 1950000000 1853000000 122000000 149000000 87000000 30000000 -78000000 -81000000 -2814000000 -2054000000 -138000000 87000000 -1238000000 -2987000000 68000000 79000000 6909000000 12773000000 92000000 79000000 5671000000 9786000000 Basis of Presentation<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Merck &amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The amended guidance is effective prospectively for all joint ventures with a formation date on or after January 1, 2025, however existing joint ventures have the option to apply the guidance retrospectively. Early adoption is permitted for both interim and annual periods. The Company anticipates there will be no impact to its consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses. The guidance is effective for annual periods beginning in 2024, and interim periods beginning in 2025. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.</span></div>In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. Early adoption is permitted. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements. Basis of Presentation<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Merck &amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2024. </span></div>The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation. <div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The amended guidance is effective prospectively for all joint ventures with a formation date on or after January 1, 2025, however existing joint ventures have the option to apply the guidance retrospectively. Early adoption is permitted for both interim and annual periods. The Company anticipates there will be no impact to its consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses. The guidance is effective for annual periods beginning in 2024, and interim periods beginning in 2025. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.</span></div>In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. Early adoption is permitted. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements. Acquisitions, Divestitures, Research Collaborations and Licensing Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments; expense reimbursements or payments to the third party; milestone, royalty or profit share arrangements contingent upon the occurrence of certain future events linked to the success of the asset in development; and can also include option and continuation payments. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024 Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2024, Merck acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases, for $765 million and also incurred $56 million of transaction costs. Harpoon’s lead candidate, MK-6070 (formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small-cell lung cancer (SCLC) and neuroendocrine tumors. MK-6070 is currently being evaluated as monotherapy in a Phase 1/2 clinical trial in certain patients with advanced cancers associated with expression of DLL3. The study is also evaluating MK-6070 in combination with atezolizumab in certain patients with SCLC. The transaction was accounted for as an asset acquisition since MK-6070 represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $165 million, as well as a charge of $656 million to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in the first quarter of 2024 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2024, Merck entered into a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (Elanco) for $1.3 billion in cash. The Elanco aqua business to be acquired consists of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. Upon closing, the acquisition will broaden Animal Health’s aqua portfolio with products, such as Clynav, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic sea lice treatment. This acquisition also brings a portfolio of water treatment products for warm water production, complementing Animal Health’s warm water vaccine portfolio. In addition to these products, the DNA-based vaccine </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">technology that is a part of the business has the potential to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. The acquisition is expected to be completed by mid-2024, subject to approvals from regulatory authorities and other customary closing conditions. The transaction will be accounted for as a business combination.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023 Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded as a charge to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in the first quarter of 2023. In October 2023, Merck notified Kelun-Biotech it was terminating two of the seven candidates under the agreement. Subsequently, in April 2024, Merck notified Kelun-Biotech it was terminating an additional candidate under the agreement. Kelun-Biotech remains eligible to receive future contingent payments aggregating up to $600 million in development-related payments, $1.6 billion in regulatory milestones, and $3.1 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all remaining candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate, bomedemstat MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A Phase 3 clinical trial evaluating bomedemstat for the treatment of certain patients with essential thrombocythemia is underway. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as a charge of $1.2 billion to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Spin-Off of Organon &amp; Co.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the 2021 spin-off of Organon &amp; Co. (Organon), Merck and Organon entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck continued to market, import and distribute such products on behalf of Organon until such time as the relevant licenses and permits transferred to Organon, with Organon receiving all of the economic benefits and burdens of such activities. As of March 31, 2024, only one jurisdiction remains under an interim operating agreement. Additionally, Merck and Organon entered into a number of manufacturing and supply agreements (MSAs) with terms ranging from four years to ten years. The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $107 million and $94 million and related cost of sales of $110 million and $107 million for the first quarter of 2024 and 2023, respectively. The amounts due from Organon for all spin-off related agreements were $462 million and $632 million at March 31, 2024 and December 31, 2023, respectively, and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $193 million and $598 million at March 31, 2024 and December 31, 2023, respectively, and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> 765000000 56000000 165000000 656000000 1300000000 7 175000000 2 7 600000000 1600000000 3100000000 100000000 1350000000 60000000 219000000 1200000000 1 P4Y P10Y 107000000 94000000 110000000 107000000 462000000 632000000 193000000 598000000 Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AstraZeneca PLC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca are developing and commercializing Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at March 31, 2024) and a corresponding increase to the intangible asset related to Lynparza. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. Lynparza received regulatory approvals triggering capitalized milestone payments from Merck to AstraZeneca of $245 million and $105 million in the first quarter of 2024 and 2023, respectively (each of which had been previously accrued for). Potential future regulatory milestone payments of $650 million remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.4 billion at March 31, 2024 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai are developing and commercializing Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a $125 million sales-based milestone payment from Merck to Eisai. Similarly, in the third quarter of 2023 an additional $125 million sales-based milestone payment to Eisai was deemed by the Company to be probable of payment. Accordingly, Merck recorded $250 million of liabilities for these payments (of which $125 million was subsequently paid in the second quarter of 2023 and $125 million remained accrued at March 31, 2024) and corresponding increases to the intangible asset related to Lenvima. Merck also recognized $72 million and $81 million of cumulative amortization catch-up expense related to the recognition of these milestones in the first and third quarters of 2023, respectively. Potential future sales-based milestone payments of $2.3 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $623 million at March 31, 2024 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents an accrued milestone payment.</span></div><div style="margin-top:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat) and Verquvo (vericiguat). The two companies have implemented a joint development and commercialization strategy. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. There are no sales-based milestone payments remaining under this collaboration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $483 million and $49 million, respectively, at March 31, 2024 and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">recorded by Merck</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalties.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Daiichi Sankyo</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments. The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Merck made payments to Daiichi Sankyo totaling $4.0 billion in 2023. These payments included $1.0 billion ($500 million each for patritumab deruxtecan and ifinatamab deruxtecan) which may be refundable on a pro-rated basis in the event of early termination of development with respect to either program. In addition, the agreement provides for a continuation payment of $750 million related to patritumab deruxtecan due from Merck in October 2024 and a continuation payment of $750 million related to raludotatug deruxtecan due from Merck in October 2025. If Merck does not make the continuation payments on the dates noted for either patritumab deruxtecan and/or raludotatug deruxtecan, the rights for the applicable program will revert to Daiichi Sankyo and the non-refundable upfront payments already paid will be retained by Daiichi Sankyo. The agreement also provides for contingent payments from Merck to Daiichi Sankyo of up to an additional $5.5 billion for each DXd ADC upon the successful achievement of certain sales-based milestones. In conjunction with this transaction, Merck recorded an aggregate pretax charge of $5.5 billion to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses in the fourth quarter of 2023 for the $4.0 billion of upfront payments and the $1.5 billion of continuation payments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck and Daiichi Sankyo will equally share research and development costs, except for raludotatug deruxtecan, where Merck will be responsible for 75% of the first $2.0 billion of research and development expenses. Merck includes its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Following regulatory approval, Daiichi Sankyo will generally record sales worldwide (Daiichi Sankyo will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights and Merck will receive a 5% sales-based royalty. Merck will record its share of product sales, net of cost of sales and commercialization costs, as alliance revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Daiichi Sankyo included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Daiichi Sankyo included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Moderna, Inc.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna). V940 (mRNA-4157) is currently being evaluated in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in multiple Phase 3 clinical trials. Merck and Moderna will share costs and any profits equally under this worldwide collaboration. Merck records its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Any reimbursements received from Moderna for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs. Merck has also capitalized certain of the shared costs, which aggregated $110 million at March 31, 2024 and will be amortized over the assets’ estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Moderna included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bristol-Myers Squibb Company</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Alliance revenue related to this collaboration, consisting of royalties (recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) was $71 million and $43 million in the first quarter of 2024 and 2023, respectively.</span></div> 600000000 600000000 2100000000 245000000 105000000 650000000 1400000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents an accrued milestone payment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">recorded by Merck</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Daiichi Sankyo included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Daiichi Sankyo included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Moderna included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 292000000 275000000 38000000 23000000 330000000 298000000 82000000 70000000 39000000 47000000 20000000 21000000 334000000 341000000 617000000 256000000 0 600000000 125000000 125000000 250000000 125000000 125000000 72000000 81000000 2300000000 623000000 255000000 232000000 60000000 126000000 39000000 51000000 8000000 39000000 255000000 226000000 125000000 125000000 72000000 0 483000000 49000000 98000000 99000000 70000000 59000000 5000000 7000000 173000000 165000000 62000000 57000000 33000000 33000000 28000000 25000000 155000000 156000000 74000000 80000000 350000000 392000000 191000000 221000000 16000000 27000000 -5000000 16000000 160000000 113000000 3 3 4000000000 1000000000 500000000 500000000 750000000 750000000 5500000000 5500000000 4000000000 1500000000 0.75 2000000000 0.05 3000000 0 69000000 0 817000000 800000000 750000000 750000000 110000000 2000000 1000000 69000000 26000000 72000000 63000000 0.20 0.24 0.50 80000000 71000000 43000000 Restructuring<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company recorded total pretax costs of $246 million in the first quarter of 2024 related to the 2024 Restructuring Program, bringing total cumulative pretax costs incurred through March 31, 2024 to $436 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2019, Merck approved a global restructuring program (2019 Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The Company recorded total pretax costs of $97 million in the first quarter of 2023 related to the 2019 Restructuring Program. The actions under the 2019 Restructuring Program were substantially complete at the end of 2023 and, as of January 1, 2024, any remaining activities are now being accounted for as part of the 2024 Restructuring Program. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the charges related to the restructuring programs by type of cost:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.678%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated Depreciation</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation Costs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other Exit Costs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2024 Restructuring Program</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.678%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated Depreciation</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation Costs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other Exit Costs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2019 Restructuring Program</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other exit costs in 2024 and 2023 include asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 9) and share-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2024:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated Depreciation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other Exit Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves March 31, 2024 </span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">736 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 4000000000 0.60 246000000 436000000 97000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the charges related to the restructuring programs by type of cost:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.678%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated Depreciation</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation Costs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other Exit Costs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2024 Restructuring Program</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.678%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated Depreciation</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation Costs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other Exit Costs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2019 Restructuring Program</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 65000000 0 51000000 116000000 0 0 5000000 5000000 0 0 2000000 2000000 0 92000000 31000000 123000000 65000000 92000000 89000000 246000000 21000000 0 8000000 29000000 0 0 1000000 1000000 0 41000000 26000000 67000000 21000000 41000000 35000000 97000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2024:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated Depreciation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other Exit Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves March 31, 2024 </span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">736 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0 681000000 31000000 712000000 65000000 92000000 89000000 246000000 0 67000000 32000000 99000000 -65000000 0 -58000000 -123000000 0 706000000 30000000 736000000 Financial Instruments<div style="margin-top:5pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and foreign exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of foreign exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of foreign exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the foreign exchange rate and the cost of the hedging instrument (primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi). The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in foreign exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Condensed Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.177%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March 31, 2024, the Company was a party to four pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of a portion of fixed-rate notes as detailed in the table below.</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Par Value of Debt</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.50% notes due 2033</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark Secured Overnight Financing Rate (SOFR) swap rate. The fair value changes in the notes attributable to changes in the SOFR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. In April 2024, the Company entered into two additional interest rate swaps with notional amounts of $250 million each also related to its 4.50% notes due 2033. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-453"><span style="-sec-ix-hidden:f-454">Long-Term Debt</span></span></span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,056 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-460"><span style="-sec-ix-hidden:f-461">Other Assets</span></span></span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-466"><span style="-sec-ix-hidden:f-467">Other current assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-472"><span style="-sec-ix-hidden:f-473">Other Assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-478"><span style="-sec-ix-hidden:f-479">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,076 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-484"><span style="-sec-ix-hidden:f-485">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-496"><span style="-sec-ix-hidden:f-497">Other current assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,428 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-502"><span style="-sec-ix-hidden:f-503">Other Assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-508"><span style="-sec-ix-hidden:f-509">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-514"><span style="-sec-ix-hidden:f-515">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,220 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,551 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:64.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.732%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Hedges are Recorded</span></div></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,775 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:f-566"><span style="-sec-ix-hidden:f-567"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.359%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts serve as economic hedges of forecasted transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March 31, 2024, the Company estimates $113 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual foreign exchange rates at maturity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,025 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Unrealized net gains of $143 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2024 on equity securities still held at March 31, 2024. Unrealized net gains of $338 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2023 on equity securities still held at March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March 31, 2024 and March 31, 2023, the Company also had $851 million and $942 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. During the first quarter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $4 million and unrealized losses of $5 million related to certain of these equity investments still held at March 31, 2024. During the first quarter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $1 million and unrealized losses of $21 million related to certain of these equity investments still held at March 31, 2023. Cumulative unrealized gains and cumulative unrealized losses based on observable </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">price changes for investments in equity investments without readily determinable fair values still held at March 31, 2024 were $297 million and $69 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March 31, 2024 and March 31, 2023, the Company also had $396 million and $725 million, respectively, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. Losses (gains) recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> relating to these investment funds were $2 million and $(132) million for the first quarter of 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Balance at March 31, 2024 includes securities with a fair value of $266 million, which are subject to a contractual sale restriction that expires in July 2024.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included $4.6 billion and $6.0 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:80.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value March 31 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Balance at March 31, 2024, includes $133 million of current liabilities, all of which relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at March 31, 2024, was $30.4 billion compared with a carrying value of $34.2 billion and at December 31, 2023, was $32.0 billion compared with a carrying value of $35.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers, distributors and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.7 billion and $3.0 billion of accounts receivable as of March 31, 2024 and December 31, 2023, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions, generally within thirty days after receipt. As of March 31, 2024 and December 31, 2023, the Company had collected $43 million and $44 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $58 million and $3 million at March 31, 2024 and December 31, 2023, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span>. P2Y P6M <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Condensed Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.177%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div> 2000000 -1000000 0 -1000000 62000000 -52000000 0 0 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March 31, 2024, the Company was a party to four pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of a portion of fixed-rate notes as detailed in the table below.</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Par Value of Debt</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.50% notes due 2033</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4 0.0450 1500000000 4 1000000000 2 250000000 0.0450 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-453"><span style="-sec-ix-hidden:f-454">Long-Term Debt</span></span></span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,056 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1026000000 1056000000 26000000 56000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-460"><span style="-sec-ix-hidden:f-461">Other Assets</span></span></span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-466"><span style="-sec-ix-hidden:f-467">Other current assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-472"><span style="-sec-ix-hidden:f-473">Other Assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-478"><span style="-sec-ix-hidden:f-479">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,076 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-484"><span style="-sec-ix-hidden:f-485">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-496"><span style="-sec-ix-hidden:f-497">Other current assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,428 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-502"><span style="-sec-ix-hidden:f-503">Other Assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-508"><span style="-sec-ix-hidden:f-509">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-514"><span style="-sec-ix-hidden:f-515">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,220 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,551 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 27000000 1000000000 57000000 1000000000 175000000 9082000000 106000000 6138000000 32000000 2062000000 26000000 1929000000 10000000 1076000000 76000000 3680000000 1000000 204000000 1000000 7000000 234000000 11000000 13424000000 189000000 77000000 12754000000 121000000 9428000000 153000000 9693000000 2000000 43000000 0 0 154000000 9282000000 162000000 8104000000 2000000 43000000 0 0 123000000 156000000 18796000000 153000000 162000000 17797000000 357000000 167000000 32220000000 342000000 239000000 30551000000 The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:64.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 357000000 167000000 342000000 239000000 111000000 111000000 215000000 215000000 58000000 0 3000000 0 188000000 56000000 124000000 24000000 <div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.732%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Hedges are Recorded</span></div></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,775 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:f-566"><span style="-sec-ix-hidden:f-567"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div> 15775000000 14487000000 33000000 -89000000 -113000000 -115000000 -30000000 0 30000000 0 209000000 -66000000 44000000 101000000 -44000000 -101000000 0 1000000 0 -1000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.359%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts serve as economic hedges of forecasted transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div> -65000000 -13000000 10000000 -2000000 113000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,025 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Unrealized net gains of $143 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2024 on equity securities still held at March 31, 2024. Unrealized net gains of $338 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2023 on equity securities still held at March 31, 2023.</span></div> 40000000 0 0 40000000 252000000 0 0 252000000 77000000 0 0 77000000 72000000 0 0 72000000 0 0 0 0 13000000 0 0 13000000 117000000 0 0 117000000 337000000 0 0 337000000 908000000 764000000 1025000000 1101000000 143000000 338000000 851000000 942000000 4000000 5000000 1000000 21000000 297000000 69000000 396000000 725000000 -2000000 132000000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Balance at March 31, 2024 includes securities with a fair value of $266 million, which are subject to a contractual sale restriction that expires in July 2024.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div> 0 40000000 0 40000000 0 252000000 0 252000000 280000000 0 0 280000000 252000000 0 0 252000000 280000000 40000000 0 320000000 252000000 252000000 0 504000000 77000000 0 0 77000000 72000000 0 0 72000000 0 0 0 0 13000000 0 0 13000000 628000000 0 0 628000000 512000000 0 0 512000000 705000000 0 0 705000000 597000000 0 0 597000000 0 204000000 0 204000000 0 202000000 0 202000000 0 126000000 0 126000000 0 83000000 0 83000000 0 27000000 0 27000000 0 57000000 0 57000000 0 357000000 0 357000000 0 342000000 0 342000000 985000000 397000000 0 1382000000 849000000 594000000 0 1443000000 0 0 226000000 226000000 0 0 354000000 354000000 0 149000000 0 149000000 0 239000000 0 239000000 0 18000000 0 18000000 0 0 0 0 0 167000000 0 167000000 0 239000000 0 239000000 0 167000000 226000000 393000000 0 239000000 354000000 593000000 266000000 4600000000 6000000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:80.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value March 31 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Balance at March 31, 2024, includes $133 million of current liabilities, all of which relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows.</span></div> 354000000 456000000 -2000000 14000000 126000000 117000000 226000000 353000000 133000000 0.115 30400000000 34200000000 32000000000 35100000000 2700000000 3000000000 43000000 44000000 58000000 3000000 Inventories<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,544 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,923 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,413 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,348 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At both March 31, 2024 and December 31, 2023, these amounts included $2.6 billion of inventories not expected to be sold within one year. In addition, these amounts included $861 million and $790 million at March 31, 2024 and December 31, 2023, respectively, of inventories produced in preparation for product launches.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,544 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,923 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,413 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,348 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,544 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,923 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,413 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,348 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1902000000 1954000000 8366000000 8037000000 276000000 277000000 10544000000 10268000000 621000000 562000000 9923000000 9706000000 6510000000 6358000000 3413000000 3348000000 2600000000 2600000000 861000000 790000000 Contingencies<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Generally, for product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Dr. Scholl’s Foot Powder</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck is a defendant in product liability lawsuits in the U.S. arising from consumers’ alleged exposure to talc in Dr. Scholl’s foot powder, which Merck acquired through its merger with Schering-Plough Corporation and sold as part of the divestiture of Merck’s consumer care business to Bayer in 2014. In these actions, plaintiffs allege that they were exposed to asbestos-contaminated talc and developed mesothelioma as a result. As of March 31, 2024, approximately 275 cases were pending against Merck in various state courts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of March 31, 2024, approximately 190 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the U.S. Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. In February 2024, the multidistrict litigation was reassigned to Judge Kenneth D. Bell. There are fewer than 15 product liability cases pending outside the U.S.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck, Merck Sharp &amp; Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) were defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck agreed to pay $572.5 million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs’ claims, which was recorded as an expense in the Company’s financial results in the first quarter of 2023. In October 2023, the court granted final approval of the indirect purchaser class settlement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc. (United Healthcare), Humana Inc. (Humana), Centene Corporation and others (Centene), and Kaiser Foundation Health Plan, Inc. (Kaiser) (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases were transferred to the Eastern District of Virginia to proceed with the Zetia MDL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. In December 2023, prior to a decision on the motion to dismiss, the U.S. Judicial Panel on Multidistrict Litigation remanded the four Insurer Plaintiff cases to the transferor courts in the Northern District of California (Kaiser), the District of Minnesota (United Healthcare), and the District of New Jersey (Humana and Centene). On March 15, 2024, the Merck Defendants filed motions to dismiss the Humana and Centene cases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company’s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In July 2023, the court denied relators’ motion for summary judgment, granted two of the Company’s motions for summary judgment, and denied the Company’s remaining motions for summary judgment as moot. The court entered judgment in favor of the Company and dismissed relators’ amended complaint in full with prejudice. Relators have appealed that decision. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine, which charge that the Company misrepresented the efficacy of the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In the antitrust case, the court granted the Company’s motion for summary judgment as to plaintiffs’ state law claims and denied the motion as to plaintiffs’ antitrust claim. The Company has appealed the antitrust decision.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies had filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey were consolidated. The West Virginia case was jointly dismissed with prejudice in August 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action stipulated to infringement of the asserted claims and withdrew all remaining claims and defenses other than a defense seeking to shorten the patent term extension (PTE) of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial in December 2022 on this remaining PTE calculation defense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2023, the U.S. District Court for the District of New Jersey ruled in Merck’s favor. The court held that Merck’s calculation of PTE for the sugammadex patent covering the compound is not invalid and that the U.S. Patent &amp; Trademark Office correctly granted a full five-year extension. This ruling affirms and validates Merck’s U.S. patent protection for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> through at least January 2026. Also in June 2023, the U.S. District Court for the District of New Jersey issued a final judgment prohibiting the FDA from approving any of the pending or tentatively approved generic applications until January 27, 2026, except for any subsequent agreements between defendants and Merck or further order by the court.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2023, defendants filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit. The appeal is currently pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While the New Jersey action was pending, the Company settled with five generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 5, 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Hikma Pharmaceuticals USA Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell a generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Injection. On March 15, 2024, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Hikma, postponing FDA approval of the Hikma generic drug for 30 months or until expiration of the sugammadex patent (January 27, 2026) and any potentially applicable pediatric exclusivity or an adverse court decision, if any, whichever may occur earlier. Expiration of the patent, and any potentially applicable pediatric exclusivity, will occur earlier than expiry of the 30-month stay.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed, the FDA granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin/metformin HCI), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed, beginning in 2019, a number of generic drug companies filed ANDAs seeking approval of generic forms of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">along with paragraph IV certifications challenging the validity of the 2027 salt/polymorph patent. The Company responded by filing infringement suits which have all been settled. The Company has settled with a total of 26 generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market in the U.S. in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of a form of sitagliptin that is a different form than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA’s Orange Book for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl Extended Release tablets. In January 2024, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable version containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these settlement agreements related to the later expiring 2027 salt/polymorph patent directed to the specific sitagliptin salt form of the products, the Company expects that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until May 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until July 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, although Zydus has received FDA approval for a non-automatically substitutable form of sitagliptin that differs from the form in the Company’s sitagliptin products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplementary Protection Certificates (SPCs) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expired in April 2023 for the majority of European countries. Prior to expiration, generic companies sought revocation of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPCs in Europe, for which an oral hearing was held in March 2023 and an Advocate General Opinion is expected in June 2024 with a decision later in 2024. If the CJEU renders a decision that negatively impacts the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2023, the Company filed a patent infringement lawsuit against Sawai Pharmaceuticals Co., Ltd. and Medisa Shinyaku Co., Ltd (collectively, Defendants) in the Tokyo District Court seeking an injunction to stop the manufacture, sale and offer for sale of the Defendants’ sitagliptin dihydrogen phosphate product, while the Company’s patents and patent term extensions are in force. The lawsuit is in response to the Defendants’ application for marketing authorization to sell a generic sitagliptin dihydrogen phosphate product, in the anhydrate form, which was approved on August 15, 2023. Merck asserts that the Defendants’ activity infringes a patent term extension associated with Merck’s patent directed to the sitagliptin compound patent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in November 2022, the Company filed a complaint against The Johns Hopkins University (JHU) in the U.S. District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Merck and JHU partnered to design and conduct a clinical study administering </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract, declaratory judgment of noninfringement, and promissory estoppel. JHU answered the complaint in April and May 2023, denying Merck’s claims, and counterclaiming for willful infringement of nine issued U.S. patents, including a demand for damages. Between November 30, 2023, and March 13, 2024, the Company filed </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">review petitions with the United States Patent &amp; Trademark Office Patent Trial and Appeal Board, challenging the validity of all nine patents asserted in the case.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey/Delaware against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2023, AstraZeneca Pharmaceuticals LP received a second Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Sandoz Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Sandoz. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2026 or until an adverse court decision, if any, whichever may occur earlier.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials; and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March 31, 2024 and December 31, 2023 of approximately $220 million and $210 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div> Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. 275 190 15 -572500000 2 2 2 2 P1D 5 2 26 9 220000000 210000000 Equity<div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.359%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> Treasury Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,489)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,058 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.73 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,467 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,039 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,577)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,905 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,509 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,895 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,161)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,450)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,635 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.77 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,598 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,697 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,274)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,445)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,424 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.359%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> Treasury Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,489)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,058 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.73 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,467 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,039 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,577)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,905 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,509 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,895 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,161)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,450)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,635 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.77 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,598 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,697 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,274)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,445)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,424 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3577000000 1788000000 44379000000 61081000000 -4768000000 1039000000 -56489000000 67000000 46058000000 2821000000 2821000000 -115000000 -115000000 0.73 1863000000 1863000000 1000000 149000000 149000000 -88000000 0 -61000000 -149000000 4000000 4000000 3577000000 1788000000 44467000000 62039000000 -4883000000 1040000000 -56577000000 71000000 46905000000 3577000000 1788000000 44509000000 53895000000 -5161000000 1045000000 -57450000000 54000000 37635000000 4762000000 4762000000 -113000000 -113000000 0.77 1960000000 1960000000 1000000 122000000 122000000 -89000000 2000000 -127000000 -1000000 -217000000 5000000 5000000 3577000000 1788000000 44598000000 56697000000 -5274000000 1044000000 -57445000000 60000000 40424000000 Pension and Other Postretirement Benefit Plans<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.676%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees e</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">iting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of $21 million in the first quarter of 2023. This partial settlement triggered a remeasurement of some of the Company’s U.S. pension plans. The remeasurement, which was calculated using discount rates and asset values as of March 31, 2023, resulted in a net increase of $44 million to net pension liabilities and also resulted in a related adjustment to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note 10), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement related to restructuring actions.</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.676%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 86000000 61000000 76000000 49000000 134000000 74000000 133000000 74000000 207000000 139000000 187000000 128000000 0 -3000000 0 -3000000 -10000000 -1000000 0 1000000 3000000 0 0 0 0 0 -2000000 0 0 0 -21000000 0 26000000 -6000000 45000000 -9000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 8000000 8000000 14000000 16000000 20000000 16000000 -11000000 -12000000 12000000 11000000 -21000000 -15000000 21000000 -44000000 Other (Income) Expense, Net<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from investments in equity securities, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net (as reflected in the table above) in the first three months of 2023 includes a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 7).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid for the three months ended March 31, 2024 and 2023 was $217 million and $208 million, respectively.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from investments in equity securities, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span>Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. 73000000 112000000 303000000 242000000 -83000000 -61000000 143000000 450000000 -160000000 -115000000 43000000 -463000000 33000000 -89000000 -572500000 217000000 208000000 Income Taxes<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effective income tax rate of 15.9% for the first quarter of 2024 reflects a 1.6 percentage point unfavorable discrete impact of a charge for the acquisition of Harpoon for which no tax benefit was recognized. The effective income tax rate of 22.6% for the first quarter of 2023 reflects a 5.5 percentage point unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the Tax Cuts and Jobs Act of 2017. If the IRS disagrees with the Company’s transition tax position, it may result in a significant tax liability. The statute of limitations for assessments with respect to the 2019 and 2020 federal return years will expire in June and October of 2024, respectively, unless extended.</span></div> 0.159 0.016 0 0.226 0.055 0 Earnings Per Share<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.236%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,533 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,538 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,544 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.88 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.87 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Issuable primarily under share-based compensation plans.</span></div>For the first quarter of 2024 and 2023, 3 million and 1 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computations of earnings per common share assuming dilution because the effect would have been antidilutive. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.236%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,533 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,538 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,544 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.88 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.87 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Issuable primarily under share-based compensation plans.</span></div> 4762000000 4762000000 2821000000 2821000000 2533000000 2538000000 11000000 13000000 2544000000 2551000000 1.88 1.11 1.87 1.11 3000000 1000000 Other Comprehensive Income (Loss)<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2023, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,433)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2023, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,458)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2024, net of taxes</span></div></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,793)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,344)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,161)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2024, net of taxes</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,798)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,582)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,274)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 9).</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2023, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,433)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2023, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,458)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2024, net of taxes</span></div></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,793)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,344)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,161)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2024, net of taxes</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,798)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,582)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,274)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 9).</span></div> 73000000 -2408000000 -2433000000 -4768000000 -66000000 -47000000 79000000 -34000000 -14000000 -2000000 20000000 4000000 -52000000 -45000000 59000000 -38000000 102000000 7000000 -9000000 100000000 21000000 2000000 0 23000000 81000000 5000000 -9000000 77000000 -133000000 -50000000 68000000 -115000000 -60000000 -2458000000 -2365000000 -4883000000 -24000000 -2793000000 -2344000000 -5161000000 209000000 5000000 -225000000 -11000000 44000000 4000000 13000000 61000000 165000000 1000000 -238000000 -72000000 44000000 15000000 0 59000000 9000000 9000000 0 18000000 35000000 6000000 0 41000000 130000000 -5000000 -238000000 -113000000 106000000 -2798000000 -2582000000 -5274000000 Segment Reporting<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.193%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"> ($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,972 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Delstrigo</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Pifeltro</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,604 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,410 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,107 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,517 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,599 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,212 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,478 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,297 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,775 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,659 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,828 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(5)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $54 million and $99 million for the three months ended March 31, 2024 and 2023, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2024 and 2023 also includes $61 million and $51 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.2 billion and $3.1 billion for the three months ended March 31, 2024 and 2023, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.674%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,659 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,775 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.528%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,459 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and amortization of purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits (losses) related to third-party manufacturing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div> 2 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.193%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"> ($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,972 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Delstrigo</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Pifeltro</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,604 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,410 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,107 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,517 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,599 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,212 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,478 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,297 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,775 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,659 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,828 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(5)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $54 million and $99 million for the three months ended March 31, 2024 and 2023, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2024 and 2023 also includes $61 million and $51 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.</span></div> 4119000000 2828000000 6947000000 3485000000 2310000000 5795000000 135000000 157000000 292000000 142000000 133000000 275000000 173000000 82000000 255000000 153000000 79000000 232000000 77000000 7000000 85000000 41000000 1000000 42000000 58000000 12000000 71000000 30000000 12000000 43000000 488000000 1761000000 2249000000 416000000 1556000000 1972000000 438000000 133000000 570000000 421000000 107000000 528000000 161000000 58000000 219000000 94000000 13000000 106000000 149000000 67000000 216000000 180000000 117000000 297000000 6000000 55000000 61000000 40000000 56000000 96000000 329000000 111000000 440000000 276000000 210000000 487000000 74000000 100000000 174000000 54000000 75000000 129000000 68000000 5000000 73000000 62000000 3000000 65000000 33000000 23000000 56000000 27000000 23000000 50000000 8000000 48000000 56000000 14000000 46000000 60000000 90000000 8000000 98000000 83000000 16000000 99000000 0 70000000 70000000 0 59000000 59000000 45000000 305000000 350000000 -2000000 394000000 392000000 50000000 61000000 111000000 52000000 71000000 123000000 12000000 44000000 56000000 11000000 33000000 44000000 29000000 13000000 42000000 24000000 10000000 34000000 15000000 32000000 46000000 16000000 40000000 56000000 0 184000000 184000000 0 180000000 180000000 0 39000000 39000000 0 51000000 51000000 183000000 236000000 419000000 271000000 280000000 551000000 39000000 212000000 251000000 56000000 272000000 329000000 157000000 419000000 576000000 171000000 457000000 626000000 6936000000 7070000000 14006000000 6117000000 6604000000 12721000000 166000000 683000000 850000000 174000000 676000000 849000000 308000000 354000000 661000000 308000000 334000000 642000000 474000000 1037000000 1511000000 482000000 1010000000 1491000000 7410000000 8107000000 15517000000 6599000000 7614000000 14212000000 68000000 190000000 258000000 60000000 214000000 275000000 7478000000 8297000000 15775000000 6659000000 7828000000 14487000000 54000000 99000000 61000000 51000000 3200000000 3100000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.674%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,659 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,775 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 7478000000 6659000000 3563000000 3303000000 1772000000 1715000000 821000000 758000000 796000000 661000000 724000000 846000000 621000000 545000000 15775000000 14487000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.528%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,459 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 10904000000 9140000000 555000000 566000000 11459000000 9706000000 146000000 164000000 73000000 112000000 303000000 242000000 473000000 543000000 452000000 398000000 3851000000 4147000000 123000000 67000000 0 -573000000 806000000 362000000 5670000000 3650000000 false false false false

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

    •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�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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 92 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 555 315 1 false 141 0 false 13 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.merck.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME CONDENSED CONSOLIDATED STATEMENT OF INCOME Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET CONDENSED CONSOLIDATED BALANCE SHEET Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation Sheet http://www.merck.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 0000009 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements Sheet http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreements Acquisitions, Divestitures, Research Collaborations and Licensing Agreements Notes 9 false false R10.htm 0000010 - Disclosure - Collaborative Arrangements Sheet http://www.merck.com/role/CollaborativeArrangements Collaborative Arrangements Notes 10 false false R11.htm 0000011 - Disclosure - Restructuring Sheet http://www.merck.com/role/Restructuring Restructuring Notes 11 false false R12.htm 0000012 - Disclosure - Financial Instruments Sheet http://www.merck.com/role/FinancialInstruments Financial Instruments Notes 12 false false R13.htm 0000013 - Disclosure - Inventories Sheet http://www.merck.com/role/Inventories Inventories Notes 13 false false R14.htm 0000014 - Disclosure - Contingencies Sheet http://www.merck.com/role/Contingencies Contingencies Notes 14 false false R15.htm 0000015 - Disclosure - Equity Sheet http://www.merck.com/role/Equity Equity Notes 15 false false R16.htm 0000016 - Disclosure - Pension and Other Postretirement Benefit Plans Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans Pension and Other Postretirement Benefit Plans Notes 16 false false R17.htm 0000017 - Disclosure - Other (Income) Expense, Net Sheet http://www.merck.com/role/OtherIncomeExpenseNet Other (Income) Expense, Net Notes 17 false false R18.htm 0000018 - Disclosure - Income Taxes Sheet http://www.merck.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 0000019 - Disclosure - Earnings Per Share Sheet http://www.merck.com/role/EarningsPerShare Earnings Per Share Notes 19 false false R20.htm 0000020 - Disclosure - Other Comprehensive Income (Loss) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLoss Other Comprehensive Income (Loss) Notes 20 false false R21.htm 0000021 - Disclosure - Segment Reporting Sheet http://www.merck.com/role/SegmentReporting Segment Reporting Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - Basis of Presentation (Policies) Sheet http://www.merck.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies 24 false false R25.htm 9954472 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.merck.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.merck.com/role/CollaborativeArrangements 25 false false R26.htm 9954473 - Disclosure - Restructuring (Tables) Sheet http://www.merck.com/role/RestructuringTables Restructuring (Tables) Tables http://www.merck.com/role/Restructuring 26 false false R27.htm 9954474 - Disclosure - Financial Instruments (Tables) Sheet http://www.merck.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.merck.com/role/FinancialInstruments 27 false false R28.htm 9954475 - Disclosure - Inventories (Tables) Sheet http://www.merck.com/role/InventoriesTables Inventories (Tables) Tables http://www.merck.com/role/Inventories 28 false false R29.htm 9954476 - Disclosure - Equity (Tables) Sheet http://www.merck.com/role/EquityTables Equity (Tables) Tables http://www.merck.com/role/Equity 29 false false R30.htm 9954477 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables Pension and Other Postretirement Benefit Plans (Tables) Tables http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans 30 false false R31.htm 9954478 - Disclosure - Other (Income) Expense, Net (Tables) Sheet http://www.merck.com/role/OtherIncomeExpenseNetTables Other (Income) Expense, Net (Tables) Tables http://www.merck.com/role/OtherIncomeExpenseNet 31 false false R32.htm 9954479 - Disclosure - Earnings Per Share (Tables) Sheet http://www.merck.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.merck.com/role/EarningsPerShare 32 false false R33.htm 9954480 - Disclosure - Other Comprehensive Income (Loss) (Tables) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossTables Other Comprehensive Income (Loss) (Tables) Tables http://www.merck.com/role/OtherComprehensiveIncomeLoss 33 false false R34.htm 9954481 - Disclosure - Segment Reporting (Tables) Sheet http://www.merck.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.merck.com/role/SegmentReporting 34 false false R35.htm 9954482 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details) Sheet http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details) Details http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreements 35 false false R36.htm 9954483 - Disclosure - Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) Details 36 false false R37.htm 9954484 - Disclosure - Collaborative Arrangements - AstraZeneca PLC (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails Collaborative Arrangements - AstraZeneca PLC (Details) Details 37 false false R38.htm 9954485 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details) Details 38 false false R39.htm 9954486 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails Collaborative Arrangements - Eisai Co., Ltd. (Details) Details 39 false false R40.htm 9954487 - Disclosure - Collaborative Arrangements - Bayer AG (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails Collaborative Arrangements - Bayer AG (Details) Details 40 false false R41.htm 9954488 - Disclosure - Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details) Details 41 false false R42.htm 9954489 - Disclosure - Collaborative Arrangements - Daiicho Sankyo - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails Collaborative Arrangements - Daiicho Sankyo - Narrative (Details) Details 42 false false R43.htm 9954490 - Disclosure - Collaborative Arrangements - Daiicho Sankyo (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails Collaborative Arrangements - Daiicho Sankyo (Details) Details 43 false false R44.htm 9954491 - Disclosure - Collaborative Arrangements - Moderna, Inc. - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails Collaborative Arrangements - Moderna, Inc. - Narrative (Details) Details 44 false false R45.htm 9954492 - Disclosure - Collaborative Arrangements - Moderna, Inc. (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails Collaborative Arrangements - Moderna, Inc. (Details) Details 45 false false R46.htm 9954493 - Disclosure - Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details) Details 46 false false R47.htm 9954494 - Disclosure - Restructuring - Narrative (Details) Sheet http://www.merck.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 47 false false R48.htm 9954495 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) Sheet http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails Restructuring - Charges Activities by Type of Cost (Details) Details 48 false false R49.htm 9954496 - Disclosure - Restructuring - Activities by Program (Details) Sheet http://www.merck.com/role/RestructuringActivitiesbyProgramDetails Restructuring - Activities by Program (Details) Details 49 false false R50.htm 9954497 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.merck.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 50 false false R51.htm 9954498 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails Financial Instruments - Effect of Net Investment Hedges (Details) Details 51 false false R52.htm 9954499 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details) Sheet http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails Financial Instruments - Summary of Interest Rate Swaps Held (Details) Details 52 false false R53.htm 9954500 - Disclosure - Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsAmountsRecordedonBalanceSheetRelatedtoFairValueHedgesDetails Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details) Details 53 false false R54.htm 9954501 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Details 54 false false R55.htm 9954502 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Details 55 false false R56.htm 9954503 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) Sheet http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) Details 56 false false R57.htm 9954504 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Details 57 false false R58.htm 9954505 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails Financial Instruments - Information on Available-for-sale Investments (Details) Details 58 false false R59.htm 9954506 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 59 false false R60.htm 9954507 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Details 60 false false R61.htm 9954508 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.merck.com/role/InventoriesScheduleofInventoriesDetails Inventories - Schedule of Inventories (Details) Details 61 false false R62.htm 9954509 - Disclosure - Inventories - Narrative (Details) Sheet http://www.merck.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 62 false false R63.htm 9954510 - Disclosure - Contingencies (Details) Sheet http://www.merck.com/role/ContingenciesDetails Contingencies (Details) Details http://www.merck.com/role/Contingencies 63 false false R64.htm 9954511 - Disclosure - Equity (Details) Sheet http://www.merck.com/role/EquityDetails Equity (Details) Details http://www.merck.com/role/EquityTables 64 false false R65.htm 9954512 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) Details 65 false false R66.htm 9954513 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails Pension and Other Postretirement Benefit Plans - Narrative (Details) Details 66 false false R67.htm 9954514 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 67 false false R68.htm 9954515 - Disclosure - Other (Income) Expense, Net - Narrative (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails Other (Income) Expense, Net - Narrative (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 68 false false R69.htm 9954516 - Disclosure - Income Taxes (Details) Sheet http://www.merck.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.merck.com/role/IncomeTaxes 69 false false R70.htm 9954517 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details) Sheet http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails Earnings Per Share - Calculations of Earnings Per Share (Details) Details 70 false false R71.htm 9954518 - Disclosure - Earnings Per Share - Narrative (Details) Sheet http://www.merck.com/role/EarningsPerShareNarrativeDetails Earnings Per Share - Narrative (Details) Details 71 false false R72.htm 9954519 - Disclosure - Other Comprehensive Income (Loss) (Details) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossDetails Other Comprehensive Income (Loss) (Details) Details http://www.merck.com/role/OtherComprehensiveIncomeLossTables 72 false false R73.htm 9954520 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.merck.com/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 73 false false R74.htm 9954521 - Disclosure - Segment Reporting - Sales from Products (Details) Sheet http://www.merck.com/role/SegmentReportingSalesfromProductsDetails Segment Reporting - Sales from Products (Details) Details 74 false false R75.htm 9954522 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details) Sheet http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails Segment Reporting - Consolidated Sales by Geographic Area (Details) Details 75 false false R76.htm 9954523 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) Sheet http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) Details 76 false false All Reports Book All Reports mrk-20240331.htm mrk-20240331.xsd mrk-20240331_cal.xml mrk-20240331_def.xml mrk-20240331_lab.xml mrk-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 94 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mrk-20240331.htm": { "nsprefix": "mrk", "nsuri": "http://www.merck.com/20240331", "dts": { "inline": { "local": [ "mrk-20240331.htm" ] }, "schema": { "local": [ "mrk-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "mrk-20240331_cal.xml" ] }, "definitionLink": { "local": [ "mrk-20240331_def.xml" ] }, "labelLink": { "local": [ "mrk-20240331_lab.xml" ] }, "presentationLink": { "local": [ "mrk-20240331_pre.xml" ] } }, "keyStandard": 275, "keyCustom": 40, "axisStandard": 40, "axisCustom": 0, "memberStandard": 65, "memberCustom": 74, "hidden": { "total": 27, "http://fasb.org/us-gaap/2023": 22, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 555, "entityCount": 1, "segmentCount": 141, "elementCount": 695, "unitCount": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1215, "http://xbrl.sec.gov/dei/2023": 41, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.merck.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrk:CostsExpensesAndOther", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R3": { "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R4": { "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R7": { "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.merck.com/role/BasisofPresentation", "longName": "0000008 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreements", "longName": "0000009 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements", "shortName": "Acquisitions, Divestitures, Research Collaborations and Licensing Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.merck.com/role/CollaborativeArrangements", "longName": "0000010 - Disclosure - Collaborative Arrangements", "shortName": "Collaborative Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.merck.com/role/Restructuring", "longName": "0000011 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.merck.com/role/FinancialInstruments", "longName": "0000012 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.merck.com/role/Inventories", "longName": "0000013 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.merck.com/role/Contingencies", "longName": "0000014 - Disclosure - Contingencies", "shortName": "Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.merck.com/role/Equity", "longName": "0000015 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans", "longName": "0000016 - Disclosure - Pension and Other Postretirement Benefit Plans", "shortName": "Pension and Other Postretirement Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.merck.com/role/OtherIncomeExpenseNet", "longName": "0000017 - Disclosure - Other (Income) Expense, Net", "shortName": "Other (Income) Expense, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.merck.com/role/IncomeTaxes", "longName": "0000018 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.merck.com/role/EarningsPerShare", "longName": "0000019 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss", "longName": "0000020 - Disclosure - Other Comprehensive Income (Loss)", "shortName": "Other Comprehensive Income (Loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.merck.com/role/SegmentReporting", "longName": "0000021 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.merck.com/role/BasisofPresentationPolicies", "longName": "9954471 - Disclosure - Basis of Presentation (Policies)", "shortName": "Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.merck.com/role/CollaborativeArrangementsTables", "longName": "9954472 - Disclosure - Collaborative Arrangements (Tables)", "shortName": "Collaborative Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.merck.com/role/RestructuringTables", "longName": "9954473 - Disclosure - Restructuring (Tables)", "shortName": "Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.merck.com/role/FinancialInstrumentsTables", "longName": "9954474 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.merck.com/role/InventoriesTables", "longName": "9954475 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.merck.com/role/EquityTables", "longName": "9954476 - Disclosure - Equity (Tables)", "shortName": "Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables", "longName": "9954477 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)", "shortName": "Pension and Other Postretirement Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-315", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-315", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables", "longName": "9954478 - Disclosure - Other (Income) Expense, Net (Tables)", "shortName": "Other (Income) Expense, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.merck.com/role/EarningsPerShareTables", "longName": "9954479 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables", "longName": "9954480 - Disclosure - Other Comprehensive Income (Loss) (Tables)", "shortName": "Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.merck.com/role/SegmentReportingTables", "longName": "9954481 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "longName": "9954482 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details)", "shortName": "Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-28", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R36": { "role": "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "longName": "9954483 - Disclosure - Collaborative Arrangements - AstraZeneca PLC - Narrative (Details)", "shortName": "Collaborative Arrangements - AstraZeneca PLC - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-34", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-34", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "longName": "9954484 - Disclosure - Collaborative Arrangements - AstraZeneca PLC (Details)", "shortName": "Collaborative Arrangements - AstraZeneca PLC (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-39", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R38": { "role": "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "longName": "9954485 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details)", "shortName": "Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-50", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-50", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "longName": "9954486 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. (Details)", "shortName": "Collaborative Arrangements - Eisai Co., Ltd. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-51", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R40": { "role": "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "longName": "9954487 - Disclosure - Collaborative Arrangements - Bayer AG (Details)", "shortName": "Collaborative Arrangements - Bayer AG (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-55", "name": "mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R41": { "role": "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "longName": "9954488 - Disclosure - Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details)", "shortName": "Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-67", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R42": { "role": "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "longName": "9954489 - Disclosure - Collaborative Arrangements - Daiicho Sankyo - Narrative (Details)", "shortName": "Collaborative Arrangements - Daiicho Sankyo - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-71", "name": "mrk:CollaborativeArrangementRightsAndObligationsNumberOfAntibodyDrugConjugates", "unitRef": "candidate", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R43": { "role": "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "longName": "9954490 - Disclosure - Collaborative Arrangements - Daiicho Sankyo (Details)", "shortName": "Collaborative Arrangements - Daiicho Sankyo (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-77", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R44": { "role": "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "longName": "9954491 - Disclosure - Collaborative Arrangements - Moderna, Inc. - Narrative (Details)", "shortName": "Collaborative Arrangements - Moderna, Inc. - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-81", "name": "us-gaap:PrepaidExpenseAndOtherAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R45": { "role": "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "longName": "9954492 - Disclosure - Collaborative Arrangements - Moderna, Inc. (Details)", "shortName": "Collaborative Arrangements - Moderna, Inc. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-82", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R46": { "role": "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "longName": "9954493 - Disclosure - Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details)", "shortName": "Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-87", "name": "mrk:RoyaltyRateDeductionPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-87", "name": "mrk:RoyaltyRateDeductionPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.merck.com/role/RestructuringNarrativeDetails", "longName": "9954494 - Disclosure - Restructuring - Narrative (Details)", "shortName": "Restructuring - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-91", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R48": { "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "longName": "9954495 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)", "shortName": "Restructuring - Charges Activities by Type of Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-110", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R49": { "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "longName": "9954496 - Disclosure - Restructuring - Activities by Program (Details)", "shortName": "Restructuring - Activities by Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "longName": "9954497 - Disclosure - Financial Instruments - Narrative (Details)", "shortName": "Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R51": { "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "longName": "9954498 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)", "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-139", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-139", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "longName": "9954499 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details)", "shortName": "Financial Instruments - Summary of Interest Rate Swaps Held (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-147", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R53": { "role": "http://www.merck.com/role/FinancialInstrumentsAmountsRecordedonBalanceSheetRelatedtoFairValueHedgesDetails", "longName": "9954500 - Disclosure - Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details)", "shortName": "Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "longName": "9954501 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "shortName": "Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R55": { "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "longName": "9954502 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "longName": "9954503 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)", "shortName": "Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-173", "name": "us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R57": { "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "longName": "9954504 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-179", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-179", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails", "longName": "9954505 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)", "shortName": "Financial Instruments - Information on Available-for-sale Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "longName": "9954506 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-212", "name": "us-gaap:Investments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R60": { "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "longName": "9954507 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R61": { "role": "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails", "longName": "9954508 - Disclosure - Inventories - Schedule of Inventories (Details)", "shortName": "Inventories - Schedule of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.merck.com/role/InventoriesNarrativeDetails", "longName": "9954509 - Disclosure - Inventories - Narrative (Details)", "shortName": "Inventories - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:InventoryNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-264", "name": "us-gaap:InventoryNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "us-gaap:InventoryNoncurrent", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R63": { "role": "http://www.merck.com/role/ContingenciesDetails", "longName": "9954510 - Disclosure - Contingencies (Details)", "shortName": "Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-273", "name": "us-gaap:LossContingencyPendingClaimsNumber", "unitRef": "case", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-273", "name": "us-gaap:LossContingencyPendingClaimsNumber", "unitRef": "case", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.merck.com/role/EquityDetails", "longName": "9954511 - Disclosure - Equity (Details)", "shortName": "Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsCommonStockCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R65": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "longName": "9954512 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-320", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-320", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "longName": "9954513 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DefinedBenefitPlanSettlementsPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:DefinedBenefitPlanSettlementsPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "longName": "9954514 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)", "shortName": "Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentIncomeInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R68": { "role": "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails", "longName": "9954515 - Disclosure - Other (Income) Expense, Net - Narrative (Details)", "shortName": "Other (Income) Expense, Net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.merck.com/role/IncomeTaxesDetails", "longName": "9954516 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails", "longName": "9954517 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)", "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.merck.com/role/EarningsPerShareNarrativeDetails", "longName": "9954518 - Disclosure - Earnings Per Share - Narrative (Details)", "shortName": "Earnings Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails", "longName": "9954519 - Disclosure - Other Comprehensive Income (Loss) (Details)", "shortName": "Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-331", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R73": { "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails", "longName": "9954520 - Disclosure - Segment Reporting - Narrative (Details)", "shortName": "Segment Reporting - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails", "longName": "9954521 - Disclosure - Segment Reporting - Sales from Products (Details)", "shortName": "Segment Reporting - Sales from Products (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrk:IncreaseDecreaseInHedgeRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R75": { "role": "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "longName": "9954522 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details)", "shortName": "Segment Reporting - Consolidated Sales by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-542", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } }, "R76": { "role": "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "longName": "9954523 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)", "shortName": "Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-528", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20240331.htm", "unique": true } } }, "tag": { "mrk_A0.500Notesdue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "A0.500Notesdue2024Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "0.500% Notes due 2024", "label": "0.500% Notes due 2024 [Member]", "documentation": "0.500% Notes due 2024 [Member]" } } }, "auth_ref": [] }, "mrk_A1.375Notesdue2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "A1.375Notesdue2036Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "1.375% Notes due 2036", "label": "1.375% Notes due 2036 [Member]", "documentation": "1.375% Notes due 2036 [Member]" } } }, "auth_ref": [] }, "mrk_A1.875Notesdue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "A1.875Notesdue2026Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "1.875% Notes due 2026", "label": "1.875% Notes due 2026 [Member]", "documentation": "1.875% Notes due 2026 [Member]" } } }, "auth_ref": [] }, "mrk_A2.500Notesdue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "A2.500Notesdue2034Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "2.500% Notes due 2034", "label": "2.500% Notes due 2034 [Member]", "documentation": "2.500% Notes due 2034 [Member]" } } }, "auth_ref": [] }, "mrk_A450NoteDue2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "A450NoteDue2033Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.50% note due 2033", "label": "4.50% note due 2033 [Member]", "documentation": "4.50% note due 2033" } } }, "auth_ref": [] }, "mrk_A450NotesDue2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "A450NotesDue2033Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.50% Notes Due 2033", "label": "4.50% Notes Due 2033 [Member]", "documentation": "4.50% Notes Due 2033" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "mrk_AcceleratedDepreciationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AcceleratedDepreciationMember", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Depreciation", "label": "Accelerated Depreciation [Member]", "documentation": "Accelerated Depreciation [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity of Counterparty, Type [Axis]", "label": "Legal Entity of Counterparty, Type [Axis]", "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30", "r919" ] }, "mrk_AccountsReceivableFactoringCollectionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AccountsReceivableFactoringCollectionsMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable Factoring Collections", "label": "Accounts Receivable Factoring Collections [Member]", "documentation": "Accounts Receivable Factoring Collections" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $80 in 2024 and $88 in 2023)", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r328", "r329" ] }, "us-gaap_AccountsReceivableSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableSale", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Factored accounts receivable", "label": "Accounts Receivable, Sale", "documentation": "Amount of decrease from sale of accounts receivable." } } }, "auth_ref": [ "r370" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r123", "r175" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefit Plans", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r6", "r16", "r43", "r1036", "r1037", "r1038" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r68", "r201", "r722" ] }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest." } } }, "auth_ref": [ "r222", "r230", "r603", "r1037", "r1038" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r222", "r231", "r232", "r603", "r884", "r1036" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r230", "r231", "r643", "r645", "r646", "r647", "r648", "r649" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r42", "r43", "r136", "r211", "r718", "r757", "r758" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r230", "r231", "r643", "r645", "r646", "r647", "r648", "r649" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.merck.com/role/EquityDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r16", "r43", "r617", "r620", "r653", "r753", "r754", "r1036", "r1037", "r1038", "r1048", "r1049", "r1050" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustment", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r5", "r16", "r43", "r231", "r232", "r645", "r646", "r647", "r648", "r649", "r1036" ] }, "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions, Divestitures, Research Collaborations and Licensing Agreements", "label": "Acquisitions Research Collaborations And License Agreements [Text Block]", "documentation": "Information related to acquisitions, divestitures, research collaborations and license agreements." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r974" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Other paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r126" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r571", "r572", "r573", "r767", "r1048", "r1049", "r1050", "r1093", "r1114" ] }, "mrk_AdempasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AdempasMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adempas", "label": "Adempas [Member]", "documentation": "Adempas" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r980" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r980" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r980" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r980" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "negatedLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r12", "r66" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r945", "r956", "r966", "r991" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r948", "r959", "r969", "r994" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r980" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r987" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r952", "r960", "r970", "r987", "r995", "r999", "r1007" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1005" ] }, "mrk_AllianceRevenueAdempasVerquvoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AllianceRevenueAdempasVerquvoMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance revenue - Adempas/Verquvo", "label": "Alliance revenue - Adempas/Verquvo [Member]", "documentation": "Alliance revenue - Adempas/Verquvo" } } }, "auth_ref": [] }, "mrk_AllianceRevenueKoselugoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AllianceRevenueKoselugoMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance revenue - Koselugo", "label": "Alliance revenue - Koselugo [Member]", "documentation": "Alliance revenue - Koselugo" } } }, "auth_ref": [] }, "mrk_AllianceRevenueReblozylMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AllianceRevenueReblozylMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance Revenue - Reblozyl", "label": "Alliance Revenue - Reblozyl [Member]", "documentation": "Alliance Revenue - Reblozyl" } } }, "auth_ref": [] }, "mrk_AlliancerevenueLynparzaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AlliancerevenueLynparzaMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance revenue - Lynparza", "label": "Alliance revenue - Lynparza [Member]", "documentation": "Alliance revenue - Lynparza [Member]" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r212", "r330", "r368" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r12", "r61", "r66" ] }, "mrk_AnimalHealthsegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AnimalHealthsegmentMember", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Animal Health", "verboseLabel": "Animal Health segment", "label": "Animal Health segment [Member]", "documentation": "Animal Health segment [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.merck.com/role/EarningsPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r287" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r597" ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific (other than China and Japan)", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r1115", "r1117", "r1118", "r1119" ] }, "mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net assets acquired", "label": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "documentation": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r1084" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred, asset acquisition", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r915", "r1085", "r1086", "r1087" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, transaction costs", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r915", "r1085", "r1086", "r1087" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r1084" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r173", "r204", "r246", "r298", "r313", "r319", "r365", "r418", "r419", "r421", "r422", "r423", "r425", "r427", "r429", "r430", "r599", "r604", "r637", "r714", "r806", "r919", "r936", "r1073", "r1074", "r1098" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "terseLabel": "Other current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r197", "r215", "r246", "r365", "r418", "r419", "r421", "r422", "r423", "r425", "r427", "r429", "r430", "r599", "r604", "r637", "r919", "r1073", "r1074", "r1098" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r110" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "mrk_AstraZenecaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "AstraZenecaMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AstraZeneca", "label": "AstraZeneca [Member]", "documentation": "AstraZeneca [Member]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities, unrealized gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r336" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt securities, unrealized losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r337" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt securities, amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r333", "r375", "r713" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities, fair value", "verboseLabel": "Investments", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r334", "r375", "r706", "r1056" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities, available-for-sale, noncurrent", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r200", "r331", "r375" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1002" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1003" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r998" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r998" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r998" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r998" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r998" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r998" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1001" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1000" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r999" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r999" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r94", "r99" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "mrk_BayerAGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "BayerAGMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bayer AG", "label": "Bayer AG [Member]", "documentation": "Bayer AG [Member]" } } }, "auth_ref": [] }, "mrk_BelsomraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "BelsomraMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Belsomra", "label": "Belsomra [Member]", "documentation": "Belsomra [Member]" } } }, "auth_ref": [] }, "mrk_BridionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "BridionMember", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bridion", "label": "Bridion [Member]", "documentation": "Bridion [Member]." } } }, "auth_ref": [] }, "mrk_BristolMyersSquibbCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "BristolMyersSquibbCompanyMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bristol Myers Squibb Company", "label": "Bristol Myers Squibb Company [Member]", "documentation": "Bristol Myers Squibb Company" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r593", "r908", "r911" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r81", "r82", "r593", "r908", "r911" ] }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionContingentConsiderationLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]", "label": "Business Acquisition, Contingent Consideration [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r593" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in estimated fair value", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r596", "r1042" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "periodStartLabel": "Fair value, beginning balance", "periodEndLabel": "Fair value, ending balance", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r1", "r84", "r595" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current liability", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r84" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, measurement input, discount rate", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r631" ] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CN", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "China", "label": "CHINA" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r49", "r199", "r877" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)", "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March\u00a031, 2024 and 2023, respectively, included in Other current assets)", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r49", "r148", "r244" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net Decrease in Cash, Cash Equivalents and Restricted Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r148" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r1028", "r1108" ] }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement." } } }, "auth_ref": [ "r171" ] }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement." } } }, "auth_ref": [ "r171" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r978" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r191", "r208", "r209", "r210", "r246", "r276", "r277", "r284", "r286", "r292", "r293", "r365", "r418", "r421", "r422", "r423", "r429", "r430", "r449", "r450", "r453", "r456", "r463", "r637", "r759", "r760", "r761", "r762", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r796", "r815", "r829", "r854", "r855", "r856", "r857", "r858", "r1013", "r1044", "r1052" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r979" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r979" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/CollaborativeArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r184", "r185", "r190" ] }, "mrk_CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponExecution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponExecution", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate upfront payments due upon execution in collaborative arrangement", "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution", "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponLapseOfTime": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponLapseOfTime", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate upfront payments due upon lapse of time in collaborative arrangement", "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time", "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsContingentMilestoneProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsContingentMilestoneProceeds", "crdr": "debit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent proceeds collaborative arrangement", "label": "Collaborative Arrangement, Rights and Obligations, Contingent Milestone Proceeds", "documentation": "Collaborative Arrangement, Rights and Obligations, Contingent Milestone Proceeds" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsFor": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsFor", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement", "label": "Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For", "documentation": "Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsForPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsForPercentage", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement, percentage", "label": "Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage", "documentation": "Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eligible future contingent development-related payments (up to)", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments", "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentMilestonePaymentsPerProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentMilestonePaymentsPerProduct", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum aggregate contingent milestone payments, per product, in collaborative arrangement", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product", "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eligible future contingent regulatory milestone payments (up to)", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments", "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eligible future contingent sales-based milestone payments (up to)", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments", "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMilestonePaymentsRegulatory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentsRegulatory", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory milestone payments", "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payments Regulatory", "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payments Regulatory" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMilestonePaymentsSalesBased": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentsSalesBased", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales-based milestone payments", "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payments Sales-Based", "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payments Sales-Based" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsNumberOfAntibodyDrugConjugates": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsNumberOfAntibodyDrugConjugates", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of antibody drug conjugates obtained right and obligations", "label": "Collaborative Arrangement, Rights And Obligations, Number Of Antibody Drug Conjugates", "documentation": "Collaborative Arrangement, Rights And Obligations, Number Of Antibody Drug Conjugates" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsProbableContingentPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsProbableContingentPayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probable contingent payments", "label": "Collaborative Arrangement, Rights and Obligations, Probable Contingent Payments", "documentation": "Collaborative Arrangement, Rights and Obligations, Probable Contingent Payments" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsRefundableUpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsRefundableUpfrontPayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable upfront payments in collaborative arrangement", "label": "Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments", "documentation": "Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsRoyaltyPercentage", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales based royalty percentage", "label": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage", "documentation": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsTerminatedNumberOfAntibodyDrugConjugates": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsTerminatedNumberOfAntibodyDrugConjugates", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of antibody drug conjugates terminated with collaborative partner", "label": "Collaborative Arrangement, Rights And Obligations, Terminated, Number Of Antibody Drug Conjugates", "documentation": "Collaborative Arrangement, Rights And Obligations, Terminated, Number Of Antibody Drug Conjugates" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsUpfrontPaymentDueUponExecution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPaymentDueUponExecution", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment made to collaborative partner", "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment Due Upon Execution", "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment Due Upon Execution" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementStockInvestmentInCounterparty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementStockInvestmentInCounterparty", "crdr": "debit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock investment in counterparty", "label": "Collaborative Arrangement, Stock Investment In Counterparty", "documentation": "Collaborative Arrangement, Stock Investment In Counterparty" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement." } } }, "auth_ref": [ "r1088" ] }, "mrk_CollaborativeArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CollaborativeArrangementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements [Abstract]", "label": "Collaborative Arrangements [Abstract]", "documentation": "Collaborative Arrangements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r597" ] }, "mrk_CommercialAndOtherLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CommercialAndOtherLitigationMember", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial and Other Litigation", "label": "Commercial and Other Litigation [Member]", "documentation": "Commercial and Other Litigation" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r159", "r925", "r926", "r927", "r930" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/Contingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r158", "r409", "r410", "r862", "r1067" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared on common stock (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r161" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.merck.com/role/CoverPage", "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock ($0.50\u00a0par value)", "verboseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r922", "r923", "r924", "r925", "r926", "r927", "r930", "r1048", "r1049", "r1093", "r1111", "r1114" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r125" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r125", "r796" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "periodStartLabel": "Common stock, beginning balance (in shares)", "periodEndLabel": "Common stock, ending balance (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r125" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r125", "r717", "r919" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r984" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r983" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r985" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r982" ] }, "mrk_CompanionAnimalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CompanionAnimalMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Companion Animal", "label": "Companion Animal [Member]", "documentation": "Companion Animal [Member]" } } }, "auth_ref": [] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Income Attributable to Merck\u00a0& Co., Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r44", "r227", "r229", "r236", "r708", "r730" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r135", "r235", "r707", "r728" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r252", "r300", "r311", "r312", "r313", "r314", "r315", "r317", "r321", "r418", "r419", "r420", "r421", "r423", "r424", "r426", "r428", "r429", "r1073", "r1074" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r252", "r300", "r311", "r312", "r313", "r314", "r315", "r317", "r321", "r418", "r419", "r420", "r421", "r423", "r424", "r426", "r428", "r429", "r1073", "r1074" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate notes and bonds", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r904", "r906", "r1110" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate, Non-Segment", "verboseLabel": "Corporate, Non-Segment", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r22", "r312", "r313", "r314", "r315", "r321", "r1055" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r141", "r690" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Costs, Expenses and Other", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "mrk_CostsExpensesAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "CostsExpensesAndOther", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total Costs, Expenses and Other", "label": "Costs Expenses And Other", "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r250", "r251", "r434", "r451", "r657", "r880", "r883" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrencySwapMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Swap", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "mrk_DaiichiSankyoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "DaiichiSankyoMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Daiichi Sankyo", "label": "Daiichi Sankyo [Member]", "documentation": "Daiichi Sankyo" } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Loans payable and current portion of long-term debt", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r206" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r27", "r122", "r123", "r174", "r176", "r252", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r652", "r896", "r897", "r898", "r899", "r900", "r1045" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Par Value of Debt", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r113", "r115", "r431", "r652", "r897", "r898" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of loans payable and long-term debt, including current portion", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r439", "r636", "r897", "r898" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r34", "r432" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r35", "r252", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r652", "r896", "r897", "r898", "r899", "r900", "r1045" ] }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtLongtermAndShorttermCombinedAmount", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, carrying amount", "label": "Debt, Long-Term and Short-Term, Combined Amount", "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343" ] }, "mrk_DebtSecuritiesandEquitySecuritiesFVNI": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "DebtSecuritiesandEquitySecuritiesFVNI", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt and publicly traded equity securities, fair value", "label": "Debt Securities and Equity Securities, FV-NI", "documentation": "Debt Securities and Equity Securities, FV-NI" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r12", "r165", "r188", "r588", "r589", "r1047" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Income Taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r577", "r578", "r715" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss (gain) amortization", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r468", "r506", "r531", "r906", "r907" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of unrecognized prior service credit", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r468", "r507", "r532", "r906", "r907" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase to pension liabilities due to remeasurement", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement", "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from remeasurement due to settlement. Excludes decrease to benefit obligation for settlement payment." } } }, "auth_ref": [ "r1077" ] }, "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination benefits", "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits", "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan." } } }, "auth_ref": [ "r520" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r468", "r505", "r530", "r906", "r907" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r468", "r472", "r504", "r529", "r906", "r907" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net periodic benefit cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r502", "r527", "r906", "r907" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Curtailments", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees." } } }, "auth_ref": [ "r467", "r509", "r534" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement." } } }, "auth_ref": [ "r467", "r509", "r534" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r470", "r503", "r528", "r906", "r907" ] }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Partial settlement charge", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": [ "r488" ] }, "mrk_DelstrigoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "DelstrigoMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Delstrigo", "label": "Delstrigo [Member]", "documentation": "Delstrigo" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "negatedLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r12", "r67" ] }, "us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net amounts, asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, after Offset", "documentation": "Fair value, after effect of master netting arrangement, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative subject to master netting arrangement not elected or qualified to offset. Excludes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r217", "r883" ] }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset." } } }, "auth_ref": [ "r21", "r25", "r186" ] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r606" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of derivative, asset", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r217", "r219", "r636", "r779", "r780", "r781", "r782", "r783", "r785", "r786", "r787", "r788", "r789", "r800", "r801", "r842", "r847", "r848", "r849", "r850", "r851", "r883", "r924", "r1112" ] }, "us-gaap_DerivativeAverageRemainingMaturity1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAverageRemainingMaturity1", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum average period of maturities of contracts in years (less than)", "label": "Derivative, Average Remaining Maturity", "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralObligationToReturnCash", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash collateral received from counterparties", "negatedLabel": "Cash collateral received, asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth_ref": [ "r25", "r106", "r218", "r881" ] }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralRightToReclaimCash", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash collateral received, liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset", "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities." } } }, "auth_ref": [ "r25", "r106", "r218", "r881" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r787", "r789", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r807", "r808", "r809", "r810", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r842", "r844", "r848", "r850", "r922", "r924" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross amounts recognized in the consolidated balance sheet, asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r24", "r97", "r134", "r216", "r883" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross amounts recognized in the consolidated balance sheet, liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r24", "r97", "r134", "r216", "r883" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r1091" ] }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative." } } }, "auth_ref": [ "r1091" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r95", "r98", "r100", "r103", "r787", "r789", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r807", "r808", "r809", "r810", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r842", "r844", "r848", "r850", "r883", "r922", "r924" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r18", "r95", "r100", "r103", "r107", "r108", "r611" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r611" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r102", "r1018" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of derivative, liability", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r217", "r219", "r636", "r779", "r780", "r781", "r782", "r785", "r786", "r787", "r788", "r789", "r807", "r809", "r810", "r844", "r845", "r847", "r848", "r849", "r850", "r851", "r883", "r1112" ] }, "us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net amounts, liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, after Offset", "documentation": "Fair value, after effect of master netting arrangement, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative subject to master netting arrangement not elected or qualified to offset. Excludes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r217", "r883" ] }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability." } } }, "auth_ref": [ "r21", "r25", "r186" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r606" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r622" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "verboseLabel": "U.S dollar notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1089", "r1090" ] }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNumberOfInstrumentsHeld", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of interest rate swaps", "label": "Derivative, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular group held by the entity." } } }, "auth_ref": [ "r91", "r92", "r788", "r842", "r843", "r846", "r924" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r18", "r89", "r90", "r92", "r93", "r96", "r100", "r104", "r105", "r108", "r622" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Designated as Hedging Instruments", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r18" ] }, "mrk_DificidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "DificidMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dificid", "label": "Dificid [Member]", "documentation": "Dificid" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of continuing involvement after disposal", "label": "Discontinued Operation, Period of Continuing Involvement after Disposal", "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r118" ] }, "us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Means Other than Sale, Spinoff", "label": "Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]", "documentation": "Component or group of components disposed of in a spinoff and representing a strategic shift that has or will have a major effect on operations and financial results." } } }, "auth_ref": [ "r117" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r195" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "mrk_DisposalGroupIncludingDiscontinuedOperationUnderInterimOperatingAgreementNumberOfJurisdiction": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20240331", "localname": "DisposalGroupIncludingDiscontinuedOperationUnderInterimOperatingAgreementNumberOfJurisdiction", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of jurisdictions remaining", "label": "Disposal Group, Including Discontinued Operation, Under Interim Operating Agreement, Number Of Jurisdiction", "documentation": "Disposal Group, Including Discontinued Operation, Under Interim Operating Agreement, Number Of Jurisdiction" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r908", "r911" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends declared on common stock", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r161" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r32" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r940" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r973" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticPlanMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Plan", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1079", "r1080", "r1081" ] }, "mrk_Dr.SchollsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "Dr.SchollsMember", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dr. Scholl's", "label": "Dr. Scholl's [Member]", "documentation": "Dr. Scholl's" } } }, "auth_ref": [] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EMEAMember", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe, Middle East and Africa", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r1115", "r1117", "r1118", "r1119" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r237", "r263", "r264", "r265", "r266", "r267", "r273", "r276", "r284", "r285", "r286", "r290", "r625", "r626", "r709", "r731", "r886" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r237", "r263", "r264", "r265", "r266", "r267", "r276", "r284", "r285", "r286", "r290", "r625", "r626", "r709", "r731", "r886" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.merck.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r272", "r287", "r288", "r289" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r642" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.merck.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r580" ] }, "mrk_EffectiveIncomeTaxRateReconciliationUnfavorableDiscreteImpactPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20240331", "localname": "EffectiveIncomeTaxRateReconciliationUnfavorableDiscreteImpactPercent", "presentation": [ "http://www.merck.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unfavorable discrete impact on tax rate", "label": "Effective Income Tax Rate Reconciliation, Unfavorable Discrete Impact, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Unfavorable Discrete Impact, Percent" } } }, "auth_ref": [] }, "mrk_EisaiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "EisaiMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eisai", "label": "Eisai [Member]", "documentation": "Eisai [Member]" } } }, "auth_ref": [] }, "mrk_ElancoAnimalHealthIncorporatedAquaBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "ElancoAnimalHealthIncorporatedAquaBusinessMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Elanco Animal Health Incorporated Aqua Business", "label": "Elanco Animal Health Incorporated Aqua Business [Member]", "documentation": "Elanco Animal Health Incorporated Aqua Business" } } }, "auth_ref": [] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Separation Costs", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r938" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r938" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r938" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1012" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r938" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r938" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r938" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r938" ] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.merck.com/role/EquityDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r192", "r230", "r231", "r232", "r258", "r259", "r260", "r262", "r268", "r270", "r291", "r366", "r367", "r464", "r571", "r572", "r573", "r584", "r585", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r643", "r645", "r646", "r647", "r648", "r649", "r653", "r753", "r754", "r755", "r767", "r829" ] }, "us-gaap_EquityFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityFundsMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Funds", "label": "Equity Funds [Member]", "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments." } } }, "auth_ref": [ "r1078" ] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity securities held through ownership interest in investments funds", "terseLabel": "Publicly traded equity securities", "label": "Equity Securities, FV-NI, Noncurrent", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": [ "r635" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI", "weight": 1.0, "order": 2.0 }, "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Publicly traded equity securities, fair value", "verboseLabel": "Publicly traded equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r205", "r635", "r879" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income from investments in equity securities, net", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r733", "r1061" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized net gains (losses)", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r732", "r1061" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Publicly traded equity securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r58", "r931", "r932", "r933", "r1116" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments without readily determinable fair values", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r362" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount", "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r363" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative unrealized losses on investments", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r363" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount", "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r364" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative unrealized gains on investments", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r364" ] }, "us-gaap_EquitySecurityFvNiContractualSaleRestriction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecurityFvNiContractualSaleRestriction", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities, fair value, which are subject to a contractual sale restriction", "label": "Equity Security, FV-NI, Contractual Sale Restriction", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) subject to contractual sale restriction. Excludes investment in equity security by investment company for which discount for contractual sale restriction is applied." } } }, "auth_ref": [ "r634" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r981" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r945", "r956", "r966", "r991" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r942", "r953", "r963", "r988" ] }, "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20240331", "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimate of cumulative pre tax costs that will be noncash", "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash", "documentation": "Estimate of cumulative pre tax costs that will be noncash." } } }, "auth_ref": [] }, "mrk_EurodominatedNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "EurodominatedNotesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro-denominated notes", "label": "Euro-dominated Notes [Member]", "documentation": "Euro-dominated Notes [Member]" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r987" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r628", "r629", "r632" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r628", "r629", "r632" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r439", "r493", "r494", "r495", "r496", "r497", "r498", "r629", "r662", "r663", "r664", "r897", "r898", "r904", "r905", "r906" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r628", "r629", "r630", "r631", "r633" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r439", "r493", "r498", "r629", "r662", "r904", "r905", "r906" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r439", "r493", "r498", "r629", "r663", "r897", "r898", "r904", "r905", "r906" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r439", "r493", "r494", "r495", "r496", "r497", "r498", "r629", "r664", "r897", "r898", "r904", "r905", "r906" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Information About the Changes in Liabilities for Contingent Consideration", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r19", "r112" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r111" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r439", "r493", "r494", "r495", "r496", "r497", "r498", "r662", "r663", "r664", "r897", "r898", "r904", "r905", "r906" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r627", "r633" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r94", "r96", "r107" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r369", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r447", "r461", "r622", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r729", "r890", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1057", "r1058", "r1059", "r1060" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r390", "r391", "r392", "r393", "r691", "r692" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r62", "r65" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r155", "r691" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pretax net unrealized gain on derivatives maturing within the next 12 months estimated to be reclassified from AOCI to sales", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r109" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exchange losses", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r638", "r639", "r640", "r641", "r826" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r883", "r904", "r918" ] }, "us-gaap_ForeignExchangeFutureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeFutureMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Future", "label": "Foreign Exchange Future [Member]", "documentation": "A standardized contract, traded on a futures exchange, to buy or sell a certain currency, at a specified future date, at a fixed exercise rate (expressed as an exchange)." } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeOptionMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency options", "label": "Foreign Exchange Option [Member]", "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignPlanMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1079", "r1080", "r1081" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r949", "r960", "r970", "r995" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r949", "r960", "r970", "r995" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r949", "r960", "r970", "r995" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r949", "r960", "r970", "r995" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r949", "r960", "r970", "r995" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss related to litigation settlement", "terseLabel": "Charge for Zetia antitrust litigation settlements", "label": "Gain (Loss) Related to Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r1068" ] }, "mrk_GardasilGardasil9Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "GardasilGardasil9Member", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gardasil/Gardasil 9", "label": "Gardasil/Gardasil 9 [Member]", "documentation": "Gardasil/Gardasil 9 [Member]." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r202", "r380", "r705", "r891", "r919", "r1063", "r1064" ] }, "mrk_HarpoonTherapeuticsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "HarpoonTherapeuticsInc.Member", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Harpoon Therapeutics, Inc.", "label": "Harpoon Therapeutics, Inc. [Member]", "documentation": "Harpoon Therapeutics, Inc." } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityFairValueHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgedLiabilityFairValueHedge", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsAmountsRecordedonBalanceSheetRelatedtoFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount of Hedged Liabilities", "label": "Hedged Liability, Fair Value Hedge", "documentation": "Amount of liability hedged in fair value hedging relationship." } } }, "auth_ref": [ "r612" ] }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsAmountsRecordedonBalanceSheetRelatedtoFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": [ "r613" ] }, "us-gaap_HedgedLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgedLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsAmountsRecordedonBalanceSheetRelatedtoFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedged Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Hedged Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes hedged liability." } } }, "auth_ref": [ "r614" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r18", "r611" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r18" ] }, "mrk_IfinatamabDeruxtecanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "IfinatamabDeruxtecanMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ifinatamab Deruxtecan", "label": "Ifinatamab Deruxtecan [Member]", "documentation": "Ifinatamab Deruxtecan" } } }, "auth_ref": [] }, "mrk_ImagoBioSciencesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "ImagoBioSciencesIncMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Imago Bio Sciences, Inc.", "label": "Imago Bio Sciences, Inc. [Member]", "documentation": "Imago Bio Sciences, Inc." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income Before Taxes", "terseLabel": "Profits", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r138", "r179", "r298", "r312", "r318", "r321", "r710", "r724", "r888" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r908", "r911" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r394", "r400", "r816" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r400", "r816" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r247", "r576", "r581", "r582", "r583", "r586", "r590", "r591", "r592", "r764" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on Income", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r182", "r189", "r269", "r270", "r306", "r579", "r587", "r734" ] }, "mrk_IncreaseDecreaseInHedgeRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "IncreaseDecreaseInHedgeRevenue", "crdr": "debit", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in hedge revenue", "label": "Increase (Decrease) In Hedge Revenue", "documentation": "Increase (Decrease) In Hedge Revenue" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapital", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Net changes in assets and liabilities", "label": "Increase (Decrease) in Operating Capital", "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r952", "r960", "r970", "r987", "r995", "r999", "r1007" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1005" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r941", "r1011" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r941", "r1011" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r941", "r1011" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangibles, Net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r60", "r64" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r114", "r181", "r233", "r302", "r651", "r817", "r934", "r1113" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r239", "r242", "r243" ] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateContractMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate contracts", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r874", "r883", "r904" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap contracts", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r874", "r928", "r929" ] }, "mrk_InternationalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "InternationalMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Int\u2019l", "label": "International [Member]", "documentation": "International [Member]" } } }, "auth_ref": [] }, "mrk_InventoriesProducedinPreparationforProductLaunchesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "InventoriesProducedinPreparationforProductLaunchesMember", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories Produced in Preparation for Product Launches", "label": "Inventories Produced in Preparation for Product Launches [Member]", "documentation": "Inventories Produced in Preparation for Product Launches [Member]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r379" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": { "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r1035" ] }, "us-gaap_InventoryLIFOReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLIFOReserve", "crdr": "credit", "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": { "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease to LIFO cost", "label": "Inventory, LIFO Reserve", "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods." } } }, "auth_ref": [ "r1034" ] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLineItems", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Line Items]", "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories (excludes inventories of $3,413 in 2024 and $3,348 in 2023 classified in Other assets - see Note\u00a06)", "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r213", "r878", "r919" ] }, "mrk_InventoryNetAndInventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "InventoryNetAndInventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current and noncurrent inventories", "label": "Inventory Net And Inventory Noncurrent", "documentation": "Total of current and noncurrent inventories." } } }, "auth_ref": [] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/InventoriesNarrativeDetails", "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories classified in Other assets", "verboseLabel": "Other Assets", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r1029" ] }, "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories Not Expected to be Sold Within One Year", "label": "Inventory Not Expected to be Sold Within One Year [Member]", "documentation": "Inventory Not Expected to be Sold Within One Year [Member]" } } }, "auth_ref": [] }, "mrk_InventoryTable": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20240331", "localname": "InventoryTable", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Table]", "label": "Inventory [Table]", "documentation": "Inventory [Table]" } } }, "auth_ref": [] }, "mrk_InventoryWorkInProcessAndRawMaterialsExcludingSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "InventoryWorkInProcessAndRawMaterialsExcludingSupplies", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials and work in process", "label": "Inventory, Work in Process and Raw Materials, Excluding Supplies", "documentation": "Inventory, Work in Process and Raw Materials, Excluding Supplies" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest income", "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r143", "r301" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Investments", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r712" ] }, "mrk_IsentressIsentressHDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "IsentressIsentressHDMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Isentress/Isentress HD", "label": "Isentress/Isentress HD [Member]", "documentation": "Isentress/Isentress HD [Member]." } } }, "auth_ref": [] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "JP", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Japan", "label": "JAPAN" } } }, "auth_ref": [] }, "mrk_JanumetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "JanumetMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Janumet", "label": "Janumet [Member]", "documentation": "Janumet [Member]." } } }, "auth_ref": [] }, "mrk_JanuviaJanumetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "JanuviaJanumetMember", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Januvia/Janumet", "label": "Januvia/Janumet [Member]", "documentation": "Januvia/Janumet" } } }, "auth_ref": [] }, "mrk_JanuviaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "JanuviaMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Januvia", "label": "Januvia [Member]", "documentation": "Januvia [Member] ." } } }, "auth_ref": [] }, "mrk_KeytrudaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "KeytrudaMember", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Keytruda", "label": "Keytruda [Member]", "documentation": "Keytruda [Member]" } } }, "auth_ref": [] }, "mrk_LagevrioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "LagevrioMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lagevrio", "label": "Lagevrio [Member]", "documentation": "Lagevrio" } } }, "auth_ref": [] }, "srt_LatinAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LatinAmericaMember", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Latin America", "label": "Latin America [Member]" } } }, "auth_ref": [ "r1115", "r1117", "r1118", "r1119" ] }, "us-gaap_LegalCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalCostsPolicyTextBlock", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Costs", "label": "Legal Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights." } } }, "auth_ref": [ "r416" ] }, "mrk_LegalDefenseCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "LegalDefenseCostsMember", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Defense Costs", "label": "Legal Defense Costs [Member]", "documentation": "Legal Defense Costs [Member]" } } }, "auth_ref": [] }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalEntityTypeOfCounterpartyDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity Type of Counterparty [Domain]", "label": "Legal Entity Type of Counterparty [Domain]", "documentation": "Nature of the other party participating in a financial transaction." } } }, "auth_ref": [] }, "mrk_LenvimaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "LenvimaMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance revenue - Lenvima", "label": "Lenvima [Member]", "documentation": "Lenvima [Member]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r31", "r246", "r365", "r418", "r419", "r421", "r422", "r423", "r425", "r427", "r429", "r430", "r600", "r604", "r605", "r637", "r795", "r887", "r936", "r1073", "r1098", "r1099" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "totalLabel": "Liabilities and Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r130", "r178", "r721", "r919", "r1046", "r1062", "r1094" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r33", "r198", "r246", "r365", "r418", "r419", "r421", "r422", "r423", "r425", "r427", "r429", "r430", "r600", "r604", "r605", "r637", "r919", "r1073", "r1098", "r1099" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r110" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r27", "r119", "r120", "r121", "r124", "r246", "r365", "r418", "r419", "r421", "r422", "r423", "r425", "r427", "r429", "r430", "r600", "r604", "r605", "r637", "r1073", "r1098", "r1099" ] }, "mrk_LicensesAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "LicensesAndOtherMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses and Other", "label": "Licenses and Other [Member]", "documentation": "Licenses and Other" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Agreements", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r83", "r575", "r1083" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserve", "crdr": "credit", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal defense costs reserve", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": [ "r37", "r1068" ] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusAxis", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1068" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusDomain", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1068" ] }, "mrk_LivestockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "LivestockMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Livestock", "label": "Livestock [Member]", "documentation": "Livestock [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r207" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r35" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r35", "r74" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r411", "r412", "r413", "r417", "r1069", "r1070" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r411", "r412", "r413", "r417", "r1069", "r1070" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r411", "r412", "r413", "r417", "r1069", "r1070" ] }, "us-gaap_LossContingencyClaimsSettledNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyClaimsSettledNumber", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, claims settled", "label": "Loss Contingency, Claims Settled, Number", "documentation": "Number of claims settled." } } }, "auth_ref": [ "r1069", "r1070" ] }, "mrk_LossContingencyMotionForSummaryJudgmentNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20240331", "localname": "LossContingencyMotionForSummaryJudgmentNumber", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, number of motion for summary judgments", "label": "Loss Contingency, Motion for Summary Judgment, Number", "documentation": "Loss Contingency, Motion for Summary Judgment, Number" } } }, "auth_ref": [] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r411", "r412", "r413", "r417", "r1069", "r1070" ] }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNumberOfPlaintiffs", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, number of plaintiffs", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency." } } }, "auth_ref": [ "r1069", "r1070" ] }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, number of patents allegedly infringed", "label": "Loss Contingency, Patents Allegedly Infringed, Number", "documentation": "Number of another entity's patents that the entity has allegedly infringed." } } }, "auth_ref": [ "r1069", "r1070" ] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, pending claims", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r1069", "r1070" ] }, "mrk_LossContingencyTrialPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.merck.com/20240331", "localname": "LossContingencyTrialPeriod", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, trial period", "label": "Loss Contingency, Trial Period", "documentation": "Loss Contingency, Trial Period" } } }, "auth_ref": [] }, "mrk_LynparzaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "LynparzaMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lynparza", "label": "Lynparza [Member]", "documentation": "Lynparza [Member]" } } }, "auth_ref": [] }, "mrk_ManufacturingAndSupplyAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "ManufacturingAndSupplyAgreementsMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing and Supply Agreements", "label": "Manufacturing And Supply Agreements [Member]", "documentation": "Manufacturing And Supply Agreements" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r1030" ] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Marketable Securities, Noncurrent", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": [ "r1030" ] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reconciling Items [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r54" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r412", "r413", "r414", "r415", "r542", "r689", "r752", "r788", "r789", "r835", "r837", "r839", "r840", "r852", "r872", "r873", "r889", "r901", "r914", "r921", "r1075", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r979" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r979" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r412", "r413", "r414", "r415", "r542", "r689", "r752", "r788", "r789", "r835", "r837", "r839", "r840", "r852", "r872", "r873", "r889", "r901", "r914", "r921", "r1075", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r41", "r177", "r246", "r365", "r418", "r421", "r422", "r423", "r429", "r430", "r637", "r720", "r798" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r998" ] }, "mrk_ModernaInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "ModernaInc.Member", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Moderna, Inc.", "label": "Moderna, Inc. [Member]", "documentation": "Moderna, Inc." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1006" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r980" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used in Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r241" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used in Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r241" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r148", "r149", "r150" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EquityDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income Attributable to Merck & Co., Inc.", "terseLabel": "Net Income Attributable to Merck\u00a0& Co., Inc.", "verboseLabel": "Net (loss) income attributable to Merck\u00a0& Co., Inc.", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r139", "r150", "r180", "r196", "r225", "r228", "r232", "r246", "r261", "r263", "r264", "r265", "r266", "r269", "r270", "r282", "r298", "r312", "r318", "r321", "r365", "r418", "r419", "r421", "r422", "r423", "r425", "r427", "r429", "r430", "r626", "r637", "r727", "r814", "r827", "r828", "r888", "r934", "r1073" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net Income Attributable to Noncontrolling Interests", "verboseLabel": "Net income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r88", "r170", "r225", "r228", "r269", "r270", "r726", "r1038" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income Attributable to Merck & Co., Inc., basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r238", "r263", "r264", "r265", "r266", "r273", "r274", "r283", "r286", "r298", "r312", "r318", "r321", "r888" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income Attributable to Merck & Co., Inc., diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r238", "r275", "r278", "r279", "r280", "r281", "r283", "r286" ] }, "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "crdr": "debit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost", "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component", "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits." } } }, "auth_ref": [ "r468" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Standard Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r979" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r949", "r960", "r970", "r987", "r995" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r977" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r976" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r987" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1006" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1006" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-US", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1115", "r1117", "r1118", "r1119" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non- controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r85", "r464", "r1048", "r1049", "r1050", "r1114" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivatives Not Designated as Hedging Instruments", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r18" ] }, "mrk_NoxafilMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "NoxafilMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noxafil", "label": "Noxafil [Member]", "documentation": "Noxafil [Member]." } } }, "auth_ref": [] }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfInterestRateDerivativesHeld", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Interest Rate Swaps Held", "label": "Number of Interest Rate Derivatives Held", "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date." } } }, "auth_ref": [ "r91", "r92" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1054" ] }, "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.merck.com/20240331", "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis", "label": "Offsetting Assets And Liabilities [Table Text Block]", "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis." } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "verboseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r321" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.merck.com/role/BasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r151", "r152", "r153", "r168" ] }, "mrk_OrganonCo.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "OrganonCo.Member", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organon & Co.", "label": "Organon & Co. [Member]", "documentation": "Organon & Co." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r214", "r919" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "totalLabel": "Other Assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r203" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefit plan net (loss) gain and prior service (cost) credit, net of amortization", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r7", "r15", "r136", "r169" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r10", "r15", "r169" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r43", "r231", "r643", "r646", "r649", "r728", "r1036" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r26", "r43", "r231", "r643", "r646", "r649", "r1036" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r8", "r230", "r728" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Net unrealized gain (loss) on derivatives, net of reclassifications", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r221" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of gain (loss) recognized in OCI on derivatives", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r220", "r221", "r607", "r608", "r615" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in Sales as a result of AOCL reclassifications", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r187", "r221", "r223" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r609" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amount of Pretax Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r610" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/EquityDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of taxes", "totalLabel": "Other comprehensive income (loss), net of taxes", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r17", "r26", "r226", "r229", "r235", "r643", "r644", "r649", "r707", "r728", "r1036", "r1037" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Loss Net of Taxes:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), net of taxes", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r10", "r15", "r169", "r226", "r229" ] }, "mrk_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "OtherCountriesMember", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Countries [Member]", "documentation": "Other Countries [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [ "r94", "r107" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNet" ], "lang": { "en-us": { "role": { "terseLabel": "Other (Income) Expense, Net", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r162", "r164" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangible Assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_OtherInventorySupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInventorySupplies", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplies", "label": "Other Inventory, Supplies, Gross", "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1032" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r32", "r919" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r36" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r150" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "mrk_CostsExpensesAndOther", "weight": -1.0, "order": 5.0 }, "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r144" ] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "mrk_OtherNonoperatingIncomeExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "OtherNonoperatingIncomeExpenseOther", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Other Nonoperating Income Expense, Other", "documentation": "Other nonoperating income and expense items not separately disclosed." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r979" ] }, "mrk_OtherPharmaceuticalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "OtherPharmaceuticalMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other pharmaceutical", "label": "Other Pharmaceutical [Member]", "documentation": "Other pharmaceutical." } } }, "auth_ref": [] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Postretirement Benefit Plans", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r466", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r514", "r515", "r517", "r520", "r523", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r540", "r541", "r906", "r907", "r908", "r909", "r910" ] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherRestructuringMember", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Exit Costs", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r892", "r893", "r894", "r895" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r947", "r958", "r968", "r993" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r950", "r961", "r971", "r996" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r950", "r961", "r971", "r996" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r166" ] }, "mrk_PatritumabDeruxtecanAndRaludotatugDeruxtecanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "PatritumabDeruxtecanAndRaludotatugDeruxtecanMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patritumab Deruxtecan And Raludotatug Deruxtecan", "label": "Patritumab Deruxtecan And Raludotatug Deruxtecan [Member]", "documentation": "Patritumab Deruxtecan And Raludotatug Deruxtecan" } } }, "auth_ref": [] }, "mrk_PatritumabDeruxtecanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "PatritumabDeruxtecanMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patritumab Deruxtecan", "label": "Patritumab Deruxtecan [Member]", "documentation": "Patritumab Deruxtecan" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r975" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1016", "r1039" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of treasury stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r47" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "(Payments) receipts, net", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r399", "r1041" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid to stockholders", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r47" ] }, "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of Imago BioSciences, Inc., net of cash acquired", "label": "Payments to Acquire Business Two, Net of Cash Acquired", "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r1039" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment to acquire business", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r46", "r594" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of Harpoon Therapeutics, Inc., net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r46" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of securities and other investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r146" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r147" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r978" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r978" ] }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PendingLitigationMember", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pending Litigation", "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": [ "r1068" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and Other Postretirement Benefit Plans", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r465", "r490", "r492", "r498", "r516", "r518", "r519", "r520", "r521", "r522", "r537", "r538", "r539", "r906" ] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Plans", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r466", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r514", "r515", "r517", "r520", "r523", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r540", "r544", "r906", "r907", "r911", "r912", "r913" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r977" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r987" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r980" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r976" ] }, "mrk_PharmaceuticalsegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "PharmaceuticalsegmentMember", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharmaceutical", "verboseLabel": "Pharmaceutical segment", "label": "Pharmaceutical segment [Member]", "documentation": "Pharmaceutical segment." } } }, "auth_ref": [] }, "mrk_PifeltroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "PifeltroMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pifeltro", "label": "Pifeltro [Member]", "documentation": "Pifeltro" } } }, "auth_ref": [] }, "mrk_Pneumovax23Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "Pneumovax23Member", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pneumovax 23", "label": "Pneumovax 23 [Member]", "documentation": "Pneumovax 23[Member]." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expense and Other Assets", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "mrk_PrevymisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "PrevymisMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prevymis", "label": "Prevymis [Member]", "documentation": "Prevymis [Member]" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1027" ] }, "mrk_ProQuadMMRIIVarivaxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "ProQuadMMRIIVarivaxMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ProQuad/M-M-R II/Varivax", "label": "ProQuad MMR II Varivax [Member]", "documentation": "ProQuad/M-M-R II/Varivax [Member]." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1017", "r1040" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of securities and other investments", "label": "Proceeds from Sale and Maturity of Other Investments", "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue related to the sale of the marketing rights", "label": "Proceeds from Sale of Intangible Assets", "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r145" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r9", "r20" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r323", "r690", "r746", "r747", "r748", "r749", "r750", "r751", "r875", "r902", "r920", "r1019", "r1071", "r1072", "r1076", "r1109" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r323", "r690", "r746", "r747", "r748", "r749", "r750", "r751", "r875", "r902", "r920", "r1019", "r1071", "r1072", "r1076", "r1109" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r196", "r225", "r228", "r240", "r246", "r261", "r269", "r270", "r298", "r312", "r318", "r321", "r365", "r418", "r419", "r421", "r422", "r423", "r425", "r427", "r429", "r430", "r598", "r601", "r602", "r626", "r637", "r710", "r725", "r766", "r814", "r827", "r828", "r888", "r916", "r917", "r935", "r1038", "r1073" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,620 in 2024 and $18,266 in 2023", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r13", "r711", "r723", "r919" ] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryAxis", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Axis]", "label": "Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": [ "r1033" ] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Domain]", "label": "Inventory [Domain]", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, "auth_ref": [ "r1033" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r975" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r975" ] }, "mrk_RaludotatugDeruxtecanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "RaludotatugDeruxtecanMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raludotatug Deruxtecan", "label": "Raludotatug Deruxtecan [Member]", "documentation": "Raludotatug Deruxtecan" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r412", "r413", "r414", "r415", "r490", "r542", "r567", "r568", "r569", "r665", "r689", "r752", "r788", "r789", "r835", "r837", "r839", "r840", "r852", "r872", "r873", "r889", "r901", "r914", "r921", "r924", "r1065", "r1075", "r1101", "r1102", "r1103", "r1104", "r1105" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r412", "r413", "r414", "r415", "r490", "r542", "r567", "r568", "r569", "r665", "r689", "r752", "r788", "r789", "r835", "r837", "r839", "r840", "r852", "r872", "r873", "r889", "r901", "r914", "r921", "r924", "r1065", "r1075", "r1101", "r1102", "r1103", "r1104", "r1105" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification adjustments, pretax", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r43", "r231", "r643", "r648", "r649", "r728", "r1036" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Reclassification adjustments, net of taxes", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r26", "r43", "r231", "r643", "r648", "r649", "r1036" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax", "label": "Reclassification from AOCI, Current Period, Tax", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r8", "r224", "r230", "r728" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r232" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r232" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r232" ] }, "mrk_RecognizedAsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20240331", "localname": "RecognizedAsAbstract", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized as:", "label": "Recognized As [Abstract]", "documentation": "Recognized as." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Segment Profits to Income before Taxes", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r53", "r54" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r942", "r953", "r963", "r988" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r517", "r654", "r655", "r790", "r791", "r792", "r793", "r794", "r811", "r813", "r834" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r248", "r249", "r654", "r655", "r656", "r657", "r790", "r791", "r792", "r793", "r794", "r811", "r813", "r834" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r654", "r655", "r1097" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r517", "r654", "r655", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r790", "r791", "r792", "r793", "r794", "r811", "r813", "r834", "r1097" ] }, "mrk_RemicadeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "RemicadeMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remicade", "label": "Remicade [Member]", "documentation": "Remicade [Member]." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r48", "r762" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r250", "r251", "r434", "r451", "r657", "r882", "r883" ] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Charge for the acquisition of Imago BioSciences, Inc.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Writeoff", "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination." } } }, "auth_ref": [ "r63", "r1082" ] }, "mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Charge for the acquisition of Harpoon Therapeutics, Inc.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two", "documentation": "Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "negatedLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r116", "r574", "r1106" ] }, "mrk_ResearchAndDevelopmentExpenseCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "ResearchAndDevelopmentExpenseCredit", "crdr": "debit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense (credit)", "label": "Research and Development Expense (Credit)", "documentation": "Research and Development Expense (Credit)" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r943", "r954", "r964", "r989" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r944", "r955", "r965", "r990" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r951", "r962", "r972", "r997" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r49", "r172", "r199", "r244", "r716" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash and Cash Equivalents [Axis]", "label": "Restricted Cash and Cash Equivalents [Axis]", "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage." } } }, "auth_ref": [ "r29" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r199" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1028", "r1043" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/Restructuring" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r396", "r397", "r399", "r402", "r408" ] }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "crdr": "debit", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative costs since program inception", "label": "Restructuring and Related Cost, Cost Incurred to Date", "documentation": "Amount of costs incurred to date for the specified restructuring cost." } } }, "auth_ref": [ "r398", "r401", "r405", "r407" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected restructuring and related cost", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r398", "r401", "r405", "r407" ] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total pretax restructuring costs", "verboseLabel": "Expenses", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r398", "r401", "r405", "r407" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "negatedLabel": "Restructuring costs", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r12", "r403", "r405", "r1066" ] }, "us-gaap_RestructuringChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringChargesMember", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "label": "Restructuring Charges [Member]", "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included." } } }, "auth_ref": [ "r156", "r157" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r398", "r399", "r405", "r406" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r398", "r399", "r400", "r401", "r405", "r406", "r407" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "mrk_RestructuringProgram2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "RestructuringProgram2019Member", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Program, 2019", "label": "Restructuring Program, 2019 [Member]", "documentation": "Restructuring Program, 2019" } } }, "auth_ref": [] }, "mrk_RestructuringProgram2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "RestructuringProgram2024Member", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Program, 2024", "label": "Restructuring Program, 2024 [Member]", "documentation": "Restructuring Program, 2024" } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Restructuring reserve, beginning balance", "periodEndLabel": "Restructuring reserve, ending balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r399", "r404" ] }, "mrk_RestructuringReserveIncreaseDecreaseNoncashActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "RestructuringReserveIncreaseDecreaseNoncashActivity", "crdr": "credit", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash activity", "label": "Restructuring Reserve, Increase (Decrease) Noncash Activity", "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r127", "r161", "r719", "r756", "r758", "r763", "r797", "r919" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r192", "r258", "r259", "r260", "r262", "r268", "r270", "r366", "r367", "r571", "r572", "r573", "r584", "r585", "r616", "r618", "r619", "r621", "r624", "r753", "r755", "r767", "r1114" ] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r517", "r520", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r1079", "r1080", "r1081" ] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r517", "r520", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r1079", "r1080", "r1081" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r466", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r514", "r515", "r517", "r520", "r523", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r540", "r541", "r544", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r466", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r514", "r515", "r517", "r520", "r523", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r540", "r541", "r544", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913" ] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from collaborative arrangement", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r183", "r1088" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r234", "r246", "r299", "r300", "r311", "r316", "r317", "r323", "r325", "r327", "r365", "r418", "r419", "r421", "r422", "r423", "r425", "r427", "r429", "r430", "r637", "r710", "r1073" ] }, "mrk_RidgebackBiotherapeuticsLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "RidgebackBiotherapeuticsLPMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ridgeback Biotherapeutics LP", "label": "Ridgeback Biotherapeutics LP [Member]", "documentation": "Ridgeback Biotherapeutics LP" } } }, "auth_ref": [] }, "mrk_RotateqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "RotateqMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RotaTeq", "label": "Rotateq [Member]", "documentation": "RotaTeq [Member]" } } }, "auth_ref": [] }, "mrk_RoyaltyRateDeductionPercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.merck.com/20240331", "localname": "RoyaltyRateDeductionPercentage", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty rate, deduction", "label": "Royalty Rate, Deduction, Percentage", "documentation": "Royalty Rate, Deduction, Percentage" } } }, "auth_ref": [] }, "mrk_RoyaltyRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20240331", "localname": "RoyaltyRatePercentage", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty rate", "label": "Royalty Rate, Percentage", "documentation": "Royalty Rate, Percentage" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1006" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1006" ] }, "mrk_SalesBasedMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "SalesBasedMilestonesMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales-Based Milestones", "label": "Sales-Based Milestones [Member]", "documentation": "Sales-Based Milestones [Member]" } } }, "auth_ref": [] }, "mrk_SalesDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "SalesDiscounts", "crdr": "debit", "presentation": [ "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales discounts", "label": "Sales Discounts", "documentation": "Sales Discounts" } } }, "auth_ref": [] }, "us-gaap_SalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Sales [Member]", "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business." } } }, "auth_ref": [ "r23" ] }, "mrk_SanofiPasteurMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "SanofiPasteurMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanofi Pasteur", "label": "Sanofi Pasteur [Member]", "documentation": "Sanofi Pasteur [Member]" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r543", "r1051" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r271", "r543", "r1014", "r1051" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in AOCI by Component", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r43", "r1095", "r1096" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Information on Investments in Debt and Equity Securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [ "r167" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r81", "r82", "r593" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r597" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Arrangements", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r1088" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r14", "r77", "r78", "r79", "r80" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Location and Amount of Pretax Gains and Losses of Derivatives", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r95", "r100", "r611" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r96" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.merck.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Calculations of Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1053" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Sales from Products", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r628", "r629" ] }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts Recorded on Balance Sheet Related to Fair Value Hedges", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r101" ] }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Interest Rate Swaps Held", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments." } } }, "auth_ref": [ "r100" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.merck.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r28", "r131", "r132", "r133" ] }, "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryNoncurrentTableTextBlock", "presentation": [ "http://www.merck.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, noncurrent", "label": "Schedule of Inventory, Noncurrent [Table Text Block]", "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Net Benefit Costs", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r163" ] }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Net Investment Hedges on OCI and the Consolidated Statement of Operations", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period." } } }, "auth_ref": [ "r1092" ] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r102", "r1018" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other (Income) Expense, Net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r398", "r399", "r400", "r401", "r405", "r406", "r407" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "lang": { "en-us": { "role": { "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r69", "r71", "r72" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "lang": { "en-us": { "role": { "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r70", "r73" ] }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Sales by Geographic Area", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r57", "r140" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r56", "r137" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r50", "r51", "r52", "r59" ] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": [ "http://www.merck.com/role/EquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity", "label": "Schedule of Stockholders Equity [Table Text Block]", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": [ "r17" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r937" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r939" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r295", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r327", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r401", "r407", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r891", "r1019", "r1109" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r325", "r326", "r781", "r784", "r786", "r836", "r838", "r841", "r853", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r876", "r903", "r924", "r1076", "r1109" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r294", "r295", "r296", "r297", "r298", "r310", "r315", "r319", "r320", "r321", "r322", "r323", "r324", "r327" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "mrk_SegmentReportingUnallocatedOtherExpensesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "SegmentReportingUnallocatedOtherExpensesNet", "crdr": "debit", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other unallocated, net", "label": "Segment Reporting Unallocated Other Expenses Net", "documentation": "Other net expenses not allocated to segments." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r142" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570" ] }, "mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "SichuanKelunBiotechBiopharmaceuticalCoLtdMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.", "label": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]", "documentation": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd." } } }, "auth_ref": [] }, "mrk_SimponiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "SimponiMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Simponi", "label": "Simponi [Member]", "documentation": "Simponi [Member]." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r194", "r295", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r327", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r395", "r401", "r407", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r891", "r1019", "r1109" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r191", "r208", "r209", "r210", "r246", "r276", "r277", "r284", "r286", "r292", "r293", "r365", "r418", "r421", "r422", "r423", "r429", "r430", "r449", "r450", "r453", "r456", "r463", "r637", "r759", "r760", "r761", "r762", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r796", "r815", "r829", "r854", "r855", "r856", "r857", "r858", "r1013", "r1044", "r1052" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.merck.com/role/EquityDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r17", "r38", "r192", "r230", "r231", "r232", "r258", "r259", "r260", "r262", "r268", "r270", "r291", "r366", "r367", "r464", "r571", "r572", "r573", "r584", "r585", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r643", "r645", "r646", "r647", "r648", "r649", "r653", "r753", "r754", "r755", "r767", "r829" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r325", "r326", "r781", "r784", "r786", "r836", "r838", "r841", "r853", "r861", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r876", "r903", "r924", "r1076", "r1109" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r271", "r543", "r1014", "r1015", "r1051" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r946", "r957", "r967", "r992" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "totalLabel": "Total Merck\u00a0& Co., Inc. stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r125", "r128", "r129", "r154", "r798", "r812", "r830", "r831", "r919", "r936", "r1046", "r1062", "r1094", "r1114" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Merck\u00a0& Co., Inc. Stockholders\u2019 Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityBeforeTreasuryStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityBeforeTreasuryStock", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "totalLabel": "Stockholders' equity before deduction for treasury stock", "label": "Stockholders' Equity before Treasury Stock", "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/EquityDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Equity, beginning balance", "periodEndLabel": "Equity, ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r85", "r86", "r87", "r192", "r193", "r231", "r258", "r259", "r260", "r262", "r268", "r366", "r367", "r464", "r571", "r572", "r573", "r584", "r585", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r643", "r645", "r649", "r653", "r754", "r755", "r765", "r798", "r812", "r830", "r831", "r859", "r935", "r1046", "r1062", "r1094", "r1114" ] }, "mrk_StockholdersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20240331", "localname": "StockholdersEquityLineItems", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders Equity [Line Items]", "label": "Stockholders Equity [Line Items]", "documentation": "[Line Items] for Stockholders Equity [Table]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r160", "r245", "r448", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r464", "r623", "r832", "r833", "r860" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-based compensation plans and other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityOtherShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOtherShares", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-based compensation plans and other (in shares)", "label": "Stockholders' Equity, Other Shares", "documentation": "Number of increase (decrease) in shares of stock classified as other." } } }, "auth_ref": [] }, "mrk_StockholdersEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20240331", "localname": "StockholdersEquityTable", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders Equity [Table]", "label": "Stockholders Equity [Table]", "documentation": "Stockholders Equity [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r650", "r658" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r650", "r658" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r650", "r658" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r986" ] }, "mrk_TaxBenefitResultingFromAcquisitionCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20240331", "localname": "TaxBenefitResultingFromAcquisitionCharge", "crdr": "debit", "presentation": [ "http://www.merck.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit resulting from acquisition charge", "label": "Tax Benefit Resulting From Acquisition Charge", "documentation": "Tax Benefit Resulting From Acquisition Charge" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r978" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r985" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1005" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1007" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r447", "r461", "r622", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r729", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1057", "r1058", "r1059", "r1060" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1008" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1009" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1007" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1007" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1010" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1008" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r75" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "periodStartLabel": "Treasury stock, beginning balance (in shares)", "periodEndLabel": "Treasury stock, ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r75" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "lang": { "en-us": { "role": { "terseLabel": "Less treasury stock, at cost: 1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r40", "r75", "r76" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock shares purchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r17", "r125", "r161" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock shares purchased", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r17", "r75", "r161" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r597" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r398", "r399", "r405", "r406" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "verboseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. government and agency securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r885", "r904", "r1107" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1004" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesDomain", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r257" ] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r257" ] }, "mrk_VaxneuvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "VaxneuvanceMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vaxneuvance", "label": "Vaxneuvance [Member]", "documentation": "Vaxneuvance" } } }, "auth_ref": [] }, "mrk_VerquvoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "VerquvoMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Verquvo", "label": "Verquvo [Member]", "documentation": "Verquvo" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares issuable (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1053" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Average common shares outstanding assuming dilution (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r275", "r286" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r273", "r286" ] }, "mrk_WeliregMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "WeliregMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Welireg", "label": "Welireg [Member]", "documentation": "Welireg" } } }, "auth_ref": [] }, "mrk_ZerbaxaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "ZerbaxaMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zerbaxa", "label": "Zerbaxa [Member]", "documentation": "Zerbaxa [Member]" } } }, "auth_ref": [] }, "mrk_ZetiaantitrustlitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20240331", "localname": "ZetiaantitrustlitigationMember", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zetia antitrust litigation", "label": "Zetia antitrust litigation [Member]", "documentation": "Zetia antitrust litigation [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-13" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "610", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//610/tableOfContent" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//720/tableOfContent" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "c", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EE" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EE" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EE" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-20" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1013": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r1014": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r1015": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 95 0001628280-24-020283-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-020283-xbrl.zip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